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Thesis outline and hypothesis
Chapter 1
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Infl ammation is instrumental in the development and progression of several vascular 
diseases such as atherosclerosis, neointima formation and abdominal aortic aneurysm 
(AAA) formation. Immunosuppressive therapy has been considered a promising tool 
for the treatment of vascular diseases. FK506 is a widely used immunosuppressive drug 
that inhibits the calcineurin-NFAT signaling pathway. We hypothesize that inhibition 
of calcineurin/NFAT signaling pathway will protect against infl ammation-related 
vascular pathologies. 
Infl ammation and extracellular matrix (ECM) degradation are linked at multiple levels 
during initiation and progression of vascular pathologies and proteolytic arterial 
remodelling is a key process in AAA, atherosclerosis and neointima formation. One of 
the most promising therapies to prevent vascular remodelling is to inhibit cathepsin 
K (catK), a potent lysosomal cysteine protease. Hence it is conceivable that genetic or 
pharmacological inhibition of catK function will protect against several vasculopathies 
that are characterized by excessive ECM/elastin degradation. 
The introduction is divided into two parts. Part 1 will review the potential of 
several immunosuppressive drugs to prevent the development and progression 
of atherosclerosis (chapter 2). Part 2 will review the importance of cathepsin family 
members in atherosclerosis (chapter 6).
Atherosclerosis is an infl ammatory disease. In a previous study, we showed that a 
low dose of FK506 blocked the progression of murine atherosclerosis. In chapter 3, we 
will investigate dose-dependent effects of FK506 in a mouse model of collar-induced 
atherosclerosis as well as on infl ammatory parameters relevant to atherosclerosis in an 
attempt to delineate dose-dependent role of FK506 in infl ammatory responses. 
Another vascular disease that was reported to show features of infl ammation is AAA. 
AAA is a permanent dilation of the arterial wall in abdominal aorta. Infl ammatory 
processes play a signifi cant role in this vascular pathology. In chapter 4, the effect of 
low-dose FK506 treatment on AAA formation will be investigated during angiotensin 
II (Ang II)-induced aneurysm formation. 
Intervention in the calcineurin-NFAT pathway in relation to the development of 
atherosclerosis will be further investigated in chapter 5. As NFATC2 is expressed 
in several leukocyte subsets and is a crucial transcriptional regulator of numerous 
infl ammatory genes during immune responses, we studied the effect of NFATC2 
defi ciency in hematopoietic cell lineages in atherosclerosis. 
Outline & hypothesis
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Chapters 7 and 8 will focus on the role of lysosomal cysteine protease-catK in various 
vascular pathologies. CatK expression was previously found to be elevated in human 
aortic aneurysm pointing to a role in this vascular disease. In chapter 7, the effect of 
catK defi ciency on Ang II-induced aneurysm formation in the abdominal aorta of apoE-
/- mice will be investigated. In chapter 8, the role of catK in two animal models of 
neointima formation will be investigated.
In chapter 9, the fi ndings in this thesis are discussed and future perspectives are given.
10
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Adapated from the following review:
Heeneman S, Donners MM, Bai L, Daemen MJ. Drug-induced immunomodulation to 
affect the development and progression of atherosclerosis: a new opportunity? 
Expert review of cardiovascular therapy. Mar 2007;5(2):345-364.
                   2
Drug-induced immuno-modulation to 
affect development and progression of 
atherosclerosis – a new opportunity?
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Chapter 2
Abstract
Infl ammation and cytokine pathways are crucial in development and progression of 
atherosclerotic lesions. In this review, the hypothesis that immuno-modulatory drugs 
are a possible therapeutic modality for cardiovascular disease is evaluated. Therefore, 
after a short overview of the specifi c infl ammatory pathways involved in atherosclerosis, 
literature on the effect of several immunosuppressive drugs (immunosuppressive drugs 
currently used in the prevention of rejection after organ transplant) on the development 
and progression of atherosclerosis is reviewed. 
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Immunosuppressive drugs such as mycophenolate mofetil (MMF), sirolimus 
(rapamycin), cyclosporine A and tacrolimus (FK506), have been studied in atherosclerotic 
animal models. In general, MMF and sirolimus treatment reduced atherosclerotic lesion 
size. For cyclosporine A and tacrolimus, results were confl icting, possibly due to the 
use of different animal models and dosage. A complication of the long-term use of 
immunosuppressive drugs is the increased risk for opportunistic infections and increased 
cardiovascular complications (due to development of hypertension and hyperlipidemia). 
However, a lower dose of immunosuppressive/anti-infl ammatory drugs could suffi ce 
to decrease the low-grade infl ammatory activation in the atherosclerotic lesion without 
generalized immunosuppressive effects. If such a long-term treatment of a low dose 
immunosuppressive/anti-infl ammatory drug is feasible, a strategy in which the drug 
is given either as a stabilizing therapy or as a preventive therapy in high-risk patients 
could be envisioned.
Atherosclerosis is a complex, progressive disease of the large systemic arteries 
and the leading cause of death in the Western World. This multi-factorial disease is 
characterized by the accumulation of lipids, cells and extracellular matrix in the vessel 
wall. Recent research has shown that infl ammation and cytokine pathways are crucial 
in the development and progression of atherosclerotic lesions. Immune cells are already 
present in early lesions and cytokine pathways are involved in every stage of the disease. 
Given its nature as an infl ammatory disease, immunomodulatory therapies have been 
proposed for the treatment of atherosclerotic disease. Potential immunosuppressive 
treatment modalities include specifi c drugs, chemokine blockades, induction of anti-
infl ammatory chemokines (e.g Il-10)1, gene therapy and immunization/vaccination 
2. In this review, the hypothesis that immuno-modulatory drugs are a possible 
therapeutic modality for cardiovascular disease is evaluated. After a short overview of 
infl ammatory pathways involved in atherosclerosis, immunosuppressive drugs such as 
mycophenolate mofetil (MMF), sirolimus (rapamycin), cyclosporine A and tacrolimus 
(FK506) will be evaluated.
Infl ammation in the initiation of atherosclerotic plaques 
Atherosclerosis is initiated by dysfunction/damage of the endothelial layer, by factors 
such as modifi ed LDL, free radicals, hemodynamic stress and hypertension3. The 
activated endothelial cells (EC) express adhesion molecules, such as E-selectin, P-selectin, 
intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM). 
In the initial stage, infl ammatory mediators such as tumor necrosis factor (TNF)-α, 
interleukin (IL)-1α, IL-1β, IL-18 and interferon (IFN)-γ have been shown to enhance 
the expression of adhesion molecules4. This specifi cally recruits circulating monocytes 
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and T-lymphocytes to the lesion site. Pro-infl ammatory cytokines, such as IL-1, IL-18, 
TNF-α and CD40L, induce the expression of monocyte chemotactic protein-1 and IL-8 
by EC, smooth muscle cells (SMC) and intimal macrophages 1, 5-7. These chemotactic 
factors mediate the recruitment of circulating monocytes and T-lymphocytes to the 
lesion site 8, 9. 
In the initial stage of atherogenesis, monocytes differentiate into macrophages under 
the infl uence of macrophage colony stimulating factor (M-CSF), a cytokine that is not 
only produced by macrophages, but also by vascular and stromal cells. Macrophages 
then become activated by cytokines, which induce the expression of scavenger receptors 
for the uptake of modifi ed lipoproteins and stimulate macrophage proliferation. 
IFN-γ, TNF-α and IL-6 regulate the expression of the scavenger receptor-A 10-12, IL-4 
upregulates CD36 13, 14 and transforming growth factor (TGF)-β and TNF-α regulate 
the expression of the oxLDL receptor (LOX-1) 15, 16. Also, the colony-stimulating 
factors (M-CSF and GM-CSF) can enhance the expression of macrophage scavenger 
receptors, probably by inducing cytokines. These scavenger receptors mediate the 
uptake of lipid by macrophages, resulting in foam cell formation. Foam cells can also 
produce infl ammatory mediators such as ILs, TNF-α or IFN-γ, which not only stimulate 
atherosclerotic plaque progression by the production of growth factors and proteolytic 
enzymes, but also act in an (auto)regulatory positive feedback loop by producing the 
cytokines, chemokines and colony stimulating factors described above, that contribute 
to the chronic nature of the infl ammatory response. 
The role of infl ammatory mediators in plaque progression
Progression of an atherosclerotic plaque is characterized by the formation of a fi brous 
cap by SMC migration and proliferation, and the development of a necrotic core. An 
important process in necrotic core formation is cell death, by the process of apoptosis 
or necrosis. Cytokines also play a role in the regulation of cell survival or apoptosis. 
IL-1α, TNF-α and IFN-γ can aggravate the production of reactive oxygen species 
(ROS) leading either directly to apoptosis 17 or sensitizing EC and SMC for apoptosis 
by upregulation of Fas-expression 18. Furthermore, TNF-α and IFN-γ can increase 
macrophage susceptibility to apoptosis induced by peroxisome-proliferator- activated 
receptor (PPAR)-α and –γ ligands 19. Although certain anti-infl ammatory cytokines, such 
as IL-4, have been shown to promote cell death 20, others (such as IL-10) can promote as 
well as inhibit apoptosis 21, 22. This demonstrates that cytokines can exert contradictory 
effects.
As already mentioned, lesion progression is accompanied by the formation of a fi brous 
cap, consisting of migrated SMC that proliferate and produce extracellular matrix 
(ECM) constituents, such as collagen and proteoglycans. Important growth factors for 
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SMC proliferation include platelet derived growth factor (PDGF), insulin-like growth 
factor-1 and TGF-β, which can be produced by foam cells. Furthermore, IL-1 and TNF-α 
produced by foam cells enhance the SMC and EC expression of PDGF, which exerts 
a variety of functions including stimulation of both proliferation and migration of 
SMC 23. IFN-γ (which can be induced by IL-12, -15 and/or IL-18) directly inhibits SMC 
proliferation and collagen synthesis 24, 25. 
ECM turnover is very important in the progression of atherosclerotic plaques, especially 
in the determination of plaque stability. An increase in ECM deposition stabilizes the 
plaque, whereas an increased degradation of the ECM can lead to weakening of the 
fi brous cap and eventually to plaque rupture. Net matrix deposition thus depends on 
the balance of ECM synthesis and degradation 26. Cytokines not only regulate collagen 
synthesis, but can also infl uence the expression of ECM degrading enzymes such as 
matrix metallo-proteinases (MMPs) 27, 28. IL-1α, TNF-α and CD40L stimulate MMP-1, 
-2, -3, -7, -8, -9, -11 and -13 expression in EC, SMC and macrophages/foam cells 29, 30. 
Interestingly, IFN-γ attenuates both collagen synthesis and degradation, indicating 
again the multi-functional effects of cytokines.
Infl ammation and plaque rupture
Inhibition of SMC proliferation, SMC apoptosis, inhibition of matrix synthesis, and 
increased matrix degradation may affect integrity and strength of the fi brous cap 
and can lead to rupture of an atherosclerotic lesion and exposure of the necrotic 
core to the blood. The necrotic core is highly thrombogenic due to its lipid content 
and the presence of pro-coagulant factors, such as Tissue Factor (TF) 31. These factors 
together with (anti-)fi brinolytic factors, such as plasminogen activators, urokinase-
type plasminogen activator, tissue plasminogen activator and plasminogen activator 
inhibitor (PAI) infl uence plaque rupture. Cytokines can also regulate the expression 
of pro-coagulant and anti-coagulant factors. IL-1, TNF-α and CD40L can induce TF 
expression in macrophages, EC and SMC 32, 33. Furthermore, IL-1α and TNF-α can 
enhance the expression of PAI-1 34, whereas IFN-γ has the opposite effect 35. Thus, by 
governing the expression of pro-coagulant, pro- or anti-fi brinolytic factors, cytokines 
may regulate the thrombogenicity of atherosclerotic plaques. 
Balance of pro-infl ammatory and anti-infl ammatory mediators 
Anti-infl ammatory cytokines, such as IL-4 and -10 can reduce the expression of 
adhesion molecules (ICAM & VCAM) 36, chemotactic factors (IL-8) 37, growth factors 
(through inhibition of IL-12, -15 and -18), proteolytic enzymes (MMPs) 38, 39 and pro-
coagulation factors (TF) 33. Therefore, these cytokines can counteract the effects of 
pro-infl ammatory cytokines and possibly protect against atherosclerosis formation. 
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Furthermore, mediators other than cytokines can infl uence the infl ammatory response. 
Angiotensin II (AngII), for example, has been shown to exert several pro-infl ammatory 
and pro-atherogenic effects, such as increasing free radicals (ROS), stimulation of SMC 
proliferation and expression of adhesion molecules, scavenger receptors, cytokines and 
chemotactic factors 40. 
The balance between pro-infl ammatory and anti-infl ammatory cytokines, chemokines 
and growth factors determines the net effect of these mediators. A key regulatory 
event is the differentiation of CD4+ T-cells into either a Th1 or Th2 subtype. The Th1 
response typically involves pro-infl ammatory and mainly pro-atherogenic mediators, 
such as IFN-γ, TNF-α and IL-1, whereas the Th2 response favors the production of anti-
infl ammatory and anti-atherogenic cytokines IL-4 and -10. The differentiation of CD4+ 
cells into Th1 or Th2 phenotypes is also regulated by cytokines 41. IL-12 induces a Th1 
response, IL-10 a Th2 response. These Th1 and Th2 cytokines are cross-regulatory, since 
IL-10 inhibits the Th-1 response, whereas IFN-γ inhibits Th2.
It has been shown that in the atherosclerotic plaque, infl ammatory mediators of the Th1 
response dominate 42. Pro-infl ammatory T-cell cytokines (IL-2 and IFN-γ) were shown 
to be highly expressed, whereas the anti-infl ammatory cytokines IL-4 and -5 were rarely 
observed in the plaques. 
In conclusion, atherosclerosis is a very complex, chronic infl ammatory disease, initiated 
by a response to injury and mediated by a constant interplay between (infl ammatory) 
cells and infl ammatory mediators. Cytokines play an important regulatory role in the 
recruitment of infl ammatory cells (by modulating the expression of adhesion molecules 
and chemotactic factors), foam cell formation (by inducing expression of scavenging 
receptors), fi brous cap formation (by regulating  SMC migration, proliferation and matrix 
turnover), necrotic core formation (by regulating cell survival, death or phagocytosis) 
and thrombogenicity of the plaques (by modulating the expression of pro-coagulant, 
pro- or anti-fi brinolytic factors).
Established immunosuppressive drugs– immuno-modulation as a ‘side-effect’. 
Established immunosuppressive drugs can, at least to a certain extent, have anti-
infl ammatory effects. It has been suggested that these pleiotropic immunomodulatory 
effects contribute to the clinical benefi ts observed. Here we will focus on the immuno-
modulating effects of MMF, sirolimus, cyclosporine A and tacrolimus.
Mycophenolate mofetil (MMF)
MMF is a potent immunosuppressant that is currently in use in the prevention of 
acute rejection after organ transplantion. MMF is converted in the liver to the active 
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compound mycophenolic acid, which is a reversible, potent, non-competitive inhibitor 
of monophosphate dehydrogenase, the central, rate-limiting enzyme in de novo purine 
synthesis. As lymphocytes only have the capacity for de novo synthesis of guanosine 
nucleotides, MMF has a potent anti-proliferative effect on these cells by depletion of the 
intracellular guanosine nucleotide pool 43, 44. In addition, MMF can inhibit expression 
of adhesion molecules on lymphocytes and EC and increase T-cell apoptosis 44. MMF 
was fi rst used in clinical trials for renal transplantation, and since 1993 MMF has also 
been used in cardiac transplantation. In a recent review in which clinical trials in 28 
centers were analyzed, MMF reduced mortality and the incidence and severity of 
cardiac transplant rejection. In addition, MMF was able to better preserve coronary 
artery luminal area 1 year after transplantation, suggesting that MMF could reduce 
progression of cardiac allograft vasculopathy,  a well-known complication and cause of 
organ loss 45. In line with this, cardiac transplant patients, treated with MMF had lower 
plasma levels of CRP compared to patients receiving other immunosuppressive drugs 
46. 
The effect of MMF and its immuno-modulating properties in atherosclerosis have been 
investigated in a limited number of studies. Although all studies used a rabbit model 
(in which a high fat diet induces fatty streak development in the aorta), the effect of 
MMF was clearly benefi cial with a reduction in lesion development and with lesions 
containing less SMCs and macrophages 47-49. Given its success in transplant patients 
and favorable side-effect profi le, MMF could be a good candidate for an immuno-
modulating  drug used to prevent progression of atherosclerosis, although more animal 
and human studies are needed to evaluate the cardiovascular effects of MMF. 
Sirolimus (Rapamycin) 
Sirolimus, also known as rapamycin, is a macrolide and the metabolic substrate of the 
fungus Streptomyces hygroscopicus. Developed initially as an anti-fungal antibiotic, it 
was later discovered that it also possessed potent immunosuppressive activities and 
was further developed for use in renal transplant rejection. Sirolimus has a structure 
similar to the bacterial macrolide FK506 (tacrolimus), and binds to the same family of 
immunophilins, the FK506 binding proteins (FKBP-12 specifi cally). While the FK506-
FKBP-12 complex will inhibit calcineurin (see next paragraph), the sirolimus -FKBP-12 
complex will inhibit the kinase mTOR (mammalian target of rapamycin). mTOR is a 
289 kD protein, evolutionarily related to lipid kinases, and has protein serine/threonine 
kinase activities 50. mTOR regulates proteins that are critical in cell cycle regulation 
(p70s6k, cyclin-dependent kinases, their cyclin partners, the cyclin dependent inhibitory 
proteins p21 and p27). The inhibition of mTOR by sirolimus will inhibit cell cycle 
progression in a number of cell types, including T and B-lymphocytes. The effectiveness 
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of sirolimus as an immunosuppressive drug is due to the fact that IL-2 dependent T-cell 
proliferation is dependent on mTOR signals to drive T-cell proliferation 51. Activation of 
mTOR also regulates proliferation of SMCs and EC in response to growth factors. The 
latter explains the successful use of sirolimus in coated stents in the prevention of in-stent 
restenosis in various clinical trials 52. As mentioned above, sirolimus has been initially 
developed for use in renal transplant rejection. In several clinical trials, sirolimus has 
been successful in preventing acute rejection and improving long term renal function 
(1 year) 51. In a prospective study, patients with coronary allograft vasculopathy were 
treated with sirolimus (on a background of ´standard´ immunosuppression). In the 
follow-up of 2 years, the patients treated with sirolimus developed signifi cantly less 
adverse events (death, myocardio infarction (MI), need for bypass surgery) 53. 
Given these anti-proliferative and immunosuppressive properties, the use of sirolimus 
in the treatment of atherosclerosis has been studied in experimental models. In all 
mouse studies 54-60, sirolimus reduced atherosclerotic lesion size. If investigated, this was 
paralleled by a reduction in infl ammatory parameters, either systemic or intralesional. In 
2 studies, sirolimus affected serum lipid levels, increasing triglyceride levels in one study 
55, and increasing both LDL and HDL levels in the other58. These changes in lipid levels are 
disadvantageous if sirolimus is to be used as a long term treatment for atherosclerosis, 
and indeed clinical trials thus far showed that hyperlipidemia is evident in most patients 
treated with sirolimus51. In addition to its anti-proliferative and anti-infl ammatory 
properties, sirolimus was able to inhibit lipid uptake and increase cholesterol effl ux 
from VSMCs, which could contribute to the anti-atherosclerotic effects of sirolimus61. 
However, there are no data available from clinical trials showing the effect of sirolimus 
on native atherosclerosis. Of the same family as sirolimus, everolimus is an orally active 
immunosuppressive and anti-proliferative compound. Everolimus, although did not 
alter total plasma cholesterol levels  in LDL receptor (LDLr) -/- mice fed with western 
diet, was found to signifi cantly reduce atherosclerosis lesions62. In addition, everolimus 
markedly decreased lesion macrophage content and this effect was associated with a 
reduction in plaque area and occurred in the absence of changes in plasma cholesterol 
concentrations63.  Pretreatment with everolimus lowered monocyte chemotaxis in 
response to various chemotactic factors. This may explain the reduced macrophage 
content in atherosclerotic lesions. Similarly, another study reported that implantation 
of everolimus eluting stents led to a reduction in macrophage content without altering 
the amount of smooth muscle cells in atherosclerotic lesions64. Subsequent in vitro 
studies indicated that everolimus only induced cell death in macrophages. This study 
indicated that stent-based delivery of everolimus may be a promising novel strategy for 
treatment of vulnerable atherosclerotic plaques64. However further studies are needed 
to validate this hypothesis.
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Cyclosporine A and tacrolimus (FK506)
Although structurally unrelated, cyclosporine A and tacrolimus both inhibit calcineurin 
(protein phosphatase 2B), a serine/threonine protein phosphatase directly regulated by 
Ca2+ and calmodulin. Cyclosporine A is a lipophilic undecapeptide, whereas tacrolimus 
is a macrolide antibiotic isolated from streptomyces tsukubaensis. They bind to different 
immunophilins to exert their effects: cyclosporine A complexes with cyclophilin and 
tacrolimus binds to FKBPs (FKBP12 is the major FKBP for tacrolimus/FK506). Both 
drug-immunophilin complexes inhibit the phosphatase activity of calcineurin and 
thereby prevent the dephosporylation and nuclear transport of the NFAT (nuclear 
factor of activated T-cells) family of transcription factors. This results in a suppression 
of NFAT regulated genes, such as IL-2, IFN-γ and TNF-α, and in turn the elimination of 
infl ammatory reactions 65, 66. 
Given these anti-infl ammatory properties, cyclosporine A or tacrolimus are currently 
the primarily used immunosuppressive therapies after organ transplantation. The 
introduction of cyclosporine A in 1982 markedly improved clinical outcome for patients 
with a heart transplantation, as 3 year survival increased by ~40-70%. The effi cacy of 
cyclosporine A and tacrolimus have been compared in several large clinical trials. 
Although survival and incidence of acute rejection are generally the same, tacrolimus is 
often preferred by clinicians due to lower incidence of hyperlipidemia and hypertension 
51. Despite improvements in preservation of the transplanted organ due to cyclosporine 
A and tacrolimus, the incidence of coronary artery disease in heart-transplant patients 
(1-18% in year 1, 20-50% after 3 years) has not decreased in the past 25 years. Allograft 
vasculopathy is an accelerated form of organ disease and a long term complication of 
patients with a heart or kidney transplantation67. Allograft vasculopathy affects both 
intramural and epicardial coronary arteries and veins. The etiology is not similar to 
atherosclerosis (as it affects veins as well), although a non-denuding arterial injury is 
thought to be a major factor in its development. Immunosuppressive drugs have been 
proposed as causative factors to allograft vasculopathy, either directly due to toxicity or 
indirectly due to hyperlipidemia and hypertension68. 
Despite the apparent discrepancy in the immunosuppressive/anti-infl ammatory effect 
versus deterioration of allograft vasculopathy by cyclosporine and tacrolimus treatment, 
the effect of these drugs on atherosclerosis and arteriosclerosis have nevertheless been 
investigated in animal models of transplant arteriosclerosis, denudation-infl icted 
vascular injury and atherosclerosis. The data of these studies69-76, however, are rather 
contradictory, possibly due to specifi c animal models used and large differences 
in dosages. The studies in models of transplant arteriosclerosis in general show a 
protective effect 72, 73, 75. In atherosclerosis, however, tacrolimus or cyclosporine either 
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increased 69, 71, 74 or decreased lesion size 70, 76. None of these studies used the same model 
or dose. The dosage, however, could be of critical importance as many of the side-
effects of tacrolimus and cyclosporine are reported in patients on high dose regimes for 
maximal suppression of the infl ammatory response against the ‘foreign’ transplanted 
organ. In atherosclerosis, however, the infl ammatory reaction is more local and 
sustained over longer periods of time, especially in the initial phases. In a study from 
our laboratory 76, using a low dose of tacrolimus/FK506 (0.05 mg/kg/d) in two models 
of atherosclerosis (collar-induced atherosclerosis and native atherosclerosis in apoE 
-/- mice), atherosclerotic plaque development was decreased in both models in the 
tacrolimus -treated mice, without affecting plasma lipid levels and without systemic 
side-effects. Moreover, tacrolimus treatment increased collagen content and decreased 
local infl ammatory parameters, suggesting that tacrolimus induced a more stable plaque 
phenotype. The chronic (subcutaneous) administration of 0.05 mg/kg/d resulted in 
(whole) blood tacrolimus concentrations of ~0.2 ng/ml, which is considerably lower 
compared to levels achieved in transplant patients (15-20 ng/ml) 77. In addition, there is 
strong evidence that the local expression of different isoforms of immunophilins (such as 
FKBP12) may determine the effect of tacrolimus on a particular tissue 78. This implies that 
the same dose of tacrolimus could affect different cell types differently76. Interestingly, 
FKBP12 was found to be upregulated in human coronary atherectomy tissue retrieved 
by helix cutter79, suggesting that the atherosclerotic human vascular wall may be more 
sensitive to tacrolimus 79. Combined, data from literature and our own data suggest that 
tacrolimus exerts its regulatory actions on plaque phenotype primarily at the level of 
the vessel wall itself and not via a systemic immuno-modulatory effect. 
Perspectives for long term (oral) use of immuno-modulatory drugs 
As suggested by several experimental studies, in animal models as well as in the limited 
number of patient studies, immuno-modulatory drugs could become a potential therapy 
for atherosclerosis. Table 2.1 gives an overview on how these drugs could interact with 
the different stages of atherosclerosis (as related to the events described in the fi rst part 
of this review). Clearly, all drugs can interact in multiple events, both in the initiation as 
well as the progression/rupture phase. However, there are several issues to consider, 
both in favor of, as well as against the use of immuno-modulatory therapy in patients 
with cardiovascular disease.
The use of systemic immunosuppressive therapy fi ts within the current paradigm 
that atherosclerosis is a systemic disease and that, although thrombotic occlusion of 
a single ruptured plaque can be the cause of a cardiovascular event, few vulnerable 
lesions are often present in the same patient. This has been shown in several studies 
using different approaches (intravascular ultrasound (IVUS), autopsy, angiography, 
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angioscopy and thermography studies (reviewed in 80). Mariello et al 81 also showed 
that, in patients who died of an acute MI, more vulnerable lesions were present (~7/
patient, compared with ~1 in patients with stable angina and control patients). Acute 
MI patients showed a diffuse and active infl ammatory process in the entire coronary 
tree, also in stable lesions distant from the culprit lesion. Buffon et al 82 also showed 
the presence of widespread coronary infl ammation in patients with unstable angina. 
A recent study by Rioufol et al 83 used IVUS to follow ruptured non-culprit lesions on 
a background therapy of statins and anti-platelet drugs. It was shown that 50% of the 
lesions healed after a follow-up of 22 months. Although only small non-culprit lesions 
were studied (as these were not treated by interventional cardiology), this study did 
show that lesions can heal with medical therapy. Thus, systemic drugs that can stabilize 
or regress the multiple vulnerable lesions are of great benefi t. Moreover, given the 
possibility of widespread coronary infl ammation in vulnerable patients, the impact of 
anti-infl ammatory/immunosuppressive drugs could be substantial. 
An important draw-back of the long-term use of immuno-modulatory drugs is the 
suppression of ´normal´ immunoregulatory functions and increased incidence of either 
bacterial or viral infections. In transplanted patients, complications or death due to 
cytomegalovirus, Epstein-barr virus or hepatitis C are a major source of mortality or 
morbidity 84. 
Although we postulated in the previous paragraph that anti-infl ammatory/
immunosuppressive drug could be a promising therapy for multiple vulnerable lesions, 
the draw-back of the long-term use of immuno-modulatory drugs is an increased 
incidence of cardiovascular complications after heart transplantation. This is refl ected 
by the fact that accelerated coronary disease is the leading cause of death in heart 
transplanted patients >1 year post transplant. In addition, death due to cardiovascular 
disease, while the transplanted organ is still functioning, is a major cause of death 
following renal and cardiac transplantation. As shown in table 2.2, most of the drugs 
described in this review increase one or more risk factors such as hyperlipidemia, 
dyslipidemia, hypertension and diabetes mellitus 68. MMF displays the most favorable 
side-effect profi le. 
Clearly there is discrepancy between the possible protective effect of immunosuppressive 
therapy against vulnerable lesions and the cardiovascular disease after long term 
immunosuppressive therapy. A point to consider that might explain this discrepancy 
is the dosage of the drug that might have pivotal importance in both the suppression 
of normal regulatory immune function and cardiovascular side-effects. It is expected 
that a lower dose of immunosuppressive drugs as currently used for the suppression of 
solid organ rejection, is needed for the suppression of the more low-grade continuous/
episodic infl ammatory activation as seen in the coronary vasculature of patients with 
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unstable angina. It is encouraging that in an animal study from our own laboratory, 
a low dose of systemic tacrolimus was able to inhibit progression of atherosclerosis 
in two models, with no apparent effects on systemic immunological parameters76. If 
a long-term treatment of a low dose immunosuppressive drug is feasible, a strategy 
in which the drug is given either as a stabilizing therapy or as a preventive therapy in 
high-risk patients could be envisioned.
Summary
Recent research has shown that infl ammation and cytokine pathways are crucial in 
the development and progression of atherosclerotic lesions. Immune cells are already 
present in early lesions and cytokine pathways are involved in every stage of the disease. 
Given its nature as an infl ammatory disease, immunomodulatory therapies have been 
proposed. Several immunosuppressive drugs are already used in the clinic, mostly to 
suppress organ rejection in patients with organ transplants. The question is whether 
these drugs could also be used to suppress infl ammatory activation that is associated 
with initiation and progression of atherosclerosis and become a potential therapeutic 
modality.  Immunosuppressive drugs such as MMF, sirolimus, cyclosporine A and 
tacrolimus and their concomitant anti-infl ammatory effects, have also been studied in 
atherosclerotic animal models. MMF has been studied only in rabbit models, in which 
an atheroprotective potential has been shown. With respect to sirolimus, more studies 
are available, and a consistent reduction in lesion size was present after treatment. For 
cyclosporine A and tacrolimus, results in animal studies are less consistent, with both an 
increase as well as a decrease in atherosclerotic burden. A complication of the long-term 
use of these  immunosuppressive drugs (MMF, sirolimus, cyclosporine A, tacrolimus) 
in patients with transplanted organs, is the increased risk for opportunistic infections 
and increased cardiovascular complications (due to development of hypertension, and 
hyperlipidemia). However, a lower dose of immuno-modulating drugs could suffi ce 
to decrease the low-grade infl ammatory activation in atherosclerotic lesions without 
generalized anti-infl ammatory or immunosuppressive effects. For tacrolimus, it 
was shown that a low-dose regime did inhibit progression of atherosclerosis in two 
mouse models of atherosclerosis, with no apparent effects on systemic immunological 
parameters 76. If a long-term treatment of a low dose immuno-modulating drug is 
feasible, a strategy in which the drug is given either as a stabilizing therapy or as a 
preventive therapy in high-risk patients could be envisioned.
23
Immunomodulation in atherosclerosis
Table 2.1 : Overview of the effect of the different drugs on plaque stage/ events
MMF Sirolimus CsA Tacro.
Plaque 
initiation
EC activation/ 
Expression adhesion 
molecules ↓ ↓ ↓ ↓
Recruitment 
infl ammatory cells ↓ ↓ ↓ ↓
Monocyte to 
macrophage transition ↓ ? ? ?
Activation macrophages 
(lipid uptake) ? ? ? ↓
Plaque 
progression/       
Plaque rupture
SMC migration/ 
proliferation ↓(prol) ↓(prol) ↑↓(prol)? =/?
ECM remodelling ↓ ?  
indirect
↓ ?  
indirect ? ↑
Apoptosis
T-cell ↑ ? ↓ ↓(smc)
Angiogenesis ? ↓ ↓ ?
Thrombosis ? ? ? ?
prol. = proliferation, SMC = smooth muscle cell, tacro. = tacrolimus, CsA=cylosporine 
A
Table 2.2:  Side-effects of immuno-modulatory drugs
Changes 
in lipid 
metabolism
Hypertension Diabetes Gastro-
intestinal 
problems
Renal 
dysfunction
MMF NR NR NR ↑ ↑ NR
Sirolimus ↑ ↑ ↑ NR NR ↑ ↑ NR
Cyclosporine 
A ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑
Tacrolimus ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑
Drugs as reported for use in patients (used for prevention of organ rejection (high dose 
regimes)).
NR = Not reported
Gastro-intestinal problems: Nausea, diarrhea and vomiting for the other drugs.
24
Chapter 2
References 
1. Mallat Z, Tedgui A. Immunomodulation to combat atherosclerosis: the potential role of immune 
regulatory cells. Expert opinion on biological therapy. Sep 2004;4(9):1387-1393.
2. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine 
development. Arterioscler Thromb Vasc Biol. Jan 2005;25(1):18-28.
3. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233-241.
4. Libby P. Infl ammation in atherosclerosis. Nature. Dec 19-26 2002;420(6917):868-874.
5. Colotta F, Borre A, Wang JM, Tattanelli M, Maddalena F, Polentarutti N, Peri G, Mantovani A. 
Expression of a monocyte chemotactic cytokine by human mononuclear phagocytes. J Immunol. 
Feb 1 1992;148(3):760-765.
6. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P, Ceska M, Lindley I, Colotta F, Mantovani 
A. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human 
vascular smooth muscle cells. Arterioscler Thromb. Sep-Oct 1991;11(5):1166-1174.
7. Wang DL, Wung BS, Shyy YJ, Lin CF, Chao YJ, Usami S, Chien S. Mechanical strain induces 
monocyte chemotactic protein-1 gene expression in endothelial cells. Effects of mechanical strain 
on monocyte adhesion to endothelial cells. Circulation research. Aug 1995;77(2):294-302.
8. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol. Oct 
1998;9(5):397-405.
9. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in infl ammation. 
N Engl J Med. Feb 9 2006;354(6):610-621.
10. Liao HS, Matsumoto A, Itakura H, Doi T, Honda M, Kodama T, Geng YJ. Transcriptional 
inhibition by interleukin-6 of the class A macrophage scavenger receptor in macrophages derived 
from human peripheral monocytes and the THP-1 monocytic cell line. Arterioscler Thromb Vasc 
Biol. Aug 1999;19(8):1872-1880.
11. Hsu HY, Nicholson AC, Hajjar DP. Inhibition of macrophage scavenger receptor activity by 
tumor necrosis factor-alpha is transcriptionally and post-transcriptionally regulated. J Biol Chem. 
Mar 29 1996;271(13):7767-7773.
12. Geng YJ, Holm J, Nygren S, Bruzelius M, Stemme S, Hansson GK. Expression of the macrophage 
scavenger receptor in atheroma. Relationship to immune activation and the T-cell cytokine 
interferon-gamma. Arterioscler Thromb Vasc Biol. Nov 1995;15(11):1995-2002.
13. Janabi M, Yamashita S, Hirano K, Sakai N, Hiraoka H, Matsumoto K, Zhang Z, Nozaki S, 
Matsuzawa Y. Oxidized LDL-induced NF-kappa B activation and subsequent expression of 
proinfl ammatory genes are defective in monocyte-derived macrophages from CD36-defi cient 
patients. Arterioscler Thromb Vasc Biol. Aug 2000;20(8):1953-1960.
14. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM, Jr., Hajjar DP, Nicholson AC. Induction of 
CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on 
protein kinase C and PPAR-gamma. J Lipid Res. May 2000;41(5):688-696.
15. Kume N, Moriwaki H, Kataoka H, Minami M, Murase T, Sawamura T, Masaki T, Kita T. Inducible 
expression of LOX-1, a novel receptor for oxidized LDL, in macrophages and vascular smooth 
muscle cells. Ann N Y Acad Sci. May 2000;902:323-327.
16. Minami M, Kume N, Kataoka H, Morimoto M, Hayashida K, Sawamura T, Masaki T, Kita T. 
Transforming growth factor-beta(1) increases the expression of lectin-like oxidized low-density 
lipoprotein receptor-1. Biochem Biophys Res Commun. Jun 7 2000;272(2):357-361.
17. Li PF, Maasch C, Haller H, Dietz R, von Harsdorf R. Requirement for protein kinase C in 
reactive oxygen species-induced apoptosis of vascular smooth muscle cells. Circulation. Aug 31 
1999;100(9):967-973.
18. Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P. Fas is expressed in human 
atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth 
muscle cells. Arterioscler Thromb Vasc Biol. Oct 1997;17(10):2200-2208.
19. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib 
J, Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of 
human monocyte-derived macrophages. J Biol Chem. Oct 2 1998;273(40):25573-25580.
20. Lee YW, Kuhn H, Hennig B, Toborek M. IL-4 induces apoptosis of endothelial cells through the 
caspase-3-dependent pathway. FEBS Lett. Nov 24 2000;485(2-3):122-126.
21. Lindner H, Holler E, Ertl B, Multhoff G, Schreglmann M, Klauke I, Schultz-Hector S, Eissner G. 
25
Immunomodulation in atherosclerosis
Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells 
and may prevent repair: role of cytokines. Blood. Mar 15 1997;89(6):1931-1938.
22. Oshima K, Sen L, Cui G, Tung T, Sacks BM, Arellano-Kruse A, Laks H. Localized interleukin-10 
gene transfer induces apoptosis of alloreactive T cells via FAS/FASL pathway, improves function, 
and prolongs survival of cardiac allograft. Transplantation. Apr 15 2002;73(7):1019-1026.
23. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth 
factor. Physiol Rev. Oct 1999;79(4):1283-1316.
24. Hansson GK, Jonasson L, Holm J, Clowes MM, Clowes AW. Gamma-interferon regulates 
vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ Res. Oct 
1988;63(4):712-719.
25. Harrop AR, Ghahary A, Scott PG, Forsyth N, Uji-Friedland A, Tredget EE. Regulation of 
collagen synthesis and mRNA expression in normal and hypertrophic scar fi broblasts in vitro by 
interferon-gamma. J Surg Res. May 1995;58(5):471-477.
26. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the 
good, the bad, and the ugly. Circ Res. Feb 22 2002;90(3):251-262.
27. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively 
regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler 
Thromb. Sep-Oct 1991;11(5):1223-1230.
28. Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P. Regulation of 
matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a 
role for CD40 signaling in plaque rupture? Circ Res. Sep 1997;81(3):448-454.
29. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of 
vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human 
atherosclerotic lesions. Ann N Y Acad Sci. Jan 17 1995;748:501-507.
30. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, 
Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of 
enzymes required for extracellular matrix digestion. Circ Res. Jul 1994;75(1):181-189.
31. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson 
Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. Jul 1997;78(1):200-204.
32. Taubman MB. Tissue factor regulation in vascular smooth muscle: a summary of studies 
performed using in vivo and in vitro models. Am J Cardiol. Sep 9 1993;72(8):55C-60C.
33. Osnes LT, Westvik AB, Joo GB, Okkenhaug C, Kierulf P. Inhibition of IL-1 induced tissue factor 
(TF) synthesis and procoagulant activity (PCA) in purifi ed human monocytes by IL-4, IL-10 and 
IL-13. Cytokine. Nov 1996;8(11):822-827.
34. Wojta J, Gallicchio M, Zoellner H, Hufnagl P, Last K, Filonzi EL, Binder BR, Hamilton JA, McGrath 
K. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen 
activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost. Sep 
1 1993;70(3):469-474.
35. Gallicchio M, Hufnagl P, Wojta J, Tipping P. IFN-gamma inhibits thrombin- and endotoxin-
induced plasminogen activator inhibitor type 1 in human endothelial cells. J Immunol. Sep 15 
1996;157(6):2610-2617.
36. Krakauer T. IL-10 inhibits the adhesion of leukocytic cells to IL-1-activated human endothelial 
cells. Immunol Lett. Feb 1995;45(1-2):61-65.
37. Van Der Meeren A, Squiban C, Gourmelon P, Lafont H, Gaugler MH. Differential regulation by 
IL-4 and IL-10 of radiation-induced IL-6 and IL-8 production and ICAM-1 expression by human 
endothelial cells. Cytokine. Nov 1999;11(11):831-838.
38. Mostafa Mtairag E, Chollet-Martin S, Oudghiri M, Laquay N, Jacob MP, Michel JB, Feldman LJ. 
Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. 
Cardiovasc Res. Mar 2001;49(4):882-890.
39. Lacraz S, Nicod L, Galve-de Rochemonteix B, Baumberger C, Dayer JM, Welgus HG. Suppression 
of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest. 
Aug 1992;90(2):382-388.
40. Brasier AR, Recinos A, 3rd, Eledrisi MS. Vascular infl ammation and the renin-angiotensin 
system. Arterioscler Thromb Vasc Biol. Aug 1 2002;22(8):1257-1266.
41. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev 
26
Chapter 2
Immunol. 1994;12:635-673.
42. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine 
expression in advanced human atherosclerotic plaques: dominance of pro-infl ammatory (Th1) 
and macrophage-stimulating cytokines. Atherosclerosis. Jul 1999;145(1):33-43.
43. van Leuven SI, Kastelein JJ, Allison AC, Hayden MR, Stroes ES. Mycophenolate mofetil (MMF): 
fi ring at the atherosclerotic plaque from different angles? Cardiovasc Res. Feb 1 2006;69(2):341-347.
44. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and 
chronic allograft rejection. Transplantation. Oct 15 2005;80(2 Suppl):S181-190.
45. Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in 
cardiac transplantation. Transplantation. Oct 15 2005;80(2 Suppl):S235-243.
46. Pethig K, Heublein B, Wahlers T, Dannenberg O, Oppelt P, Haverich A. Mycophenolate mofetil 
for secondary prevention of cardiac allograft vasculopathy: infl uence on infl ammation and 
progression of intimal hyperplasia. J Heart Lung Transplant. Jan 2004;23(1):61-66.
47. Romero F, Rodriguez-Iturbe B, Pons H, Parra G, Quiroz Y, Rincon J, Gonzalez L. Mycophenolate 
mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis. Sep 
2000;152(1):127-133.
48. Greenstein SM, Sun S, Calderon TM, Kim DY, Schreiber TC, Schechner RS, Tellis VA, Berman 
JW. Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J Surg 
Res. Jun 15 2000;91(2):123-129.
49. Schreiber TC, Greenstein SM, Kim DY, Calderon TM, Sun S, Schechner RS, Tellis VA, Berman 
JW. Effect of mycophenolate mofetil on atherosclerosis in a rabbit model: initial histologic and 
immunohistochemical analyses. Transplant Proc. Jun 1998;30(4):961-962.
50. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. Oct 
2005;56(1):47-60.
51. Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni L, Page RL, 2nd, 
Kobashigawa J. Drug therapy in the heart transplant recipient: part II: immunosuppressive 
drugs. Circulation. Dec 21 2004;110(25):3858-3865.
52. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. Feb 2 2006;354(5):483-495.
53. Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, Edwards N, Oz M, Marks AR. 
Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. Jul 8 
2003;108(1):48-53.
54. Waksman R, Pakala R, Burnett MS, Gulick CP, Leborgne L, Fournadjiev J, Wolfram R, Hellinga 
D. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc 
Radiat Med. Jan-Mar 2003;4(1):34-38.
55. Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC. Effects of rapamycin on the arterial 
infl ammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant Proc. May 
2005;37(4):1880-1884.
56. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque 
progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J 
Cardiovasc Pharmacol. Oct 2005;46(4):481-486.
57. Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andres V. Rapamycin attenuates 
atherosclerosis induced by dietary cholesterol in apolipoprotein-defi cient mice through a p27 
Kip1 -independent pathway. Atherosclerosis. Jan 2004;172(1):31-38.
58. Elloso MM, Azrolan N, Sehgal SN, Hsu PL, Phiel KL, Kopec CA, Basso MD, Adelman SJ. Protective 
effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-defi cient mice. 
Am J Transplant. May 2003;3(5):562-569.
59. Basso MD, Nambi P, Adelman SJ. Effect of sirolimus on the cholesterol content of aortic arch in 
ApoE knockout mice. Transplant Proc. Dec 2003;35(8):3136-3138.
60. Zhao L, Ding T, Cyrus T, Cheng Y, Tian H, Ma M, Falotico R, Pratico D. Low-dose oral sirolimus 
reduces atherogenesis, vascular infl ammation and modulates plaque composition in mice lacking 
the LDL receptor. British journal of pharmacology. Mar 2009;156(5):774-785.
61. Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z. Anti-atherosclerotic effects of sirolimus 
on human vascular smooth muscle cells. American journal of physiology. Jun 2007;292(6):H2721-
2728.
62. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the 
27
Immunomodulation in atherosclerosis
mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis. 
May 2008;198(1):39-48.
63. Baetta R, Granata A, Canavesi M, Ferri N, Arnaboldi L, Bellosta S, Pfi ster P, Corsini A. 
Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid 
lesions of cholesterol-fed rabbits. The Journal of pharmacology and experimental therapeutics. Feb 
2009;328(2):419-425.
64. Martinet W, Verheye S, De Meyer GR. Everolimus-induced mTOR inhibition selectively depletes 
macrophages in atherosclerotic plaques by autophagy. Autophagy. May-Jun 2007;3(3):241-244.
65. Shibasaki F, Hallin U, Uchino H. Calcineurin as a multifunctional regulator. J Biochem (Tokyo). 
2002;131(1):1-15.
66. Horsley V, Pavlath GK. NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell 
Biol. 2002;156:771-774.
67. Pinney SP, Mancini D. Cardiac allograft vasculopathy: advances in understanding its 
pathophysiology, prevention, and treatment. Curr Opin Cardiol. Mar 2004;19(2):170-176.
68. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. Oct 
2002;2(9):807-818.
69. Emeson EE, Shen ML. Accelerated atherosclerosis in hyperlipidemic C57Bl/6 mice treated with 
cyclosporin A. Am J Pathol. 1993;142(6):1906-1915.
70. Drew AF, Tipping PG. Cyclosporine treatment reduces early atherosclerosis in the cholesterol-
fed rabbit. Atherosclerosis. 1995;116:181-189.
71. Roselaar SE, Schonfeld G, Daugherty A. Enhanced development of atherosclerosis in cholesterol-
fed rabbits by suppression of cell-mediated immunity. J Clin Invest. 1995;96:1389-1394.
72. Andersen HO, Hansen BF, Holm P, Stender S, Nordestgaard BG. Effect of cyclosporine on 
arterial balloon injury lesions in cholesterol-clamped rabbits: T lymphocyte-mediated immune 
responses not involved in balloon injury-induced neointimal proliferation. Arterioscler Thromb 
Vasc Biol. 1999;19:1687-1694.
73. Andersen HO, Holm P, Stender S, Hansen BF, Nordestgaard BG. Dose-dependent suppression 
of transplant arteriosclerosis in aorta-allografted, cholesterol-clamped rabbits. Suppression 
not eliminated by the cholesterol-raising effect of cyclosporine. Arterioscler Thromb Vasc Biol. 
1997;17:2515-2523.
74. Matsumoto T, Saito E, Watanabe H, Fujioka T, Yamada T, Takahashi Y, Ueno T, Tochihara T, 
Kanmatsuse K. Infl uence of FK506 on experimental atherosclerosis in cholesterol-fed rabbits. 
Atherosclerosis. 1998;139:95-106.
75. Wu GD, Cramer DV, Chapman FA, Cajulis E, Wang HK, Starzl TE, Makowka L. FK 506 inhibits 
the development of transplant arteriosclerosis. Transplant Proc. 1991;23:3272-3274.
76. Donners MM, Bot I, De Windt LJ, van Berkel TJ, Daemen MJ, Biessen EA, Heeneman S. Low-
dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in 
ApoE-/- mice. Am J Transplant. Jun 2005;5(6):1204-1215.
77. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and 
cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney 
Transplant Study Group. Transplantation. Apr 15 1997;63(7):977-983.
78. Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and 
tacrolimus at high drug concentrations. Transplantation. Jul 27 2000;70(2):327-335.
79. Zohlnhofer D, Klein CA, Richter T, Brandl R, Murr A, Nuhrenberg T, Schomig A, Baeuerle PA, 
Neumann FJ. Gene expression profi ling of human stent-induced neointima by cDNA array 
analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-
binding protein 12 upregulation. Circulation. Mar 13 2001;103(10):1396-1402.
80. Madjid M, Zarrabi A, Litovsky S, Willerson JT, Casscells W. Finding vulnerable atherosclerotic 
plaques: is it worth the effort? Arterioscler Thromb Vasc Biol. Oct 2004;24(10):1775-1782.
81. Mauriello A, Sangiorgi G, Fratoni S, Palmieri G, Bonanno E, Anemona L, Schwartz RS, Spagnoli 
LG. Diffuse and active infl ammation occurs in both vulnerable and stable plaques of the entire 
coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll 
Cardiol. May 17 2005;45(10):1585-1593.
82. Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary 
infl ammation in unstable angina. N Engl J Med. Jul 4 2002;347(1):5-12.
28
Chapter 2
83. Rioufol G, Gilard M, Finet G, Ginon I, Boschat J, Andre-Fouet X. Evolution of spontaneous 
atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular 
ultrasound. Circulation. Nov 2 2004;110(18):2875-2880.
84. Humar A, Michaels M. American Society of Transplantation recommendations for screening, 
monitoring and reporting of infectious complications in immunosuppression trials in recipients 
of organ transplantation. Am J Transplant. Feb 2006;6(2):262-274. 
Acknowledgement
SH and MD are involved in European Vascular Genomic Network (grant LSHM CT-
2003-503254). 
29
Differential effect of FK506 dosage on the 
development of atherosclerosis due to a 
dose-dependent shift in Th1/Th2 balance
                                                                                                                
Lili Bai, Mathijs Groeneweg, Veronica Herias, Linda Beckers, Marjo Donners, 
Erwin Wijnands, Mat Rousch, Mat J.A.P. Daemen, Erik A.L. Biessen, Sylvia Heeneman 
(in revision).
3
30
Chapter 3
Abstract 
Aims: Previous studies showed both pro- and anti-atherogenic effects of 
immunosuppressant drug FK506 on atherosclerosis. As these divergent/paradoxical 
results of FK506 may at least in part be attributable to differences in FK506 dosing, we 
have in the current study, assessed dose dependent effects of FK506 on atherosclerotic 
lesion formation as well as on infl ammatory parameters relevant to atherosclerosis. 
Methods and results: Unlike low dose FK506, high dose FK506 did not protect against 
atherosclerosis in apoE-/- mice. While both low and high dose FK506 treatment 
signifi cantly reduced systemic CD3+ and CD4+CD25+ T-cell populations in lymph node, 
only high dose treatment led to a suppression of the FoxP3 regulatory T cell population 
in spleen. Conditioned media from splenic CD4+ T cells of low dose FK506-treated 
mice showed sharply increased IL-4/IFN-γ and IL-10/IFN-γ ratios suggestive of Th2 
skewing, whereas high dose FK506 treatment did not induce such a response. In vitro 
studies with FK506 exposed CD4+ T cells, Jurkat T cells and PMA-differentiated THP1 
cells confi rmed the in vivo fi ndings. 
Conclusions: These results identify dosage as a critical factor in the anti-atherogenic 
activity of FK506, probably by differentially skewing the Th1/Th2 balance. The fact that 
low dose FK506 treatment induces a minor but decisive Th2 shift suggests that it can be 
particularly effective for long-term therapy in Th1 dominated immune disorders such 
as atherosclerosis.
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Introduction
A potent immunosuppressive drug, FK506 (tacrolimus) is widely used in patients 
following transplantation. At a molecular level, FK506 binds to the cytosolic FK506 
binding protein 12 (FKBP12)-member of  FKBP family1. In T lymphocytes, FK506 interacts 
with FKBP-12 to form a FK506-FKBP-12 complex2,. This complex blocks calcineurin, a 
Ca2+-calmodulin-regulated protein phosphatase. As a consequence, calcineurin fails to 
dephosphorylate amongst others cytosolic nuclear factor of activated T cells (NFAT), 
thereby inhibiting its translocation to the nucleus. NFAT is one of the most important 
transcriptional factors involved in the activation of cytokine genes such as IL-2. In 
addition, NFAT partners with the transcription factor AP-1 (Fos-Jun) in the nucleus 
of “effector” T cells. As a consequence, FK506 will inhibit both NFAT and NFAT-AP1 
function in transactivating cytokine genes, genes that regulate T cell proliferation and 
other genes that orchestrate an active immune response3 .
Atherosclerosis is a chronic infl ammatory disease in which NFAT responsive cytokines 
such as IL-2 are deemed to play a prominent role. In a previous study, we showed 
that FK506 at a low dose of 0.05 mg/kg/day benefi cially affected the progression of 
murine atherosclerosis, reducing plaque area and increasing cell density and collagen 
content4. Intriguingly and in contrast to our fi ndings, Matsumoto et al reported that 
FK506 treatment deteriorated atherosclerosis in cholesterol-fed rabbits5. In their study, 
a relatively high dose of FK506 was applied. Conceivably dose-specifi c effects of 
FK506 on cell subsets relevant to atherosclerosis6, and most notably leukocytes, may 
explain these paradoxical fi ndings. For clinical practice, it is important to comprehend 
the mechanisms underlying these potentially dose dependent effects of FK506 on 
atherosclerosis, in particular as in organ transplant recipients a high dose regime 
was seen to be associated with substantial side-effects7, 8.  Therefore, in this study, 
we investigated effects of low and high dose FK506 treatment on atherosclerosis and 
atherosclerosis related immunomodulation in apoE-/- mice. 
As our data pointed to dose-dependent immunoregulatory effects of FK506, in vivo 
and in vitro experiments were designed to address this in more detail. Firstly, we 
studied whether in vivo low/high dose FK506 treatment differentially affected T cell 
differentiation and activity in spleen, lymph node and peripheral blood. Secondly, 
splenic gene expression of IκB and NFκB responsive gene such as ICAM-1 and P-selectin 
were analyzed by real-time PCR. Finally, the effect of ex vivo and in vitro treatment of 
low/high dose FK506 on cytokine secretion by T cells and PMA-stimulated THP1 cells 
were investigated.  
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Materials and Methods
In Vivo studies
Mouse model of collar-induced atherosclerosis
Animal experiments were approved by the regulatory authority of the University of 
Maastricht and were performed in compliance with the Dutch government guidelines. 
Male apoE-/- mice (14 weeks old, C57Bl6 background) were fed a Western-type diet 
throughout the experiment. Carotid atherosclerotic lesions were induced by silastic 
tubing (collar) around carotid artery, as described by von der Thüsen et al9. To assess 
the effect of FK506 on lesion initiation, one week after collar-placement, osmotic 
minipumps (Alzet type 2004) containing FK506 (Fujisawa GmbH) or PBS were placed 
subcutaneously to achieve pumping rate of either 0.05 mg/kg/day or 1 mg/kg/day. 
Mice were sacrifi ced 4 weeks after pump placement.
Tissue harvesting and analysis
Cross-sections from the right common carotid artery after in situ perfusion-fi xation were 
processed for morphometric analysis as described previously10. Kidneys cross-sections 
(3 μm thick) were stained with Periodic acid-Schiff (PAS) for kidney toxicity analysis. 
(Immuno)histochemical stainings were performed to detect macrophages (α-Mac3 Ab) 
and collagen (picrosirius red) as described previously10. FoxP3 immunohistochemistry 
staining was performed by incubating sections with rat anti-mouse polyclonal Ab 
against the FoxP3 protein (1:50, eBioscience).
Fluorescence-activated cell sorting (FACS)-analysis
ApoE-/- mice were treated with FK506 or phosphate-buffered saline (PBS) using 
osmotic minipumps as described above. After 4 weeks, mice were sacrifi ced. Spleen, 
lymph node cells were isolated and used to make single-cell suspensions. Erythrocytes 
in peripheral blood and spleen were removed by hypotonic lysis with NH4Cl. Cells were 
incubated fi rst with anti-CD16/32 (eBioscience) to block Fc binding and subsequently 
incubated with anti-CD3-FITC, anti-CD8-Pacifi c blue, anti-CD25-APC (eBioscience) 
and anti-CD4-PerCp (BD-Biosciences Pharmingen). Foxp3 positive cells were detected 
with PE anti-mouse/rat Foxp3 Staining Set, according to the manufacture’s instruction 
(eBioscience). 
Quantitative RT-PCR
RNA was extracted from the spleen lysate with Nucleospin RNA II kit (MACHEREY-
NAGEL). cDNA was generated with iSCript TM CDNA synthesis kit (BIO-RAD). Real-
time PCR was done with a Taqman IQ TM SYBR Green Super Mix (BIO-RAD). Primer 
sequences for FoxP3, Iкβ-α, P-selectin, ICAM-1 and cyclophilin were shown in table 3.1.
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Table 3.1. Primer sequence
Forward primer (5’-3’) Reverse primer (5’-3’)
FoxP3 CCAGTCTGGAATGGGTGTCC CTGCTTGGCAGTGCTTGAGA
Iκβ-α TGGAAGTCATTGGTCAGGTGAA CAGAAGTGCCTCAGCAATTCCT
P-selectin GGTATCCGAAAGATCAACAATAA
GTG
GTTACTCTTGATGTAGATCTCCAC
ACA
ICAM-1 GGACCACGGAGCCAATTTC CTCGGAGACATTAGAGAACAATGC
cyclophilin CAAATGCTGGACCAAACACAA TTCACCTTCCCAAAGACCACAT
Ex vivo and in vitro study on low dose FK506 mechanism (table 3.2)
Table 3.2. Ex vivo and in vitro study on low dose FK506 mechanism
Experiment Treatment FK506 dose Isolation PMA & Ionomycin in 
vitro
1 In vivo Low dose: 0.05 mg/kg/day
High dose: 1mg/kg/day
CD4+ T cells 1ng/ml & 500nM
4ng/ml &500nM
2 In vitro Low dose: 20ng/ml
High dose: 2000ng/ml
CD4+ T cells 16ng/ml & 2000nM
3 In vitro Low dose: 20ng/ml
High dose: 2000ng/ml
Jurkat T cells 8ng/ml & 1000nM
4 In vitro Low dose: 20ng/m
High dose: 2000ng/ml
PMA 
differentiated
THP1 cells
PMA: 120ng/ml
LPS: 25ng/ml
5 In vitro Low dose: 20ng/ml
High dose: 2000ng/ml
Nucleus of
Jurkat T cells
8ng/ml & 1000nM
FK506 treatment on CD4+ T cells 
CD4+ T cells were isolated from splenocytes of FK506 treated or untreated mice using 
the Negative Isolation Kit (Dynal, Biotech ASA). The purity of CD4+ T cells was 87 + 5% 
as evaluated by FACS (data not shown). 
CD4+ T cells were incubated with PMA (Sigma) and Ionomycin (Sigma) for 48 hours. 
IL-4, IL-10 and IFN-γ in supernatants were assayed by enzyme-linked immunosorbent 
assay (ELISA) using antibodies according to the manufacturer’s instructions (BD 
Bioscience). IL-4:IFN-γ and IL-10: IFN-γ ratio were calculated and used as an index of 
Th2/Th1 skewing.
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Effects of FK506 on Jurkat T cells 
Cytokin e analysis was performed on human T lymphocytic Jurkat cells to further clarify 
the mechanism.  Jurkat T cells were pretreated with FK506 at a dose of 0, 20, and 2000 
ng/ml for 1 hour. Cells were then stimulated with PMA and ionomycin for 48 hr. IFN-γ 
and IL-10 in supernatant were assayed by ELISA using antibodies according to the 
manufacturer’s instructions (Sanquin).
Effect of FK506 on PMA-differentiated THP1 cells
The human promonocytic cell line THP-1 was differentiated in the presence of PMA for 
72 h. Differentiated THP1 cells were then treated for 24h with FK506 at a concentration 
of 0, 20 and 2000 ng/ml for 24 hours. Cells were then treated for 8 hours with LPS 
(25ng/ml) in the presence of the original concentration of FK506. Supernatants were 
harvested and analyzed for human IL-10 and IFN-γ content by ELISA according to the 
manufacturer’s instructions (Sanquin).
Effects of FK506 on NFATC1 and NFATC2 expression on nucleus of Jurkat T cells
Preparation of nuclear extracts and Western blot analysis
Nuclear and cytoplasmic extracts from Jurkat T cells were prepared using NE-PER nuclear 
and cytoplasmic reagents (Pierce) according to the manufacturer’s protocol. Protein 
concentration of nuclear extracts was determined by a Bio-Rad protein assay (Bio-Rad). 
Nuclear extracts (30μg) of each sample were loaded onto 7.5% SDS polyacrylamide 
gel under reducing conditions, and transferred to nitrocellulose transfer membrane 
(Whatman). Membranes were blocked with 2% Marvel/TBS-Tween and incubated with 
mouse anti-TATA binding protein TBP antibody (1/1000, abcam) in 2% Marvel/ tris 
buffered saline (TBS)-Tween (nuclear loading control), mouse anti-NFATC1 and mouse 
anti-NFATC2 (1/2000, Santa Cruz). Membranes were washed with TBS-Tween, and 
incubated with rabbit anti-mouse polyclonal Ab labelled with (horseradish peroxidase) 
HRP (1/2000, Dako, Denmark A/S) in 2% Marvel/TBS-Tween. Protein bands were 
visualized by chemiluminescence, and the signal intensity quantifi ed by the Quantity 
One imaging system (Bio-Rad). 
Viability analysis after FK506 treatment 
Isolated splenocytes from apoE-/- mice were cultured under the same conditions as 
CD4+ T cells. Cells were exposed to FK506 treatment ranging from 0.2ng/ml to 20μg/
ml for 72 hours. Viable cells were counted using trypan blue.
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Figure 3.1 Infl uence of low/high FK506 treat-
ment on mice weight. 
Statistical analysis
All results were expressed as mean + SEM. Differences between values were considered 
signifi cant at p< 0.05 using Mann-Whitney U test.
Results
Low-dose FK506 inhibits collar-induced atherosclerosis whereas high-dose did not
Mice weight was not affected by low/high dose FK506 treatment as shown in fi gure 3.1. 
Concentrations of FK506 in blood were essentially similar as described in our previous 
study4. To determine the effect of FK506 on the histological changes in kidneys, 
histological analysis was performed using PAS staining. Focal microaneurysm was 
present in glomeruli at similar frequency in the low/high dose group. There was no 
histological evidence of tubular toxicity. Acute (indicated by isometric vacuolization 
and thrombotic mesangiopathy) or chronic kidney toxicity (indicated by arteriolar 
hyalinosis and tubularinterstitial fi brosis atrophy) were not observed.
In keeping with our earlier study4, plaque size in low dose FK506-treated mice was 
signifi cantly lower (72.1%, p=0.05) compared to untreated controls. Remarkably, plaque 
sizes of control and high dose-treated mice were essentially similar (Figure 3.2A). There 
was no signifi cant difference in macrophage content between control, low and high 
dose group (fi gure 3.2B). Lipid core size in the low dose group tended to be decreased 
compared with control group (p=0.075), an effect that was not observed after high 
dose treatment (fi gure 3.2C). In addition, both low and high dose treatment did not 
affect collagen content (fi gure 3.2D). Figure 3.2E show representative HE stained cross-
sections of control, low dose versus high dose FK506-treated mice, respectively. Full 
color fi gures of HE stained cross-sections are shown on page 172.
Low/high FK506 treatment suppressed peripheral immune activity 
To examine whether FK506 infl uenced lesion development indirectly by altering 
peripheral immune activity, single-cell suspensions of spleen, lymph nodes and blood 
were analyzed to determine the amount of T cells by FACS (fi gure 3.3). The CD3+ 
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Figure 3.2 Morphological and morphometric analysis of the effect of low and high dose FK506 treatment 
on collar-induced atherosclerotic plaque development in common carotic arteries of apoE-/- mice. (A) 
the average of intima volume *p= 0.05, control versus low; (B) amount of macrophages in plaques, macro-
phage content was expressed as Mac3-positive cell numbers relative to total number of plaque cells of the 
section with the largest plaque area. (C) lipid core area relative to plaque area (p= 0.075, control versus 
low; p= 0.083, low versus high). (D) collagen content in plaques, collagen content stained by picrosirius 
red and are expressed relative to the plaque area. E shows representative HE stained cross-sections of 
right carotid artery of control (n=10), low dose (n=9) versus high dose FK506 (n=10)-treated mice, respec-
tively. Full color fi gures of HE stained cross-sections are shown on page 172
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T cell content in spleen, lymph node and blood was signifi cantly reduced after low 
and high dose FK506 treatment (fi gure 3.3A). The relative abundance of CD4+ cells 
within the CD3+ population in lymph node was signifi cantly reduced after high dose 
FK506 treatment, whereas low dose did not alter the CD4+ cell content (fi gure 3.3B). 
Furthermore, the CD4+ to CD8+ ratio in lymph node was signifi cantly reduced with both 
low and high dose of FK506 treatment (fi gure 3.3D). This was refl ected by a reduction in 
CD4+ numbers (fi gure 3.3B) and a concomitant increase in CD8+ numbers (fi gure 3.3C) 
upon FK506 treatment. Activated T-cell numbers (CD4+CD25+) were also signifi cantly 
reduced in spleen, lymph node and blood with both low and high dose treatment as 
compared to the untreated controls (fi gure 3.3E). Thus, both low and high FK506 dosing 
led to repression of T cell activation, albeit that this effect was less pronounced after low 
than after high dose treatment.
The infl uence of low/high FK506 on Treg frequency
Immunohistochemical analysis showed that FoxP3+ cells were completely absent in 
the intima of atherosclerotic lesions of all the vessel fragments of 26 mice. FoxP3+ 
cells were detected in the adventitia, but at very low numbers (table 3.3), that did not 
allow statistical analysis. To examine the Treg population more in detail, single-cell 
suspensions of spleen, lymph node and blood were analyzed by FACs to determine 
the frequency of FoxP3+ cells within the CD3+ population (Figure 3.3F). High but not 
low FK506 treatment signifi cantly reduced the relative FoxP3+ content in spleen. FoxP3 
mRNA expression in spleen was not signifi cantly infl uenced by FK506 treatment (fi gure 
3.4). 
To examine if FK506 in vitro treatment might infl uence the viability of T cells, splenocyte 
viability was quantitatively measured. The number of viable cells after 72 hours of 
FK506 in vitro treatment was not different compared with control group (fi gure 3.5).
Effects of low/high dose FK506 treatment on NFκβ and NFAT signaling
The effect of low/high FK506 dosing on NFκβ activity in vivo was measured by 
quantitative real time PCR of IκB-α and NFκB-responsive genes such as ICAM-1 
and P-selectin11 in spleen. Both the low and high dose of FK506 did not alter Iκβ-α 
expression (fi gure 3.6A), nor did it change the expression of P-selectin and ICAM-1 
(fi gure 3.6B and C). The ratio of NFATC1 to NFATC2 has previously been shown to 
be instrumental in T-cell differentiation and polarization12. To investigate whether 
low and high dose FK506 differentially regulated NFATC1 and NFATC2 activity and 
thus Th cell polarization and T-cell-derived cytokine production we examined nuclear 
expression of NFATC1 and NFATC2 in FK506 treated Jurkat T cells by western blot 
as shown in Figure 3.7A. Densitometry analysis of NFATC1, NFATC2 protein bands 
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Figure 3.3 Flow-cytometric analysis of the effect of low and high dose FK506-treatment on % CD3+ T cells 
(A), % CD4+ of  CD3+ T cells (B), % CD8+of  CD3+ T cells (C), CD4+ to CD8+ ratio (D), CD4+CD25+ T 
cells of total cells (E), and % FoxP3 of CD3+ T cells (F) in spleen, lymph node and blood. *p< 0.05.
Table 3.3. Immunohistochemistry staining of FoxP3
Treatment
group
Ratio * Total nr of positive 
Foxp3 cells in 
adventitia
Total sections
 checked
Nr of Foxp3
 positive cells
per mouse
Nr of Foxp3
positive cells per
section
Control 0/9 0 45 0 0
Low 2/8 7 26 0.875 0.27
High 2/9 2 44 0.2 0.05
* Number of mice positive of FoxP3 in adventitia divided by the total number of mice
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Figure 3.6 IКβ (A), P-selectin (B) and ICAM 1 (C) 
mRNA expression in spleens of mice that received 
4 weeks FK506 treatment was measured by Q-
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Figure 3.4 FoxP3 mRNA expression in spleen of 
mice that received 4 weeks FK506 treatment was 
measured by Q-PCR (normalization for cyclophi-
lin).
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relative to that of TATA-binding protein showed that nuclear expression of NFATC2 
in Jurkat cells was signifi cantly reduced at low as well as high FK506 concentrations 
(Figure 3.7B). Nuclear NFATC1 expression was similarly affected by FK506 exposure, 
albeit that this effect did not reach signifi cance (fi gure 3.7C). Furthermore, low and high 
FK506 concentrations both did not differentially affect the NFATC1/C2 ratio in nuclear 
extracts of Jurkat T cells (fi gure 3.7D).
Next we set out to measure IL-4, IL-10 and IFN-γ secretion patterns by CD4+ T cells 
isolated from control mice versus mice that received low and high dose treatment with 
FK506. Importantly a low dose of FK506 (0.05 mg/kg/day) was seen to signifi cantly 
increase IL-4 to IFN-γ (fi gure 3.8A) and IL-10 to IFN-γ ratios (fi gure 3.8B), whereas high 
dose FK506 (1 mg/kg/day) signifi cantly reduced the IL-10 to IFN-γ ratio compared 
with the PBS treatment group (fi gure 3.8B). Incubation of CD4+ T cells with low and 
high concentrations of FK506 in vitro reduced both IL-10 and IFN-γ production by 
CD4+ T cells (data not shown). However, consistent with the increased IL-10/IFN-γ 
ratio observed after in vivo treatment, low FK506 concentrations dramatically increased 
the IL-10/IFN-γ ratio, while high FK506 concentrations were not effective (Figure 3.8C).
In the next experiment, we used Jurkat T cells to verify our observations in CD4+ T cells. 
IL-10 and IFN-γ secretion were signifi cantly suppressed by both 20 ng/ml and 2000 
ng/ml FK506 (fi gure 3.8D and E). Interestingly, high concentrations of FK506 (2000 ng/
ml), even led to upregulation of IFN-γ secretion (fi gure 3.8E). In agreement with our 
earlier fi ndings in CD4+ T cells, the IL-10/IFN-γ ratio was dramatically up-regulated at 
low concentrations of FK506 and normalize to base levels at higher concentrations of 
FK506 (Figure 3.8F).
To assess the general validity of our fi ndings, we extended the study to THP-1 
macrophages. IFN-γ and IL-10 secretion was analyzed in PMA-stimulated THP1 cells. 
As shown in fi gure 3.9, IL-10 secretion was signifi cantly increased by 20 ng/ml of FK506, 
whereas 2000 ng/ml did not infl uence IL-10 secretion. IFN-γ secretion in the supernatant 
was not detectable (data not shown). The latter is consistent with previous studies that 
macrophages do not release signifi cant amount of IFN-γ with LPS stimulation 13, 14.
Discussion  
Infl ammation plays an important role in atherosclerosis formation, rendering 
immunosuppressive therapy an attractive therapeutic modality in the treatment of 
this disease. Though the immunosuppressive drug FK506 is widely used in clinical 
transplantation, diverse side effects of this drug in clinical dosage limit its utility in 
other applications such as the promising treatment of (auto)immune diseases and 
atherosclerosis15. We have in this study investigated the dose-dependent effect of 
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B C
Figure 3.7 NFATC1/NFATC2 nuclear expression. 
Western blot analysis of nuclear extracts from un-
treated Jurkat T cells or cells treated with low and 
high dose of FK506 (loading 30 ug protein/lane; 
n=6 in each group). Western blots were probed with 
anti-NFATC1 and anti-NFATC2.  Probing with anti-
TATA binding protein was used as nuclear loading 
FK506 on collar-induced carotid atherogenesis in apoE-/- mice. This is an extension of 
our previous study1 in which only the low dose regime was applied in the treatment 
of atherosclerosis. Consistent with our previous study, low dose of FK506 markedly 
reduced atherosclerosis. High dose treatment on the other hand did not protect against 
atherosclerosis at all. Plaque morphometry and morphology were not infl uenced by 
FK506 treatment regardless of the dosis. Mice weight and kidney morphology were 
not affected by low or high dose treatment either. FACs analysis showed that both low 
and high FK506 treatment signifi cantly reduced systemic CD3+ and CD4+CD25+ T cell 
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control. Representative western blot was shown in A. Signal intensities of NFATC1, NFATC2 and TATA 
binding protein were determined by densitometry analysis. Nuclear NFATC2 and NFATC1 expression 
relative to that of TATA binding protein is shown in (B) and (C), respectively.  The ratio of NFATC1/
NFATC2 was determined on the basis of data from (B) and (C) and is shown in panel (D). Values repre-
sent mean values + S.E.M;  *p< 0.05.
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Figure 3.8 (A and B) Effects of FK506 on IL-4:IFN-γ ratio (A) and IL-10:IFN-γ ratio (B) secreted by CD4+ 
T cells isolated from splenocytes of mice treated with 0.05mg/kg/day and 1 mg/kg/day of FK506 and 
control mice. Isolated CD4+ T cells were stimulated with PMA (4ng/ml for analyzing IL-4 and IFN-γ; 
1ng/ml for analyzing IL-10 and IFN-γ) and Ionomycin (500nM). Cytokine concentration in the cell cul-
ture supernatants was determined by ELISA. 4 mice per group, n=12-14 wells in each group. (C) Effects 
of FK506 on IL-10/IFN-γ ratio of CD4 T cells isolated from splenocytes of 3 apoE-/- mice. Isolated CD4+ 
T cells were pretreated with FK506 of 0, 20 ng/ml and 2000 ng/ml for 1 hour before stimulated with 
PMA(16ng/ml) and Ionomycin (2000nM). Cytokine in the cell culture supernatants was determined by 
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ELISA. n=8 per group.Effects of FK506 on IL-10 (D) and IFN-γ (E) of Jurkat T cells. Jurkat T cells were 
pretreated with FK506 of 0, 20, and 2000 ng/ml for 1 hour. Cells were then stimulated with PMA (8ng/
ml) and 1000nM ionomycin. Cytokine in the cell culture supernatants was harvested after 48 h. ELISA 
was used to determine cytokine level. (F) Effects of FK506 on IL-10/IFN-γ ratio of Jurkat T cells.Values 
represent mean values + S.E.M; n=6 per group; *p< 0.05.   
Figure 3.9 Effects of FK506 treatment on IL-10 pro-
duction by PMA stimulated THP1 cells. Cells were 
treated with FK506 at a dose of 0, 20 and 2000ng/
ml for 32 hours and LPS of 25ng/ml for 8 hours 
(n=5). LPS was added 24 hr after FK506 treatment. 
Supernatants were harvested to analyze human 
IL-10 concentration by ELISA. Values represent 
mean values + S.E.M; single asterisk, *p< 0.05
population.  
In a subsequent experiment, it was shown that both the low and high dose of FK506 
did neither change splenic gene expression of IkB nor that of NFκB responsive genes 
(P-selectin and ICAM-1). Therefore, we conclude that the differential effects of the low 
and high dose of FK506 are not attributable to differential regulation of NFκB signaling 
in lymphatic tissue.
Wu et al recently showed that NFAT cooperates with the Treg specifi c transcription 
factor FoxP3 to control Treg suppressive function16. Therefore, FK506 treatment might 
indirectly infl uence Treg function by preventing NFAT to interact with FoxP3. Our 
FACs analysis showed that the high dose but not the low dose of FK506 treatment 
signifi cantly reduced the percentage of FoxP3+ CD3+ T cells in spleen. Thus, besides 
reducing CD3+, CD4+, and CD4+/CD25+ T cell counts, high dose FK506 treatment 
also suppressed Treg frequency, whereas low dose treatment did not infl uence Treg 
frequency. Different effects of the low and high dose treatment on Treg numbers 
may suggest a dose-dependent difference in Treg response. This was confi rmed in 
subsequent in vitro studies, which demonstrated that low dose FK506 shifted the CD4+ 
T cell balance towards a Th2 phenotype characterized by an anti-infl ammatory cytokine 
profi le, while the high dose regime favored a Th1-type cytokine response. It should be 
noted that FK506 only subtly infl uenced the balance rather than completely polarizing 
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towards a Th1 or Th2 response, which could lead to de-regulated Th1 or Th2 immune 
responses17. 
Given the recent data on the interaction between NFAT and regulatory T-cell activity16, 
we investigated whether NFAT can act as regulator of the Th1/Th2 balance. NFAT 
proteins are expressed in most cells of the immune system where it plays a pivotal role 
in the transcription of cytokine genes and other genes critical for the immune response. 
Among NFAT family members, NFATC1 and NFATC2 appear to be the major isoforms 
relevant to T cell activation. NFATC2 and NFATC1 are critically involved in T helper 
cell differentiation and regulation of Th1 and Th2 cytokine gene transcription12. An 
increased nuclear localization of NFATC2 correlated with poor Th2 and robust Th1 
differentiation, whereas low levels of NFATC2 nuclear localization promoted Th2 
differentiation12, 18. Thus, the NFATC1/NFATC2 ratio has been used as a measure of Th 
cell differentiation, where a relative decrease in NFATC2 nuclear localization correlated 
with an increase in Th2 cytokine transcription, and vice versa12. We demonstrate here 
that low/high doses of FK506 markedly suppresses nuclear NFATC2 and to a lesser 
extent also NFATC1 expression. FK506 did however not differentially affect nuclear 
NFATC1/C2 ratios depending on its dosis. Therefore, the observed Th2 shifted cytokine 
response with low dose FK506 treatment is not likely attributable to an altered balance 
in NFATC1/C2 transcriptional activity.
Low dose treatment of FK506 appears to induce a subtle shift towards an atheroprotective 
immune response. Atherosclerosis is generally thought to be a Th1 dominated 
infl ammatory disorder. A low dose of FK506 might slightly tilt the balance towards a 
Th2 immune response by virtue of its ability to fi ne-tune Th2 type immune responses 
which could in turn result in the reduction of atherosclerosis observed in this study. 
Although, high dose FK506 treatment vice versa has been reported to aggravate disease 
progression5, we did not observe such trend in our study as IL-4/IFN-γ ratios did not 
differ from that of untreated controls. 
The effects of FK506 on cytokine production have been intensively studied. It is well 
known that FK506 can suppress cytokine secretion and especially Th1 related cytokines 
such as IFN-γ and IL-219. Direct effects of FK506 on Th2 mediated cytokine production 
or the Th1: Th2 cytokine balance however, have not been thoroughly investigated. A 
single study reported that FK506 was able to induce Th-2 promoting IL-4 production 
by dendritic cells20. Moreover, a correlation was observed between FK506 treatment 
and the development of food allergy in post-transplant patients21, indicative of a Th2 
switch upon FK506 treatment. Consistent with the above observations of a direct role of 
FK506 in Th2 activity, we found in CD4+ T cells, Jurkat T cells and THP1 cells that low 
dose FK506 (0.05 mg/kg/day) enhanced the Th2:Th1 ratio while high dose treatment 
reversed this effect.
45
Effect of FK506 on atherosclerosis
Besides FK506, other immunosuppressive drugs, for instance mycophenolate mofetil 
(MMF), sirolimus, cyclosporine A and their concomitant anti-infl ammatory effects 
have been studied in atherosclerotic animal models22. MMF and sirolimus showed a 
consistent atheroprotective potential. Regarding cyclosporine A and FK506, results in 
animal studies are rather contradictory, probably due to specifi c animal models used 
and large-differences in dosages22. As we show, the dosage could very well be of vital 
importance as many of the side-effects of FK506 and cyclosporine A reported in patients 
occur at high-dose and long-term regimes. Indeed our animal study indicates that only 
low dose suppressed atherosclerosis, whereas high dose did not. The fi ne-tuning effect 
of FK506 on the Th1/Th2 balance renders it a potential therapy for long-term treatment 
of chronic-infl ammatory disease such as atherosclerosis.
In summary, low and high dose of FK506 differently affect atherogenesis. We show 
that this differential effect of low versus high dose FK506 unlikely involves the NFκB 
signaling cascade in lymphatic tissue. Our fi ndings instead indicate that low dose FK506 
protects against atherosclerosis by skewing T-cells towards a Th2 immune response, 
whereas the high dose did not. The fact that low dose treatment of FK506 only induces 
a mild shift in Th1/Th2 balance also implies that it might be very effective for long-term 
therapy in Th1 dominated immune disorders such as atherosclerosis.
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Abstract 
The immunosuppressive drug FK506 (tacrolimus), is widely used in patients following 
transplantation. In a previous study, we showed that low-dose FK506 treatment 
inhibited the initiation of collar-induced atherosclerosis in apoE-/- mice. An abdominal 
aortic aneurysm (AAA) is a permanent dilation of the arterial wall of the abdominal 
aorta. Infl ammatory processes play a signifi cant role in this vascular pathology. 
Given the infl ammatory feature of AAA and potential immunosuppressive effect of 
low-dose FK506, we hypothesized that low-dose FK506 treatment would decrease 
AAA formation. To test this hypothesis, we investigated the effect of low-dose FK506 
treatment in angiotensin II (Ang II)-induced aneurysm formation in the abdominal 
aorta of apoE-/- mice.
Contrary to our expectations, FK506 treatment did not protect against murine AAA 
formation.  The distinct pathological characteristics of atherosclerosis and aneurysm 
formation might explain the differential effect of low-dose FK506 in these vascular 
pathologies.  
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Introduction
AAA is a permanent dilation of the arterial wall1. Degradation of elastin and collagen 
weakens the aortic wall and allows the aneurysm to develop.
A history of atherosclerotic disease has been considered as the primary cause of AAA2. 
One of the most affected site by the atherosclerosis is the infrarenal abdominal aorta, 
which is also the most common site of AAA2. In addition to atherosclerosis as a possible 
predisposing factor for aneurysm formation, several other factors are thought to be 
involved, including genetic predisposition, infl ammation, hemodynamic factors and 
structural remodeling of the extracellular matrix (ECM)2,3.
The role of infl ammatory cells in AAA formation has been studied intensively. Treska 
et al showed that higher expression of IL-6, IL-8  and TNF-α were found in the walls of 
ruptured aneurysms compared to non-ruptured aneurysms4. Many cells within these 
infl ammatory infi ltrates were stained positive for the leukocyte common antigen, CD454. 
Satta et al showed that the infl ammatory infi ltrate was largely mononuclear and located 
at the media and adventitia junction of human AAA. Immunophenotypic analysis of 
the infl ammatory cells indicated the presence of T cells, B cells and macrophages in 
variable numbers and only occasional neutrophils. Furthermore, the presence of elastin 
degradation was associated with increased mononuclear infl ammatory cell infi ltrates5. 
Among mononuclear cells, T cells may play a signifi cant role in AAA formation given 
the observation that human aneurysm tissue displayed substantial presence of identical 
β-chain T cell receptor transcripts6.
In our previous study, low-dose FK506 treatment inhibited the initiation and 
progression of collar-induced atherosclerosis in apoE-/- mice7. FK506, a macrolide 
antibiotic with major immunosuppressive properties, is used to prevent rejection after 
organ transplantation8. At a molecular level, FK506 enters the cytoplasm and binds to 
the intracellular protein FK506 binding protein (FKBP)9. This complex binds and blocks 
calcineurin, a Ca2+-calmodulin-regulated protein phosphatase. As a consequence, 
calcineurin fails to dephosphorylate the cytoplasmic component of NFAT, thereby 
inhibiting transport of NFAT to the nucleus and NFAT-AP1 function in transactivating 
cytokine genes, genes that regulate T cell proliferation and other genes that orchestrate 
an active immune response. 
Given the infl ammatory features of AAA and the immunosuppressive function of 
FK506,  we hypothesized that FK506 treatment would protect against AAA. To test this 
hypothesis, a murine model of Ang II-induced AAA was used to study the effect of 
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FK506 treatment on aneurysm formation. Surprisingly, our data showed that low-dose 
FK506 treatment did not reduce AAA formation.
Materials and Methods
Animals
Male apoE-/- mice at 10-12 weeks of age on a C57Bl6 background were obtained from 
Charles River (Maastricht, Netherlands). Animals were maintained in accordance 
with the Dutch government guidelines and animal experiments were approved by the 
regulatory authority of the University of Maastricht. Mice were fed a normal chow diet 
throughout the experiment.
Chronic Ang II infusion to induce aneurysm formation and FK506 treatment
Aneurysm formation was induced by subcutaneous Ang II infusion10. Alzet mini-
osmotic pumps (Alzet type 2004) containing Ang II dissolved in phosphate buffered 
saline (PBS) (10 mM sodium phosphate, 150 mM sodium chloride; pH=7.4) were 
implant ed into apoE-/- mice (n=20) to result in the subcutaneous delivery of 1 ng/g/
min of Ang II for 28 days.  To study the effect of FK506 on Ang II-induced aneurysm 
formation, pumps were fi lled with equal volume of Ang II and FK506 dissolved in PBS 
in apoE-/- mice (n=18) to mediate the subcutaneous delivery of 1 ng/g/min of Ang II 
and 0.05 mg/kg/day for 28 days. Pumps were placed subcutaneously in the neck of 
anesthetized mice through a small incision that was closed using a silk suture (5-0).
Tissue harvesting and histological analysis
Aortic tissue from mice which died preliminary was dissected and fi xed in 1% 
paraformaldehyde and embedded in paraffi ne. After 4 weeks of Ang II infusion and 
FK506 treatment, mice were sacrifi ced and the arterial system was perfused with PBS 
containing 0.1 mg/ml nitroprusside (Sigma) through a catheter inserted into the left 
cardiac ventricle and subsequently with 1% paraformaldehyde. Aortic tissue was 
removed from the ascending aorta to the aortic bifurcation, fi xed overnight in 1% 
paraformaldehyde and embedded in paraffi ne. Ten cross-sections (4 μm thick) were 
cut at 200 μm intervals throughout the abdominal aorta starting at the middle of the 
aneurysm. From each level, a cross-section was stained with elastica von Gieson (EvG) 
for analysis of aneurysm area. Morphometric analysis was performed by one blinded 
investigator (LB, intra-observer variability was < 10%). 
Quantifi cation of Aneurysm Formation
Aneurysm severity was analyzed according to Daugherty et al11. In this scoring system, 
type 0 depicts no aneurysm (the suprarenal region of the aorta was not obviously 
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different from naive apoE-/- mice without Ang II treatment; type I depicts a dilated 
lumen with no thrombus; type II depicts remodeled tissue often containing thrombus; 
type III depicts a pronounced bulbous form of type II containing thrombus; and type 
IV depicts multiple aneurysms containing thrombus. To analyze this measurement 
semiquantitatively, the numerical score allocated to the type of aneurysm for each mouse 
in a group was averaged to generate a pathology score for statistical comparison12.
Statistical analysis
Values are expressed as mean + SEM and a Mann-Whitney non-parametrical test 
was used to compare individual groups of animals. Probability values of < 0.05 were 
considered signifi cant. 
Results
FK506 treatment did not protect against Ang II-induced aneurysm formation
Infusion of Ang II for 4 weeks induced AAA formation in 60% (12 out of 20, n=20 mice) 
of the mice without FK506 treatment and 44% (8 out of 18, n=18 mice) of mice with 
FK506 treatment. No aneurysm formation was found in 8 control and 10 FK506-treated 
mice.
The death of mice was caused by the rupture of the aneurysm. Fatal ruptures (death 
caused by rupture of aneurysm) were found in 15% of the control group (3 out of 
20). Comparable numbers were found in FK506-treated mice (22%, 4 out of 18). The 
occurrence of non-fatal rupture was also similar in control versus FK506-treated mice, 
occurring in 45% (9 out of 20) of the control group and 22% (4 out of 18) of the FK506 
treated mice (fi gure 4A). The majority of AAAs in both groups were characterized as 
type III (fi gure 4B)11. FK506 treatment also did not change the pathological score of the 
AAA (fi gure 4C). There was no difference between control and FK506-treated mice in 
the abdominal aneurysm area and lumen area as shown in fi gure 4D. 
Discussion
In our previous study, inhibition of calcineurin signaling pathway by FK506 at a low 
dose resulted in an athero-protective effect. In addition, the low dose of FK506 was 
able to suppress systemic T cell numbers in vivo and cytokine production in vitro. 
This triggered us to further investigate the effect of FK506 on aneurysm formation as 
infl ammatory processes play a signifi cant role in this vascular pathology. In contrast 
to our expectations, low dose FK506 treatment did not protect against AAA formation. 
The distinct pathological characteristics of atherosclerosis and aneurysm formation 
might explain the different effect of low dose FK506 in these vascular pathologies. Thus 
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although aneurysms occur in the context of atherosclerosis13, the majority of patients 
with advanced atherosclerosis do not develop an aneurysm13, 14. Conversely, patients 
that have no signs of atherosclerotic disease are presented with aneurysm formation14. 
Mechanisms involving a balance in cytokine secretion have been put forward to explain 
the differences between these two vascular pahtologies. A number of studies clearly 
indicated that human aneurysmal tissue was characterized by the predominance of Th2 
cytokines and a lack of Th1 cytokines15,16,17, although there are also reports showing 
elevated Th1 cytokines in patients with aneurysms18, 19. Shimizu et al proposed that 
aneurysm formation required initial infl ammatory cell recruitment which is characterized 
as a shift to Th1 response. However, when the local environment is skewed toward 
a Th2 reaction, aneurysms would progress14. As shown in chapter 3, low-dose FK506 
treatment was able to induce a moderate Th2 skewing by increasing the IL-4/IFN-γ and 
IL-10/IFN-γ ratio in CD4+ T cells, Jurkat T cells and PMA-differentiated THP1 cells. 
Thus, low-dose FK506 treatment resulted in skewing to a mild Th2 response, which 
might theoretically promote AAA progression. This, however, was not observed in our 
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study. We hypothesize that the differences in T cell polarization in either atherosclerosis 
or aneurysm formation may underlie the differential effect of low dose FK506 treatment 
in these two vascular pathologies. This, however needs further study. 
Many different immune cells have been linked to the initiation and the development of 
AAA20. In addition to macrophages, T and B cells have been shown to be present in human 
and mouse AAA lesions20. In addition, a signifi cant increase in mast cell numbers was 
observed in adventitia in AAA patients compared with control groups21. Furthermore, 
treating Ang II-infused apoE-/- mice with Tranilast (a mast cell degranulation inhibitor) 
signifi cantly reduced the dilatation of the aorta and the infl ammatory response 
compared with the untreated group21. FK506 inhibited mast cell cytokine production22, 23 
and inhibited cytokine secretion of IL-2, IL-3, IL-4 and granulocyte-macrophage colony 
stimulating factor by MC/9 cells (the mast cell clone)22. Furthermore, FK506 inhibited 
histamine release by peritoneal mast cells more potently compared with clinically used 
steroids23. Protease release by mast cells are thought to be involved in the pathogenesis 
of AAA20. However, the effect of FK506 on mast cell protease release is not clear. It is 
thought that  elastin degradation will critically contribute  to AAA formation1. Given 
the fact that a MMP inhibitor was able to signifi cantly inhibit AAA formation24, it is 
possible that inhibition of proteolytic activity is more effective than cytokine inhibition 
in the treatment of AAA formation. 
In addition to infl ammatory cells, growth factors have been intensively investigated 
on their roles in AAA formation (reviewed in20). TGF-β has been the subject of may 
investigations20. Firstly, heterozygous mutations in either type I or type II TGF- β receptor 
lead to more intense TGF-β signaling and this increased TGF-β signaling was correlated 
with increased incidence of AAA in patients25. Secondly, murine AAA formation was 
associated with increased TGF-β signaling and could be prevented by either a TGF- β 
antagonist or an Ang II type 1 receptor (AT1) blocker26. Ang II is known for its role 
in the initiation and propagation of AAA27. In addition, Ang II induced the secretion 
of thrombospondin-1 in human mesangial cells28 and thrombospondin-1 is a potent 
inducer of TGF-β activation28. A link between TGF-β and FK506 has been reported, thus 
FK506 promoted TGF-β receptor transphosphorylation in a mink epithelial cell line29. 
In addition, FK506 activated the TGF-β signaling by inducing Smad phosphorylation 
and nuclear translocation in vascular smooth muscle cells (SMC)30. Based on the data 
provided above, FK506 treatment might even enhance AAA formation. Nevertheless, 
FK506 did not infl uence AAA in our study. Despite the above evidence showing the 
involvement of TGF- β in the pathogenesis of AAA, there is also literature suggesting 
that TGF-β could maintain ECM integrity and inhibit mast cell function (reviewed in 
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20). On the one hand, TGF-β can promote ECM degradation31-33, stimulate the growth 
of bone marrow-derived mast cells34 and induce mast cell protease release35-37; on the 
other hand, TGF-β can stimulate collagen I38 and III 39synthesis by both fi broblasts 
and myofi broblasts, and in addition induce mast cell apoptosis40 and inhibit mast cell 
maturation, all factors that could protect against AAA formation or progression41. The 
bipolar nature of TGF-β during AAA needs further study.
In conclusion, our study showed that low-dose FK506 did not protect against Ang II-
induced AAA formation in apoE-/- mice and suggest no therapeutic opportunities of 
low dose FK506 in the treatment of AAA.
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Abstract
Nuclear Factor of Activated T-cells C2 (NFATC2) is expressed in several leukocyte 
subsets and is a crucial transcriptional regulator of numerous infl ammatory genes 
during immune responses. The recently reported role of NFATC2 in regulatory T-cell 
function as well as the fi nding that the NFAT inhibitor FK506 diminished atherosclerosis, 
suggestive of a pro-atherogenic role of this protein, led us to investigate the effect of 
leukocyte defi ciency of NFATC2 on atherosclerosis.
Contrary to our expectations, NFATC2-/- bone marrow transplanted LDLr-/- mice 
showed signifi cantly increased lesion area and progression in the aortic arch. While 
plaque macrophage, CD45+ cell and collagen content were unaltered, CD3+ T cell 
content was sharply increased in lesions of NFATC2-/- chimeras. FACS analysis of 
T-cell subsets revealed a marked decrease in CD4/CD8 ratio and a general shift 
from naïve T-cells towards migratory CD44hiCD62Llow effector/memory T-cells in 
NFATC2 defi ciency. In concert with the latter, grafting of NFATC2-/- T-cells in spleen 
was impaired, whereas homing to the atherosclerotic plaque was 2.7 fold increased. 
Moreover, NFATC2 defi cient T-cells displayed enhanced CD3 expression, a mitogenic 
response to CD3 activation and impaired IL-10 production, which was not attributable 
to a change in regulatory T cell function. Collectively, our fi ndings suggest that NFATC2 
defi ciency translates in augmented rather than compromised T-cell response, which 
may underlie the aggravated atherogenic response in NFATC2-/- mice.
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Introduction 
The transcription factor Nuclear factor of activated T cells (NFAT) is essential for an 
adequate immune response 1.  It is expressed in a variety of immune cells such as T and 
B lymphocytes, natural killer cells2, monocytes3 and myeloid cells4.  The NFAT family 
encompasses fi ve well-characterized members with NFATC1 and NFATC2 as major 
isoforms relevant to T cell activation5. NFATs regulate the induction of expression of 
several cytokine genes, such as interleukin (IL)-2, IL-3, IL-4, IL-5, interferon (IFN)-γ, 
tumour necrosis factor (TNF-α), granulocyte-macrophage colony-stimulating factor, 
and TNF family members, such as CD40L, CTLA-4, and FasL1. However, NFAT family 
members C1 and C2 were also reported to regulate T helper (Th) cell differentiation 6 and 
mice defi cient in NFATC2 showed modest splenomegaly with hyperproliferation of T- 
and B-lymphocytes and an enhanced allergic phenotype characterized by eosinophilia 
in vivo and in vitro2, 7-9. Despite the pleiotropic activity of NFAT, intervention in NFAT 
signaling by immunosuppressants such as FK506/tacrolimus is widely regarded as an 
effective therapeutic strategy in a number of chronic infl ammatory and autoimmune 
disorders as well as in transplant rejection10-12. Several lines of evidence indicate that 
NFAT is implicated in chronic infl ammatory processes that underlie atherosclerosis as 
well. Firstly low dose treatment with FK506 inhibited the initiation and progression of 
collar-induced atherosclerosis in apoE-/- mice13, although the actual molecular NFAT 
target mediating this effect remains to be identifi ed. Secondly, NFATC2 was recently 
reported to control regulatory T-cell function and its defi ciency led to a Th2 biased T-cell 
response2, 14, 15, both processes that were shown to attenuate the atherogenic response. 
However, no data is available on its role in atherosclerosis. On the basis of these fi ndings, 
it is conceivable that NFATC2 defi ciency in hematopoietic lineages will protect against 
atherosclerosis. Here, we show that, contrary to our hypothesis, leukocyte NFATC2 
defi ciency deteriorated atherosclerosis. NFATC2 defi ciency led to augmented rather 
than compromised immune responses. NFATC2 defi cient T cells showed an enhanced 
proliferative activity and displayed a memory/activated T cell phenotype more prone 
to migrate to the atherosclerotic plaque, which may have contributed to the exacerbation 
of atherosclerosis. 
Materials and Methods
Animals
Female LDLr-/- mice on a C57Bl6/J background (6- to 8-weeks-old) were obtained from 
Charles River (Maastricht, the Netherlands). The generation of NFATC2 defi cient mice 
has been described previously7. In short, NFATC2 defi cient mice were backcrossed 
seven generations onto the C57Bl6/Sv129 background. Animal experiments were 
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approved by the regulatory authority of the Maastricht University and were performed 
in compliance with the Dutch government guidelines.
Irradiation and bone marrow transplantation (BMT)
One day before the transplantation, LDLr-/- recipient mice were exposed to a single 
dose of 9 Gy of total body irradiation (Rontgen source). Bone marrow was harvested 
by fl ushing femurs and tibias of either WT or NFATC2-/- donor mice with phosphate-
buffered saline (PBS). Single cell suspensions were prepared by passing the cells fi rstly 
through an 19-gauge needle and then a 25 gauge-needle. Irradiated recipients received 
5 x 106 bone marrow cells by injection into the tail vein. BMT-recipient mice were housed 
in sterilized fi lter-top cages and fed a sterilized normal chow diet and sterile drinking 
water containing neomycin (100 mg/L) and polymyxin B (60,000 U/L). Four weeks 
after BMT, drinking water was switched to normal water and the diet was switched to 
a high-cholesterol diet (1.25% cholesterol, D12108, Research Diet) for another 23 weeks 
to induce atherosclerosis.
Characterisation of chimerism and serum lipid levels of LDLr-/-  mice after BMT
Determination of the chimerism in transplanted mice was performed as described 
previously16. Genomic DNA isolated from the blood of recipient LDLr-/- mice, at 27 
weeks after BMT using the Illustra blood genomic prep Mini spin kit (GE Healthcare). 
The standard curve was composed of DNA from LDLr–/– and LDLrWT blood mixed 
at different ratios. Chimerism was determined by quantifying the amount of LDLrWT 
DNA in samples from 40 μl peripheral blood. Samples were assayed in duplicate using 
the Taqman IQ TM SYBR Green Super Mix (BIO-RAD). Chimerism was calculated as 
the percentage of LDLrWT DNA in the blood samples. Serum cholesterol levels were 
determined with the CHOD-PAP method (Roche Diagnostics).
His tological analysis of aortic arch for atherosclerosis
Mice were sacrifi ced at 27 weeks after BMT (4 weeks on regular chow diet followed by 23 
weeks on high-cholesterol diet). To study the development of atherosclerosis, sections 
of the aortic arch were prepared and analyzed as described previously17. Briefl y, the 
arterial system was perfused with PBS containing 0.1 mg/ml nitroprusside (Sigma). 
The aortic arch, including its main branch points, was excised and fi xed with 1% 
paraformaldehyde. Forty cross-secti ons (4 μm thick) from the longitudinally imbedded 
aortic arch were cut. A series of twenty sections, which represented the complete arch 
and branch points, were analyzed. Total plaque burden is defi ned as the summed area 
of all aortic arch lesions. Lesions containing only foam cells were categorized as early 
whereas advanced lesions were characterized by the presence of necrotic core and/
or fi brous cap. The relative collagen area in atherosclerotic lesion that was stained 
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positive for Sirius red, was determined under a microscope coupled to a computerized 
morphometry system (Quantimet 570, Leica). Morphometric analysis was performed 
by one blinded investigator (LBai; intra-observer variability was < 10%). 
Immunohistochemical stainings 
Sections were stained with the following antibodies: Rabbit anti-mouse/human CD3+ 
(1:200, Dako) to detect CD3+ T cells, Mac3 rat monoclonal antibody (1:30, BD Biosciences 
Pharmingen) to detect macrophages, CD45 (1:5000, BD Biosciences Pharmingen) to 
detect leukocytes, and cleaved caspase-3 (1:100, Cell Signalling) to detect apoptotic cells. 
To de termine the relative amounts of macrophages, leukocytes and cleaved caspase-3-
positive cells in the lesions, the number of Mac3, CD45 and cleaved caspase-3-positive 
cells in the lesions were divided by the corresponding lesion area. In addition, the 
relative CD3+ T-cell content was calculated by dividing the number of CD3+ positive 
cells by the total number of cells in the lesion or by the corresponding lesion size. All 
measurements were conducted by one investigator (LBai, intra-observer variability was 
< 10%).
Quantitative RT-PCR
RNA was extracted from the spleen lysate with Nucleospin RNA II kit (MACHEREY-
NAGEL). cDNA was generated with iSCript TM CDNA synthesis kit (BIO-RAD). 
Real-time PCR was done with a Taqman IQ TM SYBR Green Super Mix (BIO-RAD). 
Primer sequences of CXCR3, CCR3, CCR4, CCR6, CCR7, Foxp3, 18S and cyclophilin 
were shown in table 5.1. An average expression of 18S and cyclophilin was considered 
reference value for total RNA expression.
Table 5.1
Forward primer (5’-3’) Reverse primer (5’-3’)
 CXCR3 TGCTAGATGCCTCGGACTTT CGCTGACTCAGTAGCACAGC
 CCR3 TGGCATTCAACACAGATGAAA TGACCCCAGCTCTTTGATTC
 CCR4 GGTCTTCCTGCCTCCTCTCT GGACAGGACGAACAGCAAAT
 CCR5 GCCAGAGGAGGTGAGACATC CCAAAGATGAATACCAGGGAG
 CCR7 GTGGTGGCTCTCCTTGTCAT GAAGCACACCGACTCGTACA
 Foxp3 CCAGTCTGGAATGGGTGTCC CTGCTTGGCAGTGCTTGAGA
Cyclophilin CAAATGCTGGACCAAACACAA TTCACCTTCCCAAAGACCACAT
 18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
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Cytokine measurements
Serum levels of IL-6, IL-10, IL-12, and IFN-γ were measured using Cytometric Bead 
Array (552364, BD Biosciences) according to the manufacturer’s instructions.
Splenocytes isolation and cytokine analysis
Spleens from donor NFATC2-/- and WT mice (n=5 mice in each group) were forced 
through mesh screens to yield a single-cell suspension in splenocyte medium (RPMI 
medium supplemented with 25 mM HEPES buffer, 2 mM L-glutamine, 100 IU/
ml penicillin/streptomycin (Gibco), and 10% FCS). Erythrocytes were lysed by 
erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3
 
and 0.1 mM EDTA; pH=7.4) 
for 5 minutes. Thereafter, cells were washed and resuspended in splenocyte medium. 
Splenocytes were seeded in 96-well plates at a density of 5x10
6 
cells/ml. Cells were 
incubated for 48 hours with 1 ng/ml PMA (Sigma) and 500 nM Ionomycin (Sigma) 
(n=9 mice per group). Supernatants were harvested and stored at –80
0
C before analysis. 
Murine IFN-γ and IL-10 were assayed by ELISA using antibodies according to the 
manufacturer’s instructions (BD Bioscience). 
Fluorescence-activated cell sorting (FACS)-analysis
Splenocytes and blood were isolated from the BMT recipient NFATC2-/- and WT 
mice for FACS analysis. Splenocytes were isolated and used to make single-cell 
suspensions. Erythrocytes in peripheral blood and spleen were removed by hypotonic 
lysis with NH4Cl. Cells were incubated fi rst with anti-CD16/32 (eBioscience) to block 
Fc binding and stained with anti-CD3-FITC, anti-CD8-Pacifi c blue, anti-CD4-Pacifi c 
blue (eBioscience), anti-CD25-APC (eBioscience) and anti-CD45R/B220-PerCP (BD-
Biosciences Pharmingen). Foxp3-positive cells were detected with PE anti-mouse/
rat Foxp3 Staining Set, according to the manufacturer’s instruction (eBioscience). 
Splenocytes and peripheral blood leukocytes were further incubated with anti-CD62L-
PE Cy7 (eBioscience) and anti-CD44-PE (BD-Biosciences Pharmingen) to identify 
naïve T cells (defi ned as CD44lowCD62Lhigh) and memory/effector T cells (defi ned as 
CD44highCD62L+).
In vivo traffi cking experiments
WT and NFATC2-/- mice received an intravenous injection of 90ug LPS. Two hours 
after LPS injection, splenocytes from WT and NFATC2-/- mice were isolated and 
labelled with 2 μM CFSE (Invitrogen) in PBS at 37oC for 15 minutes. Labelled cells were 
then incubated in RPMI medium at 370C for 30 minutes to ensure that by-products had 
passively diffused into the extracellular medium. After washing with PBS containing 
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0.1% BSA, 3 x 107 of labelled cells in 0.2 ml of PBS were injected intravenously into 
apoE-/- recipient mice (37- 40 weeks old, 4 received labelled splenocytes from WT mice 
and 5 received labelled splenocytes from NFATC2-/- mice). Forty two hours after the 
injection, mice were sacrifi ced and perfused with PBS. Spleen and aortic arch were 
harvested to identify the amount of CFSE+ positive cells that migrated to spleen and 
atherosclerotic lesions. The percentage of CFSE-labeled splenocytes was determined by 
fl ow cytometry equipped with a 488 nm excitation source.
Perfused aortic arches were placed in Tissue-Tek O.C.T. embedding medium (Miles Inc), 
snap-frozen at -160°C in liquid nitrogen–cooled isopentane (Baxter Scientifi c). Twenty 
cross-sections (4μm thick) from the longitudinally imbedded fresh-frozen aortic arches 
were sectioned. Four sections with a distance of 20 μm each were selected to analyze 
CFSE+ cells in the lesions.  Nuclei were counterstained using Mounting Medium with 
DAPI (VECTOR). Overlay images were acquired using fl uorescence microscope (Leica 
DM 5000B) with the fi lter system I3 to detect CFSE+ cells, and SGR to detect DAPI. 
Lesional CFSE+ cell content was calculated from the total number of CSFE+ cells divided 
by that of all cells in the lesion (n=57 lesions for WT and n=74 lesions for NFATC2-/-). 
Analysis was performed by one blinded investigator (LBai; intra-observer variability 
was < 10%).
T cell proliferation and regulatory T cell function assays
Cell proliferation experiment and regulatory T cell function assay were performed 
as described before18. Cells were purifi ed and pooled from 3 mice per group at the 
time of sacrifi ce. CD4+CD25– cells (0.5x105 cells) were cultured alone or in co-culture 
with CD4+CD25+ cells at diverse concentrations (0.5x105, 0.25x105, 0.12x105, 0.06x105), 
in fl at-bottomed 96-well microplates (total volume 200 μL/well). Cells were stimulated 
with purifi ed soluble CD3-specifi c antibody (1 μg/mL, Pharmingen) in the presence 
of antigen-presenting cells (0.1x105 cells) purifi ed on CD11c-coated magnetic beads 
(Miltenyi Biotech). Cells were cultured at 37°C for 72 hours, pulsed with 1 μCi of (3H) 
thymidine (Amersham) and incubated for another 18 hour. Thymidine incorporation 
was assessed using a TopCount NXT scintillation counter (Perkin Elmer). 
Statistics
Statistical analyses were performed using a nonparametric Mann–Whitney U test. The 
plaque area, plaque composition and the number of CFSE+ positive cells in the lesion 
in the in vivo traffi c experiment was compared with independent sample T test. Data 
are expressed as mean ± SEM. Probability values of < 0.05 were considered signifi cant. 
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Results
Characterization of NFATC2-/- vs WT bone marrow chimeras
At 27 weeks after bone marrow transplantation, blood was collected to determine 
chimerism in white blood cells by quantitative real-time PCR. An average of 96.8% 
of the white blood cells was of donor origin, establishing successful engraftment. The 
degree of chimerism was identical in NFATC2-/- and WT transplanted mice (97.1+0.3 
vs 96.5+0.5 %). Serum cholesterol levels were not different between the two groups 
 Total cholesterol
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0
10
20
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40
m
m
ol
/L
Figure 5.1 Effect of leukocyte NFATC2 defi ciency on 
serum total cholesterol level.
(31.3+2.0 mmol/L vs 27.2+2.6mmol/L, fi gure 5.1).
Hematopoietic deletion of NFATC2 increased atherosclerosis in LDLr–/– mice
Although NFATC2 defi ciency might infl uence infl ammatory status of non-atherosclerotic 
vessels, in this study, we focus on the effect of NFATC2 on atherosclerotic lesions. We 
analyzed 170 aortic arch lesions of the control mice (n=9) and 197 lesions of NFATC2-/- 
transplanted mice (n=8). Total plaque burden did not differ between the two groups 
(Figure 5.2A). However, signifi cantly more plaques of NFATC2-/- transplanted mice 
had progressed to an advanced stage (88% for WT vs 95% for NFATC2-/-, p=0.02, 
Figure 5.2B) and less plaques of NFATC2-/- transplanted mice were retained in the 
early stage of lesion development (12% for WT vs 5% for NFATC2, p=0.02, fi gure 5.2C). 
Average advanced plaque size was signifi cantly increased in NFATC2-/- transplanted 
mice compared to WT control (1.38 + 0.10 μm2 *105 for control vs 1.75 + 0.16 μm2 *105 
for NFATC2-/-, p=0.049, Figure 5.2D). There was no difference in average initial lesion 
size between the two groups ((Figure 5.2E, p=0.917) possibly indicating that NFATC2 
involvement was predominant in advanced plaque development. In particular, plaque 
burden at the subclavia and arcus aortae of NFATC2-/- transplanted mice was increased, 
as compared to that of controls (subclavia: 3.57 + 0.66 μm2 *104 for control vs 5.48 + 0.64 
μm2 *104 for NFATC2-/-, p=0.031; arcus aortae: 1.74 + 0.19 μm2 *105 for control vs 3.41 + 
0.44 μm2 *105 for NFATC2-/-, p=0.001, Figure 5.2F and G). Thus, deletion of NFATC2 in 
hematopoietic cells resulted in an increase in advanced atherosclerotic lesion formation. 
Representative HE stained cross sections of aortic arch were shown in fi gure 5.2H. Full 
color fi gures of HE stained cross-sections are shown on page 172.
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Figure 5.2 The absence of leukocyte NFATC2 did not affect total plaque burden (A). Leukocyte NFATC2 
defi ciency resulted in an increase in the percentage of advanced lesion (B) and decrease in the percentage 
of initial lesion (C) relative to total lesions. Average advanced plaque area was signifi cantly increased 
in NFATC2-/- transplanted mice compared to control (D). However, average initial lesion size was not 
different between the two groups (E). NFATC2 defi ciency increased lesion size in the artery subclavia (F) 
and the arcus aortae (G). H shows representative HE stained cross-sections of control versus NFATC2-/- 
transplanted mice, respectively. Full color fi gures of HE stained cross-sections are shown on page 172.
 *P < 0.05, ** P<0.01 compared with WT. 
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As for plaque composition, the relative CD3+ T-cell content of advanced lesions were 
dramatically increased in NFATC2-/- transplanted mice compared with controls on 
plaque area (9.5 + 2.1 and 3.6 + 1.0 CD3+ T cells/μm2*105, respectively; p=0.017, data 
not shown) as well as expressed as % of total cell counts (3.5 + 1.0 % and 1.1 + 0.3 
%; p=0.024, Figure 5.3A). Representative pictures of CD3+ staining from control and 
NFATC2-/-transplanted mice are shown in Figure 5.3B. Full color fi gures are shown 
on page 172. CD45+ leukocyte (Figure 5.4A) and Mac3+ macrophage numbers (Figure 
5.4B), lipid core size (Figure 5.4C) as well as collagen content (Figure 5.4D) did not differ 
between the two groups. Furthermore, the percentage of cleaved caspase-3-positive 
cells relative to advanced lesion area was not different between the two groups (Figure 
5.4E). Interestingly, the degree of calcifi cation, characterized by mineralization and the 
presence of chondrocytes was dramatically increased in NFATC2 transplanted mice 
compared with control (6.4% for control vs 20.1% for NFATC2-/-, p=0.0003, Figure 
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Figure 5.3 Leukocyte NFATC2 defi ciency signifi cantly increased the amount of CD3-positive cells rela-
tive to total cells in advanced lesions compared with controls. Representative pictures of CD3+ staining 
of aortic arch of control and NFATC2-/- transplanted mice are shown in B. Full color fi gures are shown 
on page 172. Values represent mean ± SEM, *P < 0.05 compared with WT.
WT NFATC2-/-
5.4F). 
Hematopoietic NFATC2 defi ciency alters lymphocyte pattern in spleen and circulation
The remarkable increase in plaque T-cell content prompted further investigation of T-cell 
function and differentiation. Hereto single-cell suspensions of spleen, and blood were 
analyzed for T cell subsets by FACS (Figure 5.5 and 5.6). CD3+ T cell numbers in spleen 
and blood were not altered (Figure 5.5A), while B cell counts were unchanged in spleen 
but signifi cantly increased in blood of NFATC2-/- compared with WT transplanted 
mice (Figure 5.5A). Blood T-cells in NFATC2-/- chimeras displayed a sharply reduced 
CD4+ to CD8+ ratio (Figure 5.5B). Despite this reduced ratio, CD3+ T-cells in blood 
were markedly enriched in CD4+CD25+ T cells in NFATC2-/- transplanted mice 
(Figure 5.5B). Within this subset, not only the blood CD4+CD25+Foxp3+ regulatory 
A B
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Figure 5.4 Infl uence of leukocyte NFATC2 defi ciency on plaque composition. Leukocyte content (CD45 
staining) (A) and macrophage content (Mac3 staining)(B) relative to advanced lesion area were not dif-
ferent between the two groups. Lipid core content (C) and collagen content (D) as measured by a Sirius 
red staining were not different between the two groups. Cells positive for cleaved caspase-3 relative 
to advanced lesion area was not different between the two groups (E). The percentage of calcifi cation 
characterized by mineralization and the presence of chondrocytes relative to non-calcifi ed lesions was 
increased in NFATC2-/- mice compared with NFATC2+/+ (F). Values represent mean ± SEM, ***P < 
0.001 compared with WT.
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T-cells (Treg) but also the spleen CD4+CD25+Foxp3- effector T cells were increased 
with NFATC2 defi ciency (Figure 5.5C). The signifi cant reduction in blood CD4+CD25- 
among CD3+ T cells might account for the decreased CD4/CD8 ratio (Figure 5.5B). 
NFATC2-/- chimeras did not display signifi cant difference in percentage of CD4+, 
CD8+, CD4+CD25+ and CD4+CD25- of CD3+ T cells in spleen (Figure 5.5D). Naïve 
T cells, defi ned as CD44lowCD62Lhigh CD4+ cells, wer e signifi cantly reduced in blood 
of NFATC2-/- transplanted mice, while memory/migratory CD44highCD62Llow T 
cells were increased (Figure 5.6D). Of note, the CD8+ T cell population gave a similar 
pattern with a marked decrease in naïve T cells and a minor, non-signifi cant increase 
in memory T cell numbers in spleen (Figure 5.6E). Focusing on the CD4+CD25+ T cell 
population, we observed a signifi cant decrease in the ratio of naive to memory T  cells 
(Figure 5.6F). Interestingly, not only fewer T-cells were CD62L+,  also mean CD62L 
expression by CD4+, CD8+ and CD4+CD25+ CD62Lhigh T-cells was substantially 
reduced in NFATC2-/- chimeras (Figure 5.6 G, H and I, respectively).
Although CD3+ T cell numbers in spleen and blood were not altered, CD3+ mean 
fl uorescence intensity (MFI) of CD3+ T-cells was markedly enhanced in NFATC2-/- 
transplanted mice (Figure 5.7A). This may point to an increased responsiveness of 
NFATC2-/- T lymphocytes to anti-CD3 antibody treatment. In keeping with this notion 
the mitogenic response of CD4+CD25- T cells upon anti-CD3 antibody treatment in 
vitro, as measured by incorporation of [3H] thymidine was increased by a signifi cant 
30% in NFATC2-/- T-cells (Figure 5.7B).
Splenocyte NFATC2 defi ciency reduces spleen engraftment but enhances homing to 
atherosclerotic lesions
As our FACS showed a marked increase in migratory T-cell subsets and in particular 
central memory T cells in blood and spleen of NFATC2 defi cient BMT recipients, 
we argued that this shift in migratory capacity may have accounted for the higher 
plaque T-cell content in NFATC2-/- chimeras. CSFE+ CD4+ splenocytes isolated from 
NFATC2-/- vs WT chimeras were injected into apoE-/- recipients with established 
atherosclerotic lesions. Forty two hours after injection, CFSE+ cells could be detected 
in recipient spleens as measured by FACS. In agreement with our hypothesis, recovery 
of NFATC2-/- CFSE+ cells in spleen was dramatically reduced compared to that of 
WT CFSE+ splenocytes (Figure 5.8D). In contrast, the percentage of CFSE+ cells of total 
cells in plaque was signifi cantly higher in recipients that had received NFATC2-/- 
CFSE+ splenocytes than in recipients receiving WT CFSE+ splenocytes (Figure 5.8E). 
Representative overlays of images of the aortic arch from apoE-/- mice that receive 
WT and NFATC2-/- CFSE+ splenocytes are shown in fi gure 5.8F. Full color fi gures 
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Figure 5.5 Flow-cytometric analysis of the effect of NFATC2 defi ciency on CD3+, CD4+, CD8+, 
CD4+CD25+  and CD4+CD25+Foxp3 regulatory T cells and B cells in blood and spleen. Percentage of 
CD3+ T cells in blood and spleen was not signifi cantly different in NFATC2-/- transplanted mice com-
pared with controls (A).  B cells in blood were signifi cantly increased in NFATC2-/- transplanted mice 
compared with controls (A).  A reduction of the CD4+ population and an increase in the CD8+ popula-
tion were found in blood of NFATC2-/- transplanted mice (B). A signifi cant increase in CD4+CD25+ 
T cells and decrease in CD4+CD25- T cells were found in blood of NFATC2-/- transplanted mice (B). 
Regulatory T cell population defi ned as CD4+CD25+Foxp3+was increased in NFATC2-/- transplanted 
mice in blood (C). Effector T helper cell population marked as CD4+CD25+Foxp3- was also found to be 
increased in NFATC2-/- transplanted mice in spleen (C). NFATC2-/- chimeras did not display signifi -
cant difference in percentage of CD4+, CD8+, CD4+CD25+ and CD4+CD25- of CD3+ T cells in spleen 
(D). Values represent mean ± SEM, *P < 0.05, **P <0.01, compared with WT.
A B
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are shown on page 173. Thus NFATC2 defi ciency resulted in an enhanced migration 
capacity to infl amed atherosclerotic lesions, while migration to spleen was reduced. 
NFAT defi  ciency in T-cells diminishes IL-10 production and induces T-cell 
proliferation without changing Treg cell function
The next question we addressed was how NFATC2-/- T-cells led to more advanced 
lesion progression. NFATC2 defi ciency did not affect Th1 (IL-6, IFN-γ and IL-12) or 
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Figure 5.6 Flow-cytometric analysis of the effect of leukocyte NFATC2 defi ciency on naïve and memory T 
cell in spleen and blood. (A-C) shown are the dot plot profi les of blood cells stained with anti-CD3+ (A), 
anti-CD4+ and anti-CD8+ on gated CD3+ (B) and CD44 and CD62 L staining on gated CD4+ cells (C). 
In the CD4+ T cell population, the percentage of naïve T cells defi ned as CD44lowCD62Lhigh was reduced 
in blood of NFATC2-/- transplanted mice compared with controls, while memory T cells defi ned as 
CD44highCD62Llow increased (D). In CD8+ T cells, a marked decrease in naïve T cells was found in spleen. 
However, memory T  cells in CD8+ T cells remained unchanged (E). In the CD4+CD25+ T cell popula-
tion, a decrease in native T cells and an increase in memory T cells were observed in spleen and blood 
(F).  (G-I) Flow cytometry analysis of the effect of leukocyte NFATC2 defi ciency on  CD62L mean fl uores-
cence intensity (MFI) of CD62L+ T-cells in spleen and blood. CD62L MFI was signifi cantly increased in 
NFATC2-/- transplanted mice in CD4+CD62Lhigh (G), CD8+CD62Lhigh (H) and CD4+CD25+CD62Lhigh (I) 
subsets. Values represent mean ± SEM, *P < 0.05, ** p <0.01 compared with WT.
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Figure 5.7 Flow cytometry analysis of the effect of leukocyte NFATC2 defi ciency on CD3 MFI of  CD3+ 
in spleen and blood.  A marked increase in CD3 MFI was observed in CD3+ T-cells in blood and spleen 
of NFATC2-/- transplanted mice (A). (B) NFATC2 defi ciency enhanced T cell mitogenic response to 
CD3. Assessment of the proliferation of purifi ed CD4+CD25- T cells (3[H] thymidine incorporation) after 
stimulation with anti-CD3 in the presence of purifi ed WT CD11c+ dendritic cells. An increased T cell 
proliferative response from NFATC2-/- mice compared with NFATC2+/+ mice was evident. Values 
represent mean ± SEM, *P =0.05, ** p <0.01 compared with WT.
A B
72
Chapter 5
WT NFATC2-/-
0
1
2
%
 C
FS
E+
 c
el
ls
 o
f r
ec
ip
ie
nt
 s
pl
en
oc
yt
es
***
Figure 5.8 (A-D): Flow cytometry analysis of splenocytes in recipient apoE-/- mice that received 
splenocytes labeled with CFSE isolated from either donor NFATC2-/- or WT mice. Gated live 
splenocytes were assessed for CFSE. (A) Histogram shows splenocytes isolated from apoE-/- mice with-
out receiving CFSE+ splenocytes. (B) Representative histogram shows splenocytes of recipient apoE-/- 
mice that receive WT CFSE+ splenocytes. (C) Representative histogram show splenocytes of  recipient 
apoE-/- mice that received NFATC2-/- CFSE+ splenocytes. (D) percentage of CFSE+ cells signifi cantly 
reduced in apoE-/- mice that received NFATC2-/- CFSE+ splenocytes. (E) NFATC2 defi ciency led to 
enhanced migration of CFSE+ cells to atherosclerotic aortic arch lesions. CFSE+ positive cells in sections 
from frozen aortic were quantifi ed.  Nuclei were counterstained using Mounting Medium with DAPI. 
Overlay images were acquired using fl uorescence microscope. The number of CFSE+ cells in 
atherosclerotic plaque relative to total number of cells in the plaque was signifi cantly increased in apoE-
/- mice that received NFATC2-/- CFSE+ splenocytes compared with apoE-/- mice that received 
splenocytes from control group (E). F show representative overlays of images of the aortic arch from 
apoE-/- mice that receive WT and NFATC2-/- CFSE+ splenocytes, respectively. Full color fi gures are 
shown on page 173. Values represent mean ± SEM, *P < 0.05, ***P < 0.001 compared with WT. 
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Th2 cytokine levels (IL-10) in circulation (Figure 5.9). Crude splenocytes isolated from 
NFATC2-/- and WT mice were then studied for PMA and ionomycine stimulated-
cytokine secretion. Although NFATC2 defi ciency did not alter IFN-γ secretion (n=9 
mice), it signifi cantly reduced IL-10 secretion (822 + 81 pg/ml for control vs 349 + 47 
pg/ml for NFATC2-/-, p=0.001, Figure 5.10A). Although we previously showed a 
signifi cant enhanced mitogenic response of CD4+CD25- T cells upon anti-CD3 antibody 
treatment, we did not observe any differences in suppressive capacity of Treg cells 
between NFATC2-/- and WT bone marrow transplanted mice (Figure 5.10B), despite the 
marked increase in CD4+CD25+Foxp3 Treg numbers in NFATC2-/- spleen and blood. 
This suggests that the increased mitogenic activity probably refl ects an augmented 
intrinsic response of NFATC2-/- T-cells to CD3 activation.
Hematopoietic deletion of NFATC2 did not alter gene expression of regulatory T cell, 
Th1, Th2 and migratory T cell markers in spleens 
The enhanced T-cell content of NFATC2-/- chimera lesions pointed to effects of NFATC2 
defi ciency on T-cell differentiation, migration or activation status. Therefore we studied 
effects of hematopoietic NFATC2 defi ciency on the T-cell gene expression pattern. 
Expression of FoxP3, a critical transcription factor in the commitment of T lymphocytes 
to the Treg cell lineage19, 20 was not altered in NFATC2-/- and WT-transplanted mice 
spleen. No differences were observed in CXCR3 (Th1 cell marker), CCR3 (Th2 cell 
marker), CCR4 (Treg marker), CCR5 (homing marker for infl ammatory sites), and 
CCR7 (migratory T cell marker for lymphe nodes) gene expression between the two 
groups as well (Figure 5.11).
Discussion
A critical regulator of immune responses, NFAT contributes to a variety of infl ammatory 
and autoimmune disorders. The recent fi nding that NFAT activation is indispensable 
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Figure 5.9 Infl uence of leukocyte NFATC2 
defi ciency on serum cytokine levels. There 
were no differences in the levels of IL-6, IL-
10, IFN-γ and IL-12 in serum of NFATC2-/- 
transplanted mice compared with controls. 
Values represent mean ± SEM.
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Figure 5.10 Effects of NFATC2 defi ciency on cytokine secretion from splenocytes (A). Isolated spleno-
cytes were stimulated with PMA(1ng/ml) and ionomycin (500nM). Cytokine levels in the cell culture 
supernatants were determined by ELISA. NFATC2-/- did not alter IFN-γ secretion, however it reduced 
IL-10 secretion compared with WT. NFATC2 defi ciency reduced IL-10 production, without affecting 
regulatory T cell function (B). Inhibition of proliferation of CD4+CD25– effector T cells after coculture 
with CD4+CD25+ Treg cells. There was no difference in regulatory T cell function in suppressing effector 
T cell proliferation.  **P < 0.01 (Values represent the mean ± SEM), compared with WT.  
Figure 5.11 CXCR3, CCR3, CCR4, CCR5, CCR7 
and FoxP3,  mRNA expression in spleens of 
mice measured by Q-PCR were compared in 
NFATC2-/- transplanted mice and controls 
(normalization by the average of cyclophilin 
and 18S).  There was no difference in gene ex-
pression levels between the two groups. Values 
represent mean ± SEM.
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for regulatory T-cell function15 and Th2 biased immune response 2, 9 suggests a role of 
this transcription factor in Th1 dominated process of atherosclerosis as well21. Indeed we 
previously showed that inhibition of calcineurin/NFAT signaling by low dose FK506 
inhibited the initiation and progression of collar-induced atherosclerosis13, although 
the actual molecular NFAT target mediating this effect remains to be identifi ed. 
In this study, we investigated the role of a major component in NFAT signaling in 
T-cells, NFATC2,  in atherosclerosis. Contrary to our expectations, NFATC2 defi ciency 
in hematopoietic-lineage cells resulted in more advanced lesion development and a 
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dramatic increase in lesional CD3+ T cell content. NFATC2-/- bone marrow recipients 
showed a higher blood B cell content than WT controls. In addition, NFATC2-/- T-cells 
in blood had altered CD4/CD8 ratio and were considerably enriched in CD4+CD25+ 
and in particular in CD4+CD25+Foxp3+ regulatory T cells subsets, although the T-cell 
suppressive activity of the latter subset was unchanged.
Importantly, NFATC2 defi ciency resulted in enhanced memory T cells numbers 
characterized by CD44highCD62low and reduced levels of the CD44lowCD62Lhigh naïve T 
cell phenotype in CD4+ and CD8+ T cells. CD44 expression is important for memory T 
cell extravasation at infl ammatory sites22, whereas CD62L is responsible for homing of 
naïve T cells to and retention in lymph nodes 23. Central memory T cells, unlike naïve 
T cells, are able to respond rapidly to antigen by secreting large amount of effector 
cytokines such as IL-4, IL-5, and IFN-γ, and will subsequently migrate to infl ammatory 
sites, whereas naïve T cells mainly traffi c to lymph nodes24, 25. Conceivably, the increased 
CD3+ T cell content in infl ammatory atherosclerotic lesions in NFATC2-/- transplanted 
mice may be explained by the shifted balance between central memory and naïve T 
cells. This is congruent with the fi nding that central memory T cells are the predominant 
subset in chronically infl amed tissue26.  
The increase in the central memory T cell marker CD44 was particularly pronounced 
within the CD4+CD25+ T cell population. CD4+CD25+ T cells are generally regarded 
as regulatory T cell in nonstimulated naïve mice27, but not necessarily in high-fat fed 
LDLr-/- recipients. CD44hi CD4+CD25+ T cell subset encompasses both self-antigen 
specifi c Foxp3+ memory Treg and Foxp3- effector T cells. The former cells were recently 
reported to constitute a fi rst line of tolerogenic control to self antigens28. Therefore, 
NFATC2-/- transplanted mice displayed a skewing to FoxP3- memory subsets and this 
shift was paralleled by a concomitant increase in memory Treg, possibly representing a 
compensatory response to control T-cell activity. 
NFATC1 and C2 are both expressed and operational in memory CD4+ T cells where they 
are, amongst others, required for IL-2 production. Enhanced NFATC1/C2 transcriptional 
activity was considered instrumental in the rapid response of memory CD4+ T cells 
by mediating cytokine secretion and migration29. Of interest peripheral T cells from 
NFATC2 and C3 double knockout mice were reported to display memory phenotype as 
indicated by elevated levels of CD44 expression on splenocytes30.  This was probably in 
part due to the fact that NFATC2 and C3 double defi ciency impairs the responsiveness 
of the effector T cells to Tregs31. Our study adds to this fi nding, identifying NFATC2 as 
key suppressor of CD44highCD62Llow memory T cell differentiation.
Consistent with the enhanced migratory capacity of T-cells and the higher abundance of 
plaque T-cells in NFATC2 defi ciency, our in vivo traffi cking study clearly demonstrated 
that NFATC2-/- splenocytes preferentially home to sites of infl ammation such as the 
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atherosclerotic lesion compared with WT splenocytes. In contrast spleen grafting was 
strongly reduced, possibly as a consequence of enhanced accumulation of CSFE+ cells 
to plaques or retention in lymph nodes.  
NFATC2 has been shown to directly interact with FoxP3 as part of the transcriptional 
program required for Foxp3 promoter trans activation after triggering of the T cell 
receptor32 and Treg function 15. The balance between initiation of an infl ammatory T(eff) 
cell versus Treg response depends on the nuclear concentration of NFAT to interact 
with Foxp3 or AP1 33. Pharmacological inhibition of NFAT dephosphorylation with 
cyclosporine A in CD4+CD25- T cell favored Treg activity 14. In this study, however, 
we found that while CD4+CD25+ Treg cell numbers were increased in NFATC2-/-, 
their intrinsic suppressive activity was unaltered. Thus the stronger proliferative 
response of NFATC2-/- responder T cells to CD3 activation was not attributable to 
compromised Treg function with NFATC2 defi ciency but might be associated with the 
enhanced CD3+ expression on T lymphocytes in these mice. As NFATC2 defi cient Treg 
function remained intact, Treg function was not exclusively dependent on NFATC2 
transcriptional activity.
It has been described that NFATC2-/- mice exhibit a Th2 dominated pro-allergic 
phenotype 2, 7-9. However, NFATC2-/- transplanted mice did not show any differences 
in Th1 (IL-6, IFN-γ and IL-12) or Th2 cytokine levels (IL-10) in serum compared with 
WT controls. IL-10 secretion by PMA/ionomycin elicited NFATC2-/- T-cells was 
substantially lower than that by WT T-cells, pointing to a pro-atherogenic Th1 polarized 
T-cell response. The reduct ion of IL-10 secretion in NFATC2-/- splenocytes might not 
be caused by changes in IL-10-producing memory T cell numbers as IL-10 producing T 
help cells lack a memory for IL-10 expression 34. The effects of NFATC2 on Th2 cytokine 
transcription are complex and poorly understood.  Anti-CD3-injected NFATC2-/- 
mice exhibited a striking defect in the induction of IL-4 in splenic RNA one hour after 
treatment. Despite an initial defect in IL-4 production, an increase in IL-4 was observed 
in supernatants from NFATC2-/- splenocytes 7 days after anti-CD3 stimulation7.  As 
we did not include later time points to study cytokine secretion in splenocytes, we are 
not able to draw fi rm conclusions concerning the possible Th1/Th2 bias in NFATC2-/- 
mice. 
To conclude, although NFAT family members are critical activators of immune 
response 35-37 and NFATC2 defi ciency in mice results in a Th2 biased T-cell response, 
leukocyte defi ciency in NFATC2 deteriorated rather than ameliorated atherosclerosis 
and led to an accumulation of T-cells in the plaque. NFATC2 defi cient T-cells displayed 
an augmented mitogenic response to CD3 and a memory/activated T cell phenotype, 
77
Effect of NFATC2 on atherosclerosis
had robust migratory capacity to atherosclerotic lesions and produced less IL-10 upon 
activation. The resultant proinfl ammary status of NFATC2-/- T-cells could well have 
contributed to the surprising aggravated atherogenic response observed in NFATC2 
defi ciency. 
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1. Introduction
Cathepsins are a family of proteolytic enzymes that degrade the extracellular matrix 
(ECM). The ECM consists of elastins, collagens, and proteoglycans. It gives anchorage, 
support, and structure to tissue and functions as an adhesive substrate for vascular 
endothelial cells (EC) and smooth muscle cells. ECM remodeling is critically involved 
in many physiological and pathological processes such as wound healing, tumor 
growth 1, chronic infl ammatory diseases such as rheumatoid arthritis 2, neurological 
disorders3,4 and also in cardiovascular pathologies such as atherosclerosis. Degradation 
of ECM in the vessel wall enables smooth muscle cells (SMC) to migrate from the media 
into the intima and infl ammatory cells to infi ltrate from the circulation into the arterial 
wall, processes critical in the pathogenesis of atherosclerosis. Moreover, within the 
plaque, ECM degradation causes thinning of the fi brous cap, often resulting in plaque 
rupture and thrombosis. When an occlusive thrombus forms, clinical complications of 
atherosclerosis with a high morbidity and mortality, such as myocardial infarction and 
stroke occur.
The term “cathepsin” represents lysosomal proteolytic enzymes irrespective of their 
enzyme category. Based on their catalytic actions, cathepsins are classifi ed into cysteine 
(cathepsins (cat)B, C, F, H, K, L, O, S, V, X, W), serine (catA and G) and aspartate (catD 
and E) proteases3, 5.
The function of cathepsins and their most well known inhibitor cystatin, in ECM 
degradation, vascular remodeling and atherosclerosis has been demonstrated in 
human and animal models. This chapter will emphasize and discuss the importance of 
cathepsins in atherosclerosis.
2. Synthesis and activity
Under physiologic conditions, cathepsins are localized intralysosomally. Although 
cathepsins were originally shown to be active in lysosomes and endosomes and 
execute unspecifi c proteolysis6, there is growing evidence that cathepsins can function 
outside lysosomes or endosomes7. In response to certain signals such as infl ammatory 
cytokines interleukin-1β(IL-1β), tumor necrosis factor-α (TNF-α), interferon-g (IFN-γ)8), 
angiotensin II9, or oxidized low density lipoprotein (oxLDL)10, they are released 
from the lysosomes into the cytoplasm where they activate various biological and 
pathological pathways including ECM degradation, infl ammation and apoptosis. For 
example, disruption of lysosomes results in translocation of cathepsins to the cytosol 
and induction of apoptosis through a caspase-dependent mechanism11. Cathepsins can 
also exert specifi c functions in the nucleus, and even in the mitochondrion12, 13.
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3. Regulation 
Control and regulation of proteolytic activity are indispensable processes. Failure 
of these processes inevitably result in various fatal pathologies such as metastasis of 
cancer cells or infl ammation14. Cathepsins are regulated by endogenous cathepsin 
inhibitors called cystatins. In general, cystatins function as a protection against the 
irregular release of peptidases such as cathepsins from the lysosome during apoptosis 
or phagocyte degranulation15. They also serve as defense against proteases secreted by 
proliferating cancer cells or by invading organisms, such as parasites16. 
The cystatin family is divided into four sub-families16, 17: the stefi ns (type 1), the
cystatins (type 2), the kininogens (type 3) and various structurally related but 
noninhibitory proteins (type 4). Type 1 cystatins are cystatins A (stefi n A) and B (stefi n 
B), which are present mainly intracellularly, but can also appear in body fl uids at 
signifi cant concentrations. Type 2 cystatins, including cystatin C, are found in most 
body fl uids, and mainly operate extracellularly.  Type 3 cystatins include kininogens, 
which are present in blood proteins. Among these cathepsin inhibitors, cystatin C is the 
most potent inhibitor16, 18, with the greatest inhibitory properties to cathepsins L and S, 
followed by cathepsins B and H15.
4. Cathepsins in (patho)physiological tissue remodeling
Cathepsins not only function in intra-lysosomal protein degradation, but also contribute 
to tissue remodeling by degrading the ECM. As cathepsins are expressed in several cell 
types, they participate in various tissue remodeling processes (Table 6.1). CatK is the 
most abundant cysteine protease expressed in osteoclasts and is instrumental in bone 
matrix degradation necessary for bone resorption19. CatS is expressed and secreted 
by the human adipose tissue and is up-regulated in obesity20. The increase of catS in 
adipose tissue causes local degradation of fi bronectin network, a key preadipocyte-ECM 
component, supporting the development of fat mass21. In addition, circulating levels of 
catS were also increased in obese subjects20. CatS mRNA or protein in the left ventricular 
tissues was more abundant in rats or humans with heart failure compared to control, 
suggesting that catS participates in pathological left ventricular remodeling22. Patients 
with heart failure were found to have increased expression of catB in the myocardium, 
suggesting that catB plays a role in the development of heart failure23. Furthermore, 
enhanced expression of several cathepsins (B, D, L and S) was observed in several types 
of tumors, and are thought to contribute to tumor growth and metastasis.24, 25. Increased 
catD expression was present in activated astrocytes in neurodegenerative diseases, such 
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as scrapie in mice and Alzheimer’s disease in human. The increase in cathepsin D may 
be an ongoing response to the deposition of abnormal aggregated proteins that have 
neurotoxic effects26. 
Some in vitro and in vivo studies suggested that cysteine proteinases play an important 
role in renal pathophysiology. CatB, H, and L were present in glomeruli and other 
fractions prepared from normal rat kidney and were able to degrade the intact 
glomerular basement membrane in vitro27. 
Table 6.1 Cathepsins in tissue remodeling
Tissue remodeling Description
Bone resorption catK
 
Fat tissue turnover catS 
Cardiac remodeling catB and S 
Tumor catB, D, L, and S 
Neurodegeneration catD 
Renal pathology catB, H and L 
5. Cathepsins in atherosclerosis
5.1 Expression of cathepsins in human atherosclerosis
Considering the widespread functions of cathepsins in the different pathologies, it is not 
surprising that cathepsins play a key role in cardiovascular disease. In atherosclerotic 
arteries, cathepsins are expressed by most of the plaque cell types, including 
macrophages, ECs and SMCs28, 29. Various studies showed that cathepsin B30, F31, L32, K33 
and S8 mRNA or protein level were increased in either human or mouse atherosclerotic 
lesions, whereas they were only weakly expressed in normal arteries. Cathepsins F, L, 
K and S were mainly found in macrophages, SMCs and ECs. Specifi cally, macrophages 
in the shoulder region of human atheroma contained abundant catK and S8. Likewise, 
SMCs that appeared to transverse the internal elastic laminae and of the fi brous cap also 
expressed catK and S8, suggesting that SMC and macrophages utilize these cathepsins 
to enter the atherosclerotic plaque. ECs aligning the lumen of the vessel itself and the 
intraplaque microvessels in human atheroma lesions expressed catS29, suggesting an 
involvement of this protein in neovascularization.
The enhanced cathepsin expression in human and murine atherosclerotic lesions 
suggests an involvement of cathepsins in the process of atherosclerosis. The next 
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paragraphs outline the consequences of cathepsin defi ciency on plaque progression 
and plaque phenotype (5.2) and describe the potential mechanisms how the different 
cathepsins affect atherogenesis (5.3; Figure 6.1). 
5.2 The role of cathepsins in atherogenesis: lessons learned from animal models
Cathepsin S defi ciency in LDL receptor (LDLr-/-) mice protected against atherosclerosis: 
reducing atherosclerotic plaque area, plaque progression, the number of elastin breaks 
and elastase activity. Furthermore, catS defi ciency induced a reduction in SMC and 
collagen content and decreased fi brous cap thickness34.  CatS defi ciency in apolipoprotein 
E defi cient (apoE-/-) mice was also found to reduce plaque ruptures, defi ned as visible 
defects in the cap of atheromatous lesions and accompanied by intrusion of erythrocytes 
into the region below8. In addition, catS expression in macrophages colocalized with 
areas of elastin fragmentation in mice35.  
CatK defi ciency was found to protect against ECM remodeling in atherosclerosis as 
well. CatK defi ciency in apoE-/-  mice resulted in a 42% reduction in atherosclerotic 
plaque area; although the total number of plaques remained unchanged, there was a 
relative increase in early lesions and a relative decrease of the number of advanced 
lesions when catK was absent33. Furthermore, catK defi ciency led to an increase in 
collagen content and macrophage size, and a decrease in elastin breaks33.  These results 
were confi rmed by Samokhin et al who demonstrated that catK defi ciency inhibited 
plaque progression and increased fi brous cap thickness in the brachiocephalic artery 
after high fat feeding36. Interestingly, opposite results were found when only leukocyte-
catK was absent. In a bone marrow transplantation model in which catK defi cient bone 
marrow was transplanted into irradiated atherosclerotic LDLr-/- mice, atherosclerotic 
lesions had a vulnerable atherosclerotic plaque phenotype with reduced collagen 
levels, an increase in macrophage content and an accelerated necrotic core formation37. 
However, these data are supported by the paper of Lutgens et al, where catK defi cient 
macrophages showed an increase in lipid uptake and foam cell formation[33]. 
Atherosclerotic lesions in either human or apoE-/- mice have comparatively low levels 
of cystatin C (cathepsin inhibitor), whereas normal arteries have abundant cystatin 
C expression in medial SMCs and in ECs29, 38. Defi ciency of cystatin C in apoE-/- mice 
signifi cantly increased plaque size39 and increased elastolytic activity40, suggesting an 
important role played by cystatin C in atherosclerosis development.
All the above fi ndings demonstrate the importance of cysteine proteases and the 
cathepsin inhibitor cystatin C in atherosclerosis. 
5.3 Cathepsins in atherosclerosis: potential mechanisms
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5.3.1 Cathepsins are regulated by shear stress
The mechanic force (shear stress) that is constantly present over vascular ECs regulates 
the structure and function of ECs41. This mechanic force is generated by blood fl ow over 
the vascular endothelium and tends to develop different patterns of hemodynamic force 
based on the region and curvature of the artery. Oscillatory shear stress, which occurs 
in branched or curved regions, is associated with pro-atherogenic events. Laminar 
shear stress occurs in “straight” arteries, and is associated with low susceptibility to 
atherosclerosis41.  Platt et al showed that atheroprotective laminar shear stress decreased 
catL activity, while pro-atherogenic oscillatory shear stress signifi cantly enhanced 
catL activity compared with laminar shear stress. These observations suggested 
that cathepsin L could participate in the development of vascular remodeling and 
atherosclerosis partly by a shear stress sensitive response42. CatK was also found to be 
mechanosensitive. Laminar shear stress decreased catK protein expression in ECs in 
vitro compared to oscillatory shear stress, suggesting a potential role for catK at sites of 
disturbed fl ow associated with vascular pathology. This study also showed a positive 
correlation between catK levels in endothelium and human atherosclerotic lesion 
development, supporting the evidence for a role of catK in atherosclerosis formation.  
The above fi ndings suggest that catL and K expression in ECs are regulated by shear 
stress and partially contribute to the shear-dependent regulation of the ECM protease 
activity leading to vascular remodeling and atherosclerosis.
5.3.2 Cathepsins mediate leukocyte and SMC Migration
One of the fi rst signs of atherosclerosis is recruitment of leukocytes from the vascular 
lumen into the arterial wall, followed by adhesion and migration through the endothelial 
layer and arterial basement membrane43. Blood-born monocytes use cathepsins to 
degrade ECM and migrate through endothelial layers. For example, catS-defi cient 
monocytes displayed less migration through a SMC layer than wild-type monocytes in 
vitro34.
The role of cathepsins in leukocyte migration has also been illustrated in Jurkat T cells44. 
The migration activity of T lymphocytes through ECM did not require ECM degradation 
but was mediated by adhesion molecules and cytoskeletal rearrangements. CatX 
overexpressing T lymphocytes displayed polarized migration-associated morphology 
and enhanced migration on 2D and 3D models using intercellular adhesion molecule 1 
(ICAM-1) and Matrigel-coated surfaces. The proteolytic activity of catX was not involved 
in the increased invasiveness of catX overexpressing cells. Instead, an active form of 
catX colocalised with lymphocyte-function-associated antigen 1 (LFA-1) in migrating 
cells. LFA-1 is found on leukocytes and binds to ICAM-1 on  antigen-presenting cells 
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and functions as an adhesion molecule45.
In addition to the migration of monocytes into the arterial wall, migration of SMCs 
from the media into the intima also play a key role in atherosclerotic lesion formation, 
as well as in restenosis 46, 47. Migration of SMCs from the medial to the subendothelial 
space requires degradation of ECM. The interaction of catS with ECM components 
during SMC migration was examined by Cheng et al. A selective cat S inhibitor-
(Morpholinurea-leucine-homophenylalanine-vinylsulfonephenyl) and the endogenous 
inhibitor cystatin C signifi cantly attenuated SMC invasion through ECM, suggesting 
that cathepsins released from SMCs contribute to SMC invasion through collagen 
and elastin substrates. Western blot analysis on subcellular fractions showed that the 
active form of catS was present on the SMC plasma membrane but not in the cytosol. In 
contrast, the active forms of catK, B, L, and D were not expressed on the SMC plasma 
membranes. These fi ndings suggested that membrane-bound catS facilitated SMC 
proteolytic activity and thereby SMC invasion through ECM. This notion was further 
confi rmed by the fi nding of partial co-localization of catS and integrin ανß3 at the 
cell surfaces. ανß3 integrin is a receptor for several proteases such as matrix metallo-
proteinases (MMPs)48-50 and involved in SMC adhesion and migration. Thus catS might 
cooperate with integrin ανß3 to facilitate SMC invasion. In the study by Cheng et al, the 
inhibition of catS reduced SMC invasion through ECM but had no effect on adhesion 
or on migration through ECM. It suggests that catS likely contributes to the proteolytic 
process during SMC invasion through ECM but does not play a role in mediating the 
migration process itself51. 
5.3.3 Cathepsin-induced ECM degradation in atherosclerosis
ECM degradation plays an important role in development and destabilization of 
the atherosclerotic plaque52. Modifi cations in ECM homeostasis, as a consequence 
of alteration in the degradation and/or synthesis of the vessel wall ECM, have 
been associated with vascular diseases. Plaque formation occurs as a result of SMC 
migration and proliferation accompanied by degradation of ECM. In the latter stages 
of atherosclerosis, thrombotic complications frequently develop from rupture of the 
fi brous cap or superfi cial erosion of the endothelium, both of which are the result of 
ECM degradation. 
Cathepsins were found to exert strong elastinolytic and collagenolytic activity in culture 
media conditioned by various cell types. Cultured SMC stimulated with cytokines, 
secreted active catB and L and degraded substantial amounts of insoluble elastin8, 32. 
Monocyte-derived macrophages synthesized not only metalloproteinases, but also cat 
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B, L, and S. However only the cathepsins were detected in the extracellular milieu, and 
macrophage-mediated elastinolytic activity was completely abrogated by inhibiting 
catL and S but not by MMP inhibitors44.  Cultured EC stimulated with pro-infl ammatory 
cytokines or growth factors induced the expression of catL, and enabled catL dependent 
degradation of extracellular collagen and elastin53. These fi ndings suggested that 
SMC, macrophages and EC use cysteine proteinases-dependent processes for ECM 
remodeling and this contributes to atherosclerosis formation. 
Besides the above in vitro data, one in vivo study also suggested that cathepsins play 
important roles in ECM degradation. In addition to abundant expression of catK and S 
in macrophages and intima SMCs, extracts from human atheroma showed a two-fold 
increase in elastolytic activity compared with normal vessels, which could be inhibited 
signifi cantly by a cysteine protease inhibitor E648. 
5.3.4 Cathepsin mediated neovascularization
The microvascular network of vasa vasorum is found in the adventitia and the outer 
media of normal vessels. However, during atherosclerotic plaque development, these 
networks grow and expand into the plaque54. Plaque neovascularization is thought to 
contribute to lesion progression in various ways. It offers a port of entry for leukocyte and 
plasma constituents such as lipoproteins into atherosclerotic lesions55, 56. Furthermore, 
the fragile nature of these neovessels can lead to focal intraplaque hemorrhage, which 
further promotes infl ammation and  thrombotic complications of atherosclerosis57.  The 
effects of cathepsins on neovascularization have been studied intensively in tumors 
and wound healing, but less in cardiovascular diseases. Cathepsin activity has been 
shown to be critical during tumor invasion and angiogenesis58, which requires lysis 
of the ECM to pave the way for neovasculature59 and proteolysis of the endothelial 
basement membrane60.  
The role of cathepsins has been further investigated in the context of endothelial 
progenitor cells (EPC)-mediated neovascularization. EPCs have been shown to improve 
neovascularization in ischemic tissues61, 62. Gene expression profi ling of EPCs and EC 
showed that catL was highly expressed in EPCs compared to EC.  Mice receiving cat L 
defi cient bone marrow cells showed impaired functional recovery following hind limb 
ischemia. However, inhibition of other proteases such as catS and D, and MMPs did 
not affect EPC metalloproteinase activity63, suggesting that cathepsin L is specifi cally 
required for EPC-mediated neovascularization. Endothelium-derived cathepsins may 
also contribute to angiogenesis as well. CatS inhibition reduced microtubule formation 
in ECs by impairing cell invasion. Furthermore, catS defi cient mice displayed fewer 
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microvessels in healing wounds64.Taken together, these data suggested that cathepsins 
are involved in the processes of neovascularization. However, until now, direct evidence 
for a signifi cant role for cathepsins in plaque neovascularization is lacking. 
5.3.5 Cathepsins mediate infl ammation
Atherosclerosis is an infl ammatory disease in which both innate and adaptive immune 
responses are involved65. Innate, but also adaptive immune responses such as antigen 
presentation occur within the atherosclerotic plaque, which is rich in T lymphocytes, but 
also in antigen-presenting macrophages and dendritic cells66. In addition, to proteolytic 
activity, cathepsins also play roles in infl ammatory processes involving both innate 
immunity, such as Toll-like receptor-9 (TLR9) signaling and processes of adaptive 
immunity, including antigen presentation.
5.3.5.1 Cathepsins in innate immunity: TLR9 signaling 
Matsumot et al found that catB and L inhibitors suppress the interaction of CpG-B (TLR 
ligand) with TLR9 in 293T cells, suggesting a role for cathepsins in regulating CpG-B-
TLR9 interaction, and thus innate immunity67. Moreover, catS and F, but not H, are able 
to complement TLR9 responses in Ba/F3 cells, which are defective in TLR9 responses 
(unable to activate NF-κB in response to CpG-B)67.
The involvement of cathepsins in TLR9 signaling was also present in dendritic cells68. 
Administration of a potent orally active catK inhibitor named NC-2300 in rats with 
adjuvant-induced arthritis not only suppressed bone resorption by osteoclasts, but also 
showed anti-infl ammatory effects, resulting in reduced paw swelling. Further studies 
showed that catK inactivation led to the blockade of essentially all the downstream 
pathways of TLR9 signalling in dendritic cells, showing a crucial role for cathepsin K in 
TLR9 signaling. 
TLRs, especially TLR1, 2, 4, have been recognized for their roles in atherosclerotic lesion 
development and progression69. Unfortunately, the involvement of TLR9 signaling in 
atherosclerosis is not yet clear. Further research on the role of cathepsin-mediated TLR9 
response in the development of atherosclerosis is warranted.
5.3.5.2 Cathepsins and antigen presentation 
The function of cathepsins in antigen presentation has been intensively studied. MHC 
class II molecules present antigen peptides on the surface of antigen presenting cells 
(APC), which are recognized by CD4+ T cells.  The cooperation of invariant (Ii) chain 
with MHC class II dimers is required for proper antigen presentation to CD4+ T cells. 
The Li cytoplasmic tail targets the MHC classII-Ii complex to the endosomal pathway 
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and prevents early loading of antigenic protein on MHC class II with class II-associated 
invariant chain peptide. Degradation of Ii is an important regulatory step in the 
maturation of MHC class II dimers. Maturation of the endosome leads to the activation of 
lysosomal enzymes, which degrade Li from class II-Ii complexes and induce subsequent 
maturation of class II molecules. CatF,L,S,K, and V have all degrade MHC II- associated 
Ii in professional APC and are thus required for antigen processing70. 
Compared with other lysosomal cysteine proteases, catS has displayed some unique 
characteristics in that it can not only degrade MHC II-associated Ii in professional APC, 
but also in non-professional APC such as intestinal epithelial cells71, 72. Several studies 
describe the functional signifi cance of cathepsin inhibition in antigen presentation, thus 
inhibition of catS reduced autoantigen presentation and development of organ-specifi c 
autoimmunity in mice73, 74.
In atherosclerosis, a well known auto-antigen in the cellular immune response of 
atherosclerosis is oxLDL75. Anti-oxLDL antibodies were detected within rabbit and 
human atherosclerotic lesions76. In addition, anti-oxLDL antibodies titers signifi cantly 
correlated with the extent of atherosclerosis in mice77. Moreover, immunization 
with splenic B cells led to the production of anti-oxLDL antibodies, which conferred 
protection against atherosclerosis in mice78. Interestingly, cathepsin S defi cient 
LDLr-/- mice showed signifi cant reduction in atherosclerotic lesion size and lower titers 
of autoantibody against both malondialdehyde-oxLDL and copper-oxLDL epitopes29.
5.3.5.3 Cathepsins mediate TGF-β signaling
Cathepsins might be involved in anti-infl ammatory responses via the TGF-β pathway. 
Lutgens et al showed that besides reduced atherosclerotic lesion size, defi ciency of 
catK induced expression of genes involved TGF-β signaling in atherosclerotic lesions79. 
As inhibition of TGF-β in apoE-/- mice initiated an infl ammatory plaque phenotype80, 
induction of TFG-β signaling might partly explain the protective effect of catK defi ciency 
in atherosclerosis formation.
5.3.6 Apoptosis
Apoptosis of foam cells contributes to necrotic core formation, a hallmark of plaque 
severity. Several cysteine proteases have been described to participate in this process81-83.
Z-FAFMK (a selective inhibitor of catB and L) prevents oxysterol-induced apoptosis 
of mononuclear cells84. The expression of catL in human atherosclerotic plaques was 
correlated with apoptosis, suggesting that catL is involved in macrophage apoptosis. 
Moreover, macrophage apoptosis in atherosclerotic coronary artery specimens 
was signifi cantly correlated with expression of catL in cell membranes and nuclei85. 
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Furthermore, selective catS inhibition by 05141 and a null mutation of catS, ameliorated 
IFN-γ-induced apoptosis as manifested by reduced activation of caspases-3, -8, and -9 
and reduced expression of Bim, Bid, Fas, Fas ligand, TNF-α, TNF-related apoptosis-
inducing ligand, and protein kinase C-δ in lung. These observations highlight the 
suppressive effects of catS inhibitor in IFN-γ-induced apoptosis activation via both the 
intrinsic/mitochondrial and extrinsic pathways86. 
The mechanism by which cysteine proteases induce apoptosis is thought to involve 
both caspase-dependent and caspase-independent cell death pathways87. Cathepsins 
are located in the lysosomes under physiological conditions. Nonetheless, oxidative 
stress causes lysosomal leakage and rapidly initiates cathepsin translocation from 
lysosomes to the cytosol and participation in both apoptotic pathways. The caspase-
dependent pathway includes a direct cleavage of Bid and/or Bak/Bim. Translocation 
of these pro-apoptotic proteins to the mitochondrial outer membrane leads to release of 
apoptotic factors such as cytochrome C. This results in an indirect activation of caspases 
and subsequent apoptosis. Cathepsins are also able to directly cleave caspases, which is 
followed by cleavage of Bid and/or Bax, translocation of these proteins to mitochondria 
and subsequent downstream events that cause apoptosis. Cathepsins are also able to 
trigger the release of apoptosis-inducing factor and cause caspase-independent cell 
death84, 88, 89. 
5.3.7 Lipid metabolism
Lipid retention in macrophage derived foam cells is one of the hallmarks of atherosclerotic 
plaque development and progression. Cathepsins have been shown to affect foam cell 
formation bivalently. Some cathepsin family members enhance foam cell formation, 
while others impair the formation of foam cells28. 
5.3.7.1 Cathepsins reduce foam cell formation
Cathepsins are able to degrade (modifi ed) LDL. CatB inhibition reduced modifi ed 
LDL degradation in human aortic SMC lysates. Decreased lysosomal degradation 
may cause LDL accumulation in SMCs and subsequent foam cell formation90. Several 
studies showed that catK defi ciency was able to increase lipid uptake and consequently 
foam cell formation. Bone marrow-derived macrophages from catK defi cient apoE-/- 
mice showed an increased uptake of modifi ed LDL33. Pathway analysis revealed that 
the increased lipid uptake was regulated by both CD36 and caveolins79 Furthermore, 
bone marrow-derived macrophages from catK defi cient apoE-/- mice showed an 
increase in cholesterol ester accumulation compared with apoE-/- bone marrow-derived 
macrophages, which was stored in lysosomal compartments33. These data indicate that 
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catB and K are able to reduce foam cell formation by degrading (modifi ed) LDL and 
inhibiting lipid uptake.
5.3.7.2 Cathepsins stimulate extracelllular lipid accumulation and foam cell formation
In vitro studies showed that recombinant catF strongly degraded apoB-10031. Degradation 
of apoB-100 by catF induced accumulation and fusion of LDL particles and enhanced 
the ability of LDL to bind proteoglycans, consequently leading to the accumulation 
of extracellular lipid droplets31. This study indicates that cathepsins could contribute 
to extracellular lipid accumulation in the arterial wall, an important characteristic of 
atherosclerosis. Degradation of cholesterol acceptors by cathepsins not only induced 
extracellular lipid accumulation, but also inhibited lipid effl ux. CatS completely (100%) 
degraded apolipoprotein A-1 (apoA-1), which caused total loss of the ability of apoA-1 
to induce cholesterol effl ux. Cathepsins F and K incompletely degraded apoA-1 leading 
to a reduction of cholesterol effl ux by 30% and 15% respectively91. These data suggest 
that cathepsin-mediated degradation of cholesterol acceptors can inhibit lipid effl ux 
and thereby aggravate foam cell formation.
5. 3.8 Thrombus formation
Cardiovascular disease is characterized by end-stage thrombotic complications, either 
due to rupture of the fi brous cap or superfi cial erosion. CatG is known to be involved 
in thrombosis. After release from neutrophils, catG leads to calcium mobilization via 
the catG platelet receptor (protease-activated receptor 4)92, thereby inducing platelet 
aggregation93. CatG can also affect the morphological integrity of EC through a 
mechanism involving vitronectin-bound plasminogen-activator-inhibitor-1 (PAI-1) 
detachment. The detachment of PAI-1 from the subendothelial matrix induces F-actin 
cytoskeleton rearrangement with consequent changes in morphological integrity of EC. 
These events expose a highly thrombogenic surface to which platelets can adhere and 
become activated94. 
Despite large amount of data implying a functional role of catG in thrombosis formation, 
catS seems to have anti-thrombotic property.  CatS-defi cient mice had accelerated 
thrombotic responses to artery injury and shorter plasma clotting time29.The mechanism 
of catS on thrombus formation in atherosclerosis development however needs to be 
further investigated.
5.4 Cathepsins in plaque instability
Rupture of atherosclerotic plaques is the most common cause for thrombotic 
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complications, resulting in high morbidity and mortality95. Rupture-prone lesions 
are characterized by a large lipid core and a thin fi brous cap. Morphological studies 
showed that cathepsins were particularly expressed in macrophages in the shoulder 
regions of plaques, an area prone to rupture35.  In a human study, comparison of 
gene expression in a stable versus a ruptured (an ulcerated surface with or without 
thrombosis or hemorrhage) atherosclerotic plaque obtained from the same patient, 
identifi ed signifi cantly greater amounts of catB (mRNA and protein) and catS (mRNA) 
in ruptured segments compared with stable segments96.  Furthermore, catL was 
signifi cantly increased in atherosclerotic plaques containing a large necrotic core and 
a ruptured plaque, suggesting that catL was involved in the development of unstable 
plaques94. It is likely that the presence of cathepsins in atherosclerotic lesions can 
degrade ECM and thereby contribute to plaque vulnerability. In contrast, upregulation 
of catK was identifi ed in advanced stable plaques compared with plaques containing 
thrombus97. 
6. Therapeutic potential
Given their role in bone resorption, cathepsins have been considered valuable 
therapeutic targets in osteoporosis by pharmaceutical companies. Several catK 
inhibiting compounds in clinical trials to study their effects on osteoporosis or 
osteoarthritis, have inhibited bone resorption and improved bone formation98, 99. The 
recent discovery of the involvement of cathepsins in atherosclerosis development 
directed attention of pharmaceutical companies to investigate the therapeutic potential 
of cathepsin inhibitors on the initiation and/or progression of atherosclerosis. Until 
now, one cathepsin K inhibitor compound was patented and claimed to be useful for 
treating or preventing atherosclerosis and atherosclerotic cardiovascular disease
(http://www.wipo.int/pctdb/en/wo.jsp?WO=2006076797). However, before catK 
inhibitors are suitable for treating patients with cardiovascular disease, mechanisms 
on its detrimental effects on foam cell formation should be further investigated.
7. Conclusions
In the past years, several studies have indicated important roles for cathepsins in the 
process of atherosclerosis. Their capacity to degrade ECM paves the way for monocyte 
recruitment from the circulation into the intima and for SMCs to migrate from the 
media into the intima. In addition, cathepsins cooperate with adhesion molecules 
such as LFA1 and ανß3 during leukocyte invasion and modulate cytoskeletal 
rearragengement. Within the atherosclerotic lesion itself, ECM degradation induces 
rupture of the fi brous cap. Cathepsins are also implicated in several infl ammatory 
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responses. Cathepsins are needed for processes involved in both innate immune 
reactions such as TLR3, 7, and 9 responses and adaptive responses by participating in 
antigen presentation, processes crucial in atherosclerosis. Furthermore, cathepsins might 
affect sprouting of neovessels of the existing vasa vasorum into the plaque, apoptosis, 
foam cell formation and thrombus formation and thereby contribute to atherosclerotic 
plaque vulnerability.
As shown in this review, the different members of the cathepsin family are very versatile 
molecules, modulating proteolysis, infl ammation, lipid uptake by macrophages, 
apoptosis and coagulation, all processes known to work in concert during the process 
of atherosclerosis. Therefore, cathepsin-antagonists are considered an attractive 
treatment for atherosclerosis. Several of these antagonists have been patented and 
further patient-related studies need to be performed to reveal the value of cathepsin-
antagonists in preventing morbidity and mortality as a result of clinical complications 
of atherosclerosis. 
Figure 6.1 Overview of potential roles of cathepsins in atherosclerosis formation.
Overview of potential roles of cathepsins in atherosclerosis formation. Cathepsins are expressed in ECs, 
SMCs, macrophages and foam cells. Cathepsins are able to degrade ECM containing elastin and collagen,
which facilitate SMC to migrate from media and monocyte and T lymphocytes from circulation to intima.
ECM degradation by cathepsins might facilitate neovessel formation. Both macrophages and SMCs take
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up oxLDL and become foam cells, these processes involve cathepsins as well. The apoptosis of foam cells 
contribute to necrotic core formation, cathepsins might participate in this process. Cathepsins might 
compromise anti-oxLDL antibody production by interfering with antigen presentation process. Cathepsin
may also induce plaque rupture and thrombosis formation. 
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Abstract 
Cathepsin K (catK), a lysosomal cysteine protease, exerts strong elastinolytic and 
collagenolytic activity and is implicated in a range of pathological disorders including 
cardiovascular disease. CatK expression was found to be elevated in human aortic 
aneurysm pointing to a role in this vascular disease. In the angiotensin II (Ang II)-
induced mouse model for aneurysm formation, catK, S and C expression was strongly 
upregulated. Therefore, we investigated the effect of catK defi ciency on Ang II-induced 
aneurysm formation in the abdominal aorta of apoE-/- mice.
Contrary to our expectations, catK defi ciency did not protect against aneurysm formation, 
nor did it affect medial elastin breaks. Proteolytic activity in abdominal aortic lysates were 
comparable between apoE-/- and catK-/-//apoE-/- mice. Adventitial presence of catS 
and catC-expressing cells was signifi cantly increased in catK-/-//apoE-/- versus apoE-
/- mice, which might have compensated for the defi ciency of catK-derived proteolysis 
in the aneurysm tissue of catK defi cient apoE-/- mice. Circulating granulocytes and 
activated T cell numbers were signifi cantly increased in Ang II-infused catK-/-//apoE-
/- mice, which was consistent with the borderline signifi cant increase in adventitial 
leukocyte content in catK-/-//apoE-/- compared to apoE-/- mice. Strikingly, despite 
unchanged proteolytic activity in abdominal aortic aneurysms (AAA) lesions, collagen 
content in the aneurysm was signifi cantly increased in catK-//-apoE-/- mice. In 
conclusion, while catK defi ciency has major impact on various vascular pathologies, it 
did not affect murine aneurysm formation.
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Introduction
AAA are permanent dilations of the arterial wall in the abdominal aorta1, which after 
rupture can cause life-threatening bleeding. The prevalence of AAA in western society, 
as diagnosed by means of autopsy, ultrasound screening, and hospital discharge data, 
is substantial, ranging from 19-34% in women to 66-81% in men2. Women are usually 
older when they undergo AAA repair2.  Although a history of atherosclerotic disease 
predisposes to aneurysm formation, several other factors contribute to its ontogenesis, 
including genetic predisposition, infl ammation, hypertension and hyperlipidemia 3,4.
Excessive degradation of extracellular matrix (ECM) components such as elastin and 
collagen5,6, a critical process in AAA, was shown to be at least in part dependent on 
a local disbalance between matrix metalloproteinases (MMPs) and cognate inhibitors, 
the tissue inhibitors of metalloproteinases (TIMPs). Indeed doxycycline, a broad 
spectrum MMP inhibitor, was shown to prevent Ang II-induced aneurysm formation 
in hyperlipidemic LDL receptor defi cient mice7.  In addition to MMP, other cysteine 
proteases like cathepsins are involved in ECM degradation8. 
CatK is a papain-like cysteine protease that has a distinct ECM degrading potential. 
It is one of the most potent elastases in mammals, and in addition harbors unique 
collagenolytic activity9,10, 11,12. In AAA wall, protein levels and activities of catK, L and S 
were elevated compared to that in healthy arteries, whereas levels of the endogenous 
cysteine protease inhibitor cystatin C were decreased13, 14,15.  In a previous study, we 
already showed that catK defi ciency in apoE-/- mice reduced plaque progression with 
a concomitant increase in plaque collagen content and macrophage size16. In addition, 
the number of elastin breaks in the media underlying the atherosclerotic plaque was 
sharply decreased in advanced lesions of catK-/-//apoE-/- compared to apoE-/- mice. 
Taken together, the profound effect of catK on atherosclerosis, an established risk factor 
for AAA, and its enhanced expression in human aneurysms point to a potentially 
important, adverse role for catK in aneurysm formation. This hypothesis was tested 
in an established mouse model of AAA in which aneurysm formation is induced by 
sustained subcutaneous infusion of Ang II in apoE-/- and catK-/-//apoE-/- mice. 
Surprisingly, our data showed that catK defi ciency neither reduced aneurysm formation 
nor reduced proteolytic activity in abdominal aortic lysates, although we did notice 
increased collagen content in the aneurysm itself. Remarkably, catS and C staining 
revealed a more abundant presence of catS and catC-positive cells in the adventitia of 
catK defi cient animals. Apparently, in the absence of catK, other cysteine proteinases 
may compensate for the loss in catK-derived proteolytic activity in the arterial wall. 
Moreover, catK defi ciency dramatically increased circulating granulocyte and activated 
T cell numbers in Ang II-infused but not in untreated mice, which might counteract the 
potentially protective pro-fi brotic effect of catK defi ciency in AAA.
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Materials and Methods
Animals
Male apoE-/- mice on a C57Bl6 background were obtained from IffaCredo (Lyon, 
France). The catK-/- mice,  kindly provided by Dr P Saftig, were generated on an outbred 
129SVJ-C57Bl/6J genetic background 17. After import, we subsequently intercrossed the 
catK-/- mice at least 9 times with apoE-/- mice to generate catK-/-//apoE-/- mice 
and syngenic catK+/+//apoE-/- control mice. Animals were maintained in accordance 
with the Dutch government guidelines and animal experiments were approved by the 
regulatory authority of the University of Maastricht. Mice were fed a normal chow diet 
throughout the experiment.
Induction of aneurysm formation by chronic Ang II infusion
Aneurysm formation was induced by subcutaneous Ang II infusion 18. Alzet mini-
osmotic pumps (Alze type 2004) were implanted into apoE-/- (n=19 mice) and catK-/-
//apoE-/- mice (n=20 mice) at 10 weeks of age. Pumps were fi lled with Ang II (Sigma) 
dissolved in phosphate buffered saline (10 mM sodium phosphate, 150 mM sodium 
chloride; pH=7.4) to mediate the subcutaneous delivery of 1 ng/g/min of Ang II for 28 
days. Pumps were placed subcutaneously in the neck of anesthetized mice through a 
small incision that was closed using a silk suture (5-0).
Tissue harvesting and histological analysis
After 4 weeks of Ang II infusion, mice were sacrifi ced and the arterial system was 
perfused with PBS containing 0.1 mg/ml nitroprusside (Sigma) through a catheter 
inserted into the left cardiac ventricle and subsequently with 1% paraformaldehyde. 
The aortic piece comprising the ascending aorta to the aortic bifurcation was fi xed 
overnight in 1% paraformaldehyde and embedded in paraffi ne. We also investigated 
aortic tissue from mice which died before sacrifi cing. Ten cross -sections (4 μm thick) 
were cut at 200 μm intervals throughout the abdominal aorta starting at the middle of 
the aneurysm. From each level, a cross-section was stained with Elastica-von Gieson 
(EvG) for total vessel area and number of elastic lamina breaks. Transmural breaks 
(complete medial disruption) and more focal destructions of single elastic lamina were 
both scored as elastin break but at a different extent. More specifi cally, a transverse 
section containing a focal destruction of a single elastic lamina was scored as one break; 
while a transmural break encompassing four to fi ve elastic lamina breaks were counted 
as four or fi ve breaks, respectively.
The relative collagen area in the media and the aneurysm area, i.e. the percentage of total 
area that stained positive for Sirius red, was determined under a microscope coupled to 
a computerized morphometry system (Quantimet 570, Leica). Morphometric analysis 
was performed by one blinded investigator (LBai; intra-observer variability was < 10%). 
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Quantifi cation of aneurysm formation
Severity of aneurysms in the suprarenal region of the aorta was analyzed according to 
Daugherty et al19. In this scoring system, a healthy artery not obviously different from 
untreated apoE-/- mice was classifi ed type 0, a dilated aorta/lumen without thrombus 
as type I; remodeled tissue often containing thrombus as type II; a pronounced bulbous 
form of type II containing thrombus as type III; while lesions with multiple aneurysms 
containing thrombus as type IV. A numerical score was allocated to each mouse. For 
statistical comparison of disease progression stages, a semi quantitative pathology score 
was calculated by averaging the numerical aneurysm score of apoE-/- and catK-/-//
apoE-/- mice20. 
Immunohistochemistry
Ruptured aneurysm lesions (containing fatal and non-fatal rupture) were used to 
study lesion morphology. Sections were stained with the following antibodies: Mac3 
rat monoclonal antibody (1:30, BD Biosciences Pharmingen) to detect macrophages, 
CD45 (1:5000, BD Biosciences Pharmingen) to detect leukocytes, α-smooth muscle 
actin (α-SMA, 1:500, Dako) to detect smooth muscle cells (SMC)  and Ly-6G (1:200, 
BD Biosciences Pharmingen) to detect granulocytes. Immunostaining of catS and catC 
were performed using rabbit anti-mouse catS (1:500, Calbiochem) and goat anti-mouse 
catC (1:30, Santa cruz) antibodies. Mouse lymph node was used as positive control 
for CD45 staining, mouse spleen as positive control for Ly-6G staining, and mouse 
atherosclerotic lesions as positive control of both Mac3 and catS/C staining.  Deletion 
of the primary antibody served as negative control and did not show any staining for 
any of the antibodies.
The section containing the largest aneurysm area was used to quantify the number of 
CD45+, Mac3+ and cats/C + cells. The relative macrophage, leukocyte and granulocyte 
content in aneurysm and adventitial area was calculated by correcting the Mac3+ and 
CD45+ cell number for the total cell content of aneurysm and adventitia, respectively. 
As Ly-6G+ cells were not present in every slide, the number of Ly6G+ cells counted in 
6 slides was divided by the sum of 6 corresponding aneurysm lesion area. CatC+ and 
catS+ cells were primarily detected in the adventitia of the aneurysm lesion. To quantify 
the relative catC + and catS + cell density, the number of catC+ and catS+ cells in either 
the aneurysm region or in the adventitia was divided by the total number of cells in 
the aneurysm and adventitia, respectively. All measurements were conducted by one 
investigator (LBai; intra-observer variability was < 10%).
Bone marrow-derived macrophage isolation and culturing
Bone marrow–derived macrophages were isolated from the femur and tibia of apoE-
/- mice. Cells were cultured in standard RPMI containing L-glutamine, HEPES, 10% 
fetal calf serum, 100 IU/mL penicillin/streptomycin, and 15% L929 cell conditioned 
medium. After 7 days of culturing, bone marrow-derived macrophages were seeded 
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at a density of 1x 106 cells/ml in culture medium supplemented with 2.5 mM Ang II 
(Sigma) and incubated for 24h.
Quantitative RT-PCR
CatK, S and C gene expression levels were determined in bone marrow-derived 
macrophages exposed to Ang II (2.5 mM), in AAA tissue from Ang-II infused apoE-/- 
mice and in abdominal aorta tissue from untreated apoE-/- mice. RNA was extracted 
from cell or tissue lysates with Nucleospin RNA II kit (MACHEREY-NAGEL). cDNA 
was generated with iSCript TM CDNA synthesis kit (BIO-RAD). Real-time PCR was 
done with a Taqman IQ TM SYBR Green Super Mix (BIO-RAD). Cyclophilin was used as 
a house keeping gene. Primer sequences of catK, catS, catC and cyclophilin were shown 
in table 7.1.
Table 7.1
Forward primer (5’-3’) Reverse primer (5’-3’)
catK GGGCCAGGATGAAAGTTGTA CACTGCTCTCTTCAGGGCTT
catS AGAGAAGGGCTGCGTCACT GATATCAGCTTCCCCGTTTTCAG
catC CAACTGCACCTACCCTGATC CTCGTCGTAGGCAGTATCCA
cyclophilin CAAATGCTGGACCAAACACAA TTCACCTTCCCAAAGACCACAT
Collagenase and elastase activity assay
Abdominal aortas from apoE-/- mice (n=7) and catK-/-//apoE-/- mice (n=6) were 
harvested four weeks after Ang II infusion and snap frozen in liquid nitrogen. Protein 
extracts from abdominal aortas were made using a lysis buffer containing 1% Triton 
X-100, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, and 0.2% sodium azide 
in PBS, as described previously21. Collagenase and elastase activities in abdominal aortas 
were determined using EnzChek gelatinase/collagenase assay kit (Molecular Probes). 
Assays were performed at room temperature in 200 ul reaction buffer containing 20 
ul of DQ collagen I (D-12060, Molecular probe), 20 ul of DQ collagen IV (D-12052, 
Molecular probe), or 50 ul of DQ elastin (provided by the kit) and 100 ul of the protein 
extracts at 200 ug/ml. Substrate hydrolysis was monitored at 0, 2, 4, and 6 hours at 
room temperature and fl uorescence was detected in a fl uorescence microplate reader 
(λexc=485 nm; λem=538 nm; with a lower cut-off at 515 nm). Background fl uorescence, 
refl ecting non-enzymatic hydrolysis, was subtracted and each value was normalized 
for the baseline fl uorescence at 0 h. The proteolytic activity in the samples was derived 
directly from the initial slope and expressed as arbitrary units/hour (AU/hour).
Fluorescence-activated cell sorting (FACS)-analysis
ApoE-/- mice were treated with Ang II using osmotic minipumps as described above. 
After 4 weeks, mice were sacrifi ced. Splenocytes were isolated to make single-cell 
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suspensions and analyzed using FACS CantoII (Becton Dickenson) fl ow cytometer. 
Erythrocytes in peripheral blood and spleen were removed by hypotonic lysis with 
NH4Cl. Cells were fi rst incubated with anti-CD16/32 (eBioscience) to block Fc receptor 
binding to antibodies in macrophages, neutrophils and mast cells and stained with anti-
CD3-FITC, anti-CD8-Pacifi c blue, anti-CD25-APC (eBioscience) and anti-CD4-PerCp 
(BD-Biosciences Pharmingen, San  Diego, CA). Foxp3-positive cells were detected with 
PE anti-mouse/rat Foxp3 Staining Set, according to the manufacturer’s instruction 
(eBioscience). Peripheral blood leukocytes were further incubated with anti-CD11b-
pacifi c blue (eBioscience, San Diego, CA) and anti-ly6G-pacifi c blue (BD-Biosciences 
Pharmingen) to detect monocytes (CD11b+ly6G-) and granulocytes (CD11b+ly6G+). 
Statistical analysis
Values are expressed as mean + SEM and a Mann-Whitney non-parametrical test 
was used to compare individual groups of animals. Probability values of < 0.05 were 
considered signifi cant. 
Results
Cathepsin K, S and C expression is elevated in AAA lesions but unaltered in Ang-II 
stimulated macrophages
CatK, S and C mRNA expression was unchanged in abdominal aortas of apoE-/- mice 
(n=3, fi gure 7.1A), but sharply increased in AAA tissue of Ang-II infused apoE-/- mice 
(n=3, fi gure 7.1A). In order to study if the upregulated cathepsin expression is attributable 
to Ang II exposure itself, independent of the underlying vasculopathy, catK, S and C 
mRNA expression was determined in bone marrow-derived macrophages from apoE-
/- and catK-/-//apoE-/- mice after in vitro stimulation with 2.5 mM Ang II for 24 
hours. Ang II exposure in vitro did not alter catK, S and C mRNA expression in apoE-/- 
macrophages (fi gure 7.1B), nor did it differentially affect catS and C expression in catK-
/-//apoE-/- macrophages (fi gure 7.1B) (n=6 in each group). Therefore, Ang II treatment 
by itself can not be held accountable for the induced catK, S and C mRNA expression in 
aneurysm tissue, suggesting that in this AAA model, cathepsin dysregulation is a direct 
consequence of aneurysm formation. 
Cathepsin K defi ciency did not protect against Ang II-induced aneurysm formation
Infusion of Ang II for 4 weeks induced AAA formation in 74% (14 out of 19, n=19 mice) 
of the apoE-/- and 75% (15 out of 20, n=20 mice) of the catK-/-//apoE-/- mice. 5 mice 
from both apoE-/- and catK-/-//apoE-/- did not show any aneurysm formation.
Figure 7.2A shows the survival curve of mice before sacrifi cing, indicating that apoE-/- 
and catK-/-//apoE-/- had similar mortality rates. Mortality in all cases was attributable 
to AAA rupture. 47% of apoE-/- mice (9 out of 19) had non-fatal and 26% (5 out of 19) 
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had fatal rupture (death caused by AAA rupture). Similarly, of catK-/-//apoE-/- mice, 
45% (9 out of 20) had a non-fatal and 30% (6 out of 20) a fatal rupture (fi gure 7.2B). The 
AAAs observed in both groups were mostly type III (fi gure 7.2C). CatK defi ciency did 
not change the pathological score of the AAA (fi gure 7.2D). There was no difference 
between apoE-/- and catK-/-//apoE-/- mice regarding AAA lesion area as shown in 
fi gure 7.2E (1.04*106 μm2 + 0.25*106 μm2 versus 1.97*106 μm2 + 0.59*106 μm2; n=10 for 
each group). All AAAs in catK-/-//apoE-/- mice and 86% of AAAs in apoE-/- mice 
displayed complete medial breaks that resulted in marked dilation of the lumen (fi gure 
7.2F, left panel). Both groups displayed media thickening (fi gure 7.2F, right panel). Full 
color fi gures are shown on page 173.
Cathepsin K defi ciency altered collagen but not infl ammatory cell content of AAA 
lesions 
In the aneurysm area, Mac3+ macrophage (0.8 + 0.3% versus 1.0 + 0.3%, p=0.48, n=5-
6) and CD45+ leukocyte content (0.4 + 0.1% versus 1.0 + 0.4%, p=0.199, n=5-6) did not 
differ between apoE-/- and catK-/-//apoE-/-mice (fi gure 7.3A and B). We also did 
not observe any signifi cant differences in adventitial Mac3+ macrophage content of 
AAA lesions of apoE-/- and catK-/-//apoE-/- mice (0.03 + 0.01% versus 0.21 + 0.10%, 
respectively; p=0.27, n=5-6) (fi gure 7.3A). The number of CD45+ leukocytes tended to 
be increased in the adventitia of catK-/-//apoE-/- compared with apoE-/- mice (1.5 
+ 0.7% versus 2.8 + 0.5%, respectively; p=0.068, n=5-6) (fi gure 7.3B). Lesional Ly-6G+ 
granulocytes were rather scarce in AAA. The relative number of Ly-6G+ granulocytes 
A B
Figure 7.1A CatK, S and C mRNA expression in AAA of Ang-II infused apoE-/- mice and in nondiseased 
abdominal aorta of untreated apoE-/- mice were measured by Q-PCR (relative expression values are 
normalized for cyclophilin expression). Figure 7.1B CatK, S and C mRNA expression in bone marrow-
derived macrophages from apoE-/- and catK-/-//apoE-/- mice after incubation for 24 h with and with-
out Ang II (2.5 uM) were measured by Q-PCR (relative expression values are normalized for cyclophilin 
expression).*P=0.05.
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Figure 7.2 Cathepsin K defi ciency did not protect against Ang II-induced aneurysm formation. (A) Ka-
plan-Meyer survival curve of mice. Premature death could in all cases be attributed to AAA rupture. 
(B) CatK defi ciency did not affect the incidence of fatal and non-fatal rupture of catK-/-//apoE-/- and 
apoE-/- mice following treatment with Ang II . (C and D) CatK defi ciency did not alter the severity of 
AAA as measured by pathology categorization (C) and average pathological score (D). CatK defi ciency 
did not affect aneurysm size (E). Representative photographs showing EvG staining of aneurysms in 
apoE-/- and catK-/-//apoE-/- mice. Both groups displayed complete medial breaks and subsequent 
lumen expansion (F, left panel) and adventitial thickening (F, right panel). Full color fi gures are shown 
on page 173.
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in the aneurysm area (0.99+0.79*10-5/μm2 versus 0.08+0.06*10-5/μm2, p=0.372, n=6) 
was not signifi cantly different between apoE-/- and catK-/-//apoE-/- mice (fi gure 
7.3C). The average number of medial elastin breaks did not differ between apoE-/- and 
catK-/-//apoE-/-mice (20.9 + 3.4 (n=8) versus 26.0 + 2.7 (n=10), respectively; p=0.062) 
(Figure 7.3D/E). 
Collagen content increased signifi cantly in the aneurysm area of catK-/-//apoE-/-mice 
(0.7 + 0.4% versus 4.0 +1.4%, p=0.04, n=5 and 7, respe ctively) (fi gure 7.3F) However, 
there was no signifi cant difference in medial collagen content between apoE-/- and 
catK-/-//apoE-/- mice (58.2 + 0.9% versus 60.5 + 3.6%, p=0.74; n=10 for each group) 
(Figure 7.3G). Representative pictures from Sirius red staining of AAA lesions from 
catK-/-//apoE/- and apoE-/- animals were shown in fi gure 7.3H. Full color fi gures are 
shown on page 173. Thus, catK defi ciency increased aneurysm but not medial collagen 
content.
CatS and catC positive cells were higher in catK-//-apoE-/- versus apoE-/- mice
As catS+ cells were mainly present in the adventitia, analysis was confi ned to this 
location. Surprisingly, the percentage of catS+ cells in the adventitia in catK-/-//apoE-
/- was signifi cantly increased compared with apoE-/- mice (1.1 + 0.3% versus 3.8 + 0.8%; 
p=0.007, n=7 and 6, respectively) (fi gure 7.4A). Likewise, we observed more catC+ cells 
in the adventitia of AAA lesions of catK-/-/apoE-/- than in that of apoE-/- mice (0.02 + 
0.02% versus 0.2 + 0.10%, p=0.013; n=6 for each group) (fi gure 7.4B). The percentage of 
catC+ cells in the aneurysm area of apoE-/- and catK-/-//apoE-/-mice was similar (0 
% versus 0.04 + 0.03 %, p=0.14, n=6 for each group)(fi gure 7.4B). Representative pictures 
of catS staining from catK-/-//apoE-/- and apoE-/- mice are shown in fi gure 7.4C. 
Representative pictures of catC staining in adventitia and in aneurysm area from catK-
/-//apoE-/- and apoE-/- mice are shown in fi gure 7.4D and E, respectively. In order 
to determine cathepsin producing cells, serial sections were stained with antibodies 
against catS, catC, α-SMA and CD45. The catS-positive and catC-positive cells were 
mainly SMCs and leukocytes as shown in fi gure 7.5A for catK-/-//apoE-/- mice and 
7.5B for apoE-/- mice..
Cathepsin K defi ciency did not change aortic proteolytic activity 
The collagenolytic and elastinolytic activities in AAA lysates were determined using 
EnzChek Gelatinase/Collagenase Assay kit, as shown in fi gure 7.6 (n=6 for apoE-/-, 
n=7 for catK-/-//apoE-/-). Cat K defi ciency did not infl uence collagen type I, IV and 
elastin degradation in AAA lysates (fi gure 7.6A). As a positive control, assay of the 
degradation of collagen I, IV and elastin in the presence of collagenase and elastase 
provided by the EnzChek Gelatinase/Collagenase Assay Kit was shown in fi gure 7.6B. 
Cathepsin K defi ciency with Ang II infusion increased granulocyte population and 
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Figure 7.3. CatK defi ciency altered collagen but not infl ammatory cell content of AAA lesions. (A, B and 
C) CatK defi ciency did not affect macrophage, leukocyte and neutrophil content in AAA. The number of 
Mac3-positive (A) and CD45-positive (B) cells in the aneurysm area and in the adventitia were corrected 
for the total number of cells in the entire aneurysm lesion and adventitia respectively. The Ly-6G+ cell 
density in the aneurysm area was obtained by calculating the number of LyC6+ cells per lesion area (C). 
(D and E) The average number of elastin breaks in media was not signifi cantly different between catK-
/-//apoE-/- and apoE-/- mice (D). Representative pictures of elastin breaks in AAA lesions from catK-
/-//apoE-/- and apoE-/- mice are shown in E. Arrows point to full transmural breaks and arrowheads 
point to focal breaks of a single elastic lamina.  (F and G) CatK defi ciency increased aneurysm (F; *p=0.04) 
but not medial collagen content (G). Representative pictures of Sirius red stainings of AAA lesions from 
catK-/-//apoE/- and apoE-/- animals were shown in fi gure 7.3H. Full color fi gures are shown on page 
173.
activated T cell numbers
FACS was performed to study the systemic effect of catK defi ciency in untreated (n=7 
for apoE-/-, n= 8 for catK-/-//apoE-/- mice) versus Ang II-infused (n=7 for each 
group) apoE-/- mice. CatK defi ciency in Ang II-infused mice did not infl uence CD3+ 
T cell, Foxp3+ regulatory T cell and monocyte (CD11b+ly6G-) population in blood and 
spleen (data not shown). Surprisingly, granulocyte (CD11b+Ly6G+) counts in blood 
were signifi cantly increased in catK-/-//apoE-/- compared with apoE-/- mice upon 
Ang II infusion (Figure 7.7A). Moreover, in Ang II-infused mice with catK defi ciency, 
the number of effector T-helper cells in blood as manifested by the relative abundance 
of CD4+CD25+FoxP3- within the CD4+ signifi cantly enhanced (Figure 7.7B). However, 
such effects were not observed in mice without Ang II infusion (Figure 7.7A and B).
Discussion
AAA is a life-threatening vascular disease characterized by chronic infl ammation, 
excessive degradation of the ECM, and increased expression of proteases such as MMPs 
and cathepsins8, 22. In view of the strong elastolytic and collagenolytic activity of catK 
and its elevated expression in human AAA lesions, we hypothesized that a defi ciency of 
this cysteine protease would decrease AAA formation in Ang II-infused apoE-/-mice. 
In line with the human data, catK, S and C were all shown to be strongly upregulated 
in AAA in Ang II-infused apoE-/- mice compared with nondiseased abdominal aorta 
apoE-/- catK-/-//apoE-/-
H
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Figure 7.4. CatK defi ciency led to enhanced presence of catS+ (A) and catC+ cells (B) in aneurysms. 
Expressed is the relative catS+ cell content in the adventitia of aneurysms calculated by dividing the 
number of catS+ cells by the total number of cells in adventitia (A; *P=0.007). Representative pictures of 
catS staining from catK-/-//apoE-/- and apoE-/- mice are shown in C.  The relative catC+ cell content 
in adventitia (*p=0.013) or aneurysm (p=0.14) was calculated as described above (B). Representative pic-
tures of catC staining in adventitia and in aneurysm area from catK-/-//apoE-/- and apoE-/- mice are 
shown in D and E, respectively.
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Figure 7.5. Representative micrographs of catS, catC, α-SMA and CD45+ stained serial sections of 
adventitia of catK-/-//apoE-/-  (A) and apoE-/- mice (B). CatS+ or catC+ cells that are also positive for 
α-SMA or CD45 are encircled.
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from untreated apoE-/- mice, confi rming the validity of our model to study the effects of 
catK defi ciency on AAA formation. Interestingly, macrophage catK, S and C expression 
was not affected by Ang II stimulation, suggesting that catK, S and C upregulation is 
associated with the pathophysiology of AAA rather than with Ang II treatment per se. 
Unexpectedly, despite a strong upregulation of catK in Ang II-induced AAA in 
apoE-/- mice, catK defi ciency did not reduce aneurysm formation nor did it reduce 
aneurysm size, severity, and elastic lamina degradation. We demonstrate that the lack 
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Figure 7.6. CatK defi ciency does not lead to altered collagen I, IV and elastin degradation in aneurysm 
lysates between catK-/-//apoE-/- mice and apoE-/- mice as measured by fl uorometric enzyme  (A). As 
a positive control, proteolytic activity was measured upon addition of reference enzymes of collagenase 
and elastase, both at 0.02U/well (B).
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Figure 7.7. Flow cytometry analysis of circulating T cells and granulocytes. CatK defi ciency signifi cantly 
increased circulating granulocyte percentage (A) as well as the relative abundance of CD4+CD25+FoxP3- 
within the CD4+ population (B) in Ang II infused apoE-/- mice. However catK-/-//apoE-/- did not alter 
granulocyte percentage (A) and CD4+CD25+FoxP3- percentage of CD4+ cells (B) in non-infused apoE-
/- mice. *p< 0.05
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of protective effect of catK defi ciency against aneurysm formation might at least in part 
be explained by a compensatory activation of other cysteine proteinases in the vascular 
wall. Punturieri, et al has demonstrated that macrophages from catK-defi cient patients 
(compound heterozygous), maintained full elastolytic potential by mobilizing catL and 
catS but not MMPs23. Our fi nding of similar medial elastin breaks and proteolytic activity 
in AAA lysates of catK-/-//apoE-/- mice and apoE-/- mice corroborates this notion. 
Furthermore, catS+ and catC+ cells were more abundantly present in the aneurysm area 
of catK-/-//apoE-/- mice compared with apoE-/- mice, again confi rming proteolytic 
activity in catK defi cient animals is compensated by other cysteine proteinases. In an 
earlier study, we determined gene expression profi les of aortic arches of catK-/-//
apoE-/- and apoE-/- animals. A closer look at gene expression profi les of aortic arches 
of catK-/-//apoE-/- versus apoE-/- mice, showed that the major MMPs (MMP 1, 2, 
7, 9, 11, 14 and 23) in aortic tissue were not differentially expressed between the two 
groups24. 
The role of infl ammatory cells in AAA formation has been intensively studied25, 26. 
Granulocytes are considered to be critical in the formation of AAA, as granulocyte 
depletion was seen to inhibit AAA development associated with attenuated infl ammatory 
cell recruitment27. T cells may also play a signifi cant role in AAA formation as aneurysms 
in patients have substantial proportions of identical β-chain TCR transcripts28. These 
fi ndings suggest that active infl ammation is present in AAA. Therefore, the effects of 
catK defi ciency were further studied at systemic level in catK-/-//apoE-/- and apoE-
/- mice that had or had not received Ang II infusion. Surprisingly, there was a dramatic 
increase in the granulocyte and effector T cell population in catK defi cient mice after 
Ang II infusion, which is consistent with the increased adventitial leukocyte content 
in catK-/-//apoE-/- compared to apoE-/- mice observed in our study. Strikingly, the 
above mentioned systemic effects were not observed in mice without Ang II infusion. 
The results suggest that the effects of catK defi ciency on the hematopoietic system only 
manifest under conditions of Ang II induced infl ammation. In an earlier study, we 
observed decreased plaque progression and atherosclerotic plaque area in catK-/-//
apoE-/- compared with apoE-/- mice16. In addition, the number of elastin breaks in the 
media underlying the atherosclerotic plaque was substantially decreased in advanced 
lesions of catK-/-//apoE-/- compared with apoE-/- mice. In contrast, this study showed 
that catK defi ciency in apoE-/- mice did not confer protection against AAA formation, 
and did not reveal any effect on the number of elastin breaks and on proteolytic activity 
in AAA lysates. Unlike the atherosclerosis study, which was performed in non-infused 
apoE-/- mice, here apoE-/- mice were infused with Ang II to induce AAA. Combined 
with the observed pro-infl ammatory effects of catK defi ciency on circulating leukocyte 
subsets, which were strictly Ang II dependent as well, this raises the intriguing option 
that the observed pro-infl ammatory effects of catK defi ciency are opportune only in 
Ang II infused apoE-/- mice. 
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In conclusion, although catK has strong elastinolytic and collagenolytic activity, both of 
which are regarded critical processes in AAA, its defi ciency surprisingly did not protect 
against aneurysm formation. Our data suggest that the apparent lack of effects of catK 
defi ciency on medial elastin breaks and on elastinolytic and collagenolytic activity in 
AAA lysates may point to a compensatory increase in proteolytic activity exerted by 
other ECM degrading enzymes, such as catS and catC in the aneurysm. Although catK 
defi ciency did increase aneurysm collagen content, it clearly was unable to reverse 
aneurysm formation or severity. In addition, catK defi ciency was associated with an 
unexpected increase in the number of circulating granulocytes and effector T-helper cells, 
which might counteract the potentially protective pro-fi brotic effect of catK defi ciency 
in AAA. These data are remarkable given the previously reported deleterious effects of 
this protease in atherosclerosis and point to fundamental differences in the proteolytic 
processes that underlie AAA and atherosclerosis. 
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Abstract
Cathepsin K (catK) is a potent lysosomal cysteine protease involved in extracellular 
matrix (ECM) degradation and infl ammatory remodelling responses. Here we have 
investigated the contribution of catK defi ciency on carotid arterial remodeling in 
response to fl ow cessation in apoE-/- and wild type (WT) background. 
CatK protein expression was signifi cantly increased in carotid artery ligation-induced 
intimal lesions in apoE-/- compared with WT mice, suggesting that catK contributes 
differently in intimal hyperplasia in apoE-/- and WT mice. In keeping with data on 
previous studies, ligation-induced hyperplasia was more pronounced in apoE-/- 
compared to WT mice. Surprisingly, catK defi ciency completely blunted the augmented 
hyperplastic response to fl ow cessation in apoE-/-, while having no effect at all on 
vascular remodelling in WT mice. As catK defi ciency did not markedly alter lesion 
collagen content and elastic laminae fragmentation in vivo, nor macrophage elastolytic 
and collagenolytic activity in vitro, we focused on effects of catK on (systemic) 
infl ammatory response. CatK defi ciency signifi cantly reduced circulating CD3 T-cell 
numbers, but increased the regulatory T cell subset in apoE-/- but not WT mice. 
Moreover, catK defi ciency changed CD11b+Ly6G-Ly6C high monocyte distribution in 
apoE-/- but not WT mice and tended to bias macrophage polarization towards a M2a 
differentiation. In conclusion, catK defi ciency almost completely blunted the increased 
vascular remodeling response of apoE-/- mice to fl ow cessation, possibly by correcting 
hyperlipidemia-associated pro-infl ammatory effects on peripheral immune response.
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Introduction
CatK is the most potent mammalian elastase of the cathepsin family of proteases 
yet known and possesses collagenolytic as well as elastinolytic activity1, 2. Next to 
its involvement in ECM degradation, catK was reported to modulate infl ammatory 
responses via the TGF-β3 and TLR-94 signaling pathway.  In a previous study, apoE-
/- mice with a targeted disruption of the catK gene showed reduced atherosclerotic 
lesion growth3. In addition, uptake of modifi ed lipoproteins was enhanced in catK-/- 
macrophages, potentially via a caveolin-1- and scavenger receptor CD-36- dependent 
pathway 3, 5. Selective disruption of leukocyte catK was seen to dramatically decrease 
collagen and increase macrophage content of atherosclerotic lesions, leaving lesion size 
unaffected. It was suggested that smooth muscle cell (SMC) migration was hampered 
due to the abolished elastinolytic activity of macrophage catK6. Clearly both these 
studies suggested a role for macrophage catK in atherosclerosis.  
In the vascular remodeling process, proliferation and migration of SMC from the media 
to the intima contribute to intima formation7,8. Migration of SMCs requires degradation 
of ECM. In balloon-injured rat carotid arteries, increased mRNA and protein levels of 
catK were found to be enhanced in the neointima 9. There was a signifi cant increase 
in elastolytic and collagenolytic activity in the intima tissue extracts compared with 
uninjured control vessels9. The enhanced ECM degrading potential and the increased 
expression and activity of catK during neointima formation suggest that catK may 
participate in the remodeling processes during neointima formation.  To further study 
the potential role of catK in vascular remodeling, we compared carotid artery remodeling 
in the fl ow cessation model in both the catK-defi cient apoE-/- background and catK-
defi cient WT background (catK-/-//apoE-/- vs apoE-/- and catK-/- vs C57Bl6). In this 
model, fl ow cessation is used to accelerate the formation of macrophage-rich neointima 
lesions in hypercholesteremic apoE-defi cient mice and the formation of a macrophage-
poor neointima lesion in the WT mice10.   
We found that catK defi ciency signifi cantly reduced macrophage-rich neointima 
formation in the hyperlipidemic apoE-/- mice. However, macrophage-poor neointima 
formation in C57Bl6/WT mice was unaffected. Furthermore, catK defi ciency 
signifi cantly reduced circulating CD3 T-cell numbers, but increased the regulatory T cell 
subset in apoE-/- but not WT mice, suggesting that catK defi ciency protected against 
macrophage-rich lesion formation possibly by correcting hyperlipideia-associated pro-
infl ammatory effects on peripheral immune response.
Materials and Methods
Experimental model of fl ow cessation induced intimal hyperplasia/vessel retraction
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In this study, fl ow cessation was induced in C57Bl6, catK-/-, apoE-/- and catK-/-
//apoE-/- mice. Male apoE-/- mice on a C57Bl6/J background were obtained from 
IffaCredo (Lyon, France). CatK-/- mice,  kindly provided by Dr P Saftig, were generated 
on an outbred 129SVJ-C57Bl/6J genetic background 11. We subsequently backcrossed 
the catK-/- mice at least 9 times with C57Bl6/J mice and apoE-/- mice to generate 
catK+/+ and catK-/- mice on a C57Bl6/J (WT) or apoE-/- background,  respectively. 
Animals were maintained in accordance with the Dutch government guidelines and 
animal experiments were approved by the regulatory authority of the University of 
Maastricht. 
Macrophage-rich and -poor intimal lesions were induced by unilateral fl ow cessation of 
the common carotid artery in hypercholesterolemic apoE-/- and WT mice, respectively 
as described by Ivan et al10.  WT and catK-/- mice from C57Bl6/J background (17-18 
weeks of age ) were fed a normal chow (SNIFF, V1534) throughout the experiment. 
In brief, mice were anesthetized with 2.5% isofl uorane, and the common right carotid 
artery was ligated with a silk suture (5-0) near the bifurcation The same procedure was 
pursued for  apoE-/- and catK-/-//apoE-/- mice (13-16 weeks of age), at which mice 
were fed a western type diet containing 0.25% cholesterol (Research Diet, diet number 
4021.06) from two weeks before ligation onwards10, 12. 
Tissue harvesting and analysis
Four weeks after ligation, mice were sacrifi ced. The arterial tree was perfused 
with PBS containing 0.1 mg/ml nitroprusside (Sigma) and subsequently with 1% 
paraformaldehyde via a catheter inserted into the left cardiac ventr icle. Right carotid 
artery cross-sections (4 μm thick) were cut at 100 μm intervals. At each level of 100 
μm, a cross-section was stained with Lawson solution and used to determine intima, 
lumen and total vessel area as well as elastic lamina fragmentation. The relative intimal 
collagen content, i.e. the percentage of total intima area that stained positive for Sirius 
red, was determined under a microscope coupled to a computerized morphometry 
system (Quantimet 570, Leica). Morphometric analyses were performed by one blinded 
investigator (L Bai, intra-observer variability was < 10%) using a computerized 
morphometry system (Quantimet 570, Leica). Serum cholesterol level was determined 
with the CHOD-PAP method (Roche Diagnostics).
Immunohistochemistry
Immunohistochemical stainings were performed to determine macrophage (anti-Mac3), 
T cell (anti-CD3+) and SMC (α-smooth muscle actin, α-SMA) content, as described 
previously5. The relative intimal macrophage, T cell and SMC content, was calculated 
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by dividing the number of lesional Mac3+, CD3+ and α-SMA+ cells, respectively by 
the total number of cells in the lesion. Expression of catK was determined using a goat 
anti-human catK (c16) antibody (1:100, Santa Cruz). The relative catK-positive area was 
determined by a computerized morphometry (Quantimet 570, Leica). Mouse spleen 
was used as positive control for CD3 and catK staining, and mouse atherosclerotic 
lesions as positive control of both Mac3 and α-SMA staining. Deletion of the primary 
antibody served as negative control. No positive staining for any of the antibodies was 
observed on negative controls.
All measurements were conducted by a single investigator (L Bai, intra-observer 
variability was < 10%). 
Fluorescence-activated cell sorting (FACS)-analysis
Splenocytes and blood were isolated from apoE-/-, catK-/-//apoE-/-, WT, and catK-
/- mice. Erythrocytes in peripheral blood and spleen were removed by hypotonic 
lysis with NH4Cl. Cells were incubated fi rst with anti-CD16/32 (eBioscience) to block 
Fc receptor binding to antibodies on macrophages, neutrophils and mast cells and 
stained with anti-CD3-FITC, anti-CD8-Pacifi c blue, anti-CD25-APC, anti-CD45R(B220)-
Pe-Cy7 (eBioscience) and anti-CD4-PerCp (BD-Biosciences Pharmingen). Foxp3-
positive cells were detected with PE anti-mouse/rat Foxp3 Staining Set, according 
to the manufacturer’s instruction (eBioscience). Peripheral blood leukocytes were 
incubated with anti-CD11b-pacifi c blue (eBioscience) and anti-ly6G-PE (BD-Biosciences 
Pharmingen) to detect monocytes (CD11b+ly6G-) and granulocytes (CD11b+ly6G+). For 
measurement of infl ammatory monocytes (CD11b+Ly6G-Ly6Chigh) cells were stained 
with anti-Ly6C-FITC (Miltenyi Biotec). Blood natural killer (NK) cells were stained by 
anti-CD49b(DX5)-APC (Miltenyi Biotec).
Cell isolation and culturing
Bone marro w–derived macrophages (BMM) were isolated from the femur and tibia of 
WT, catK-/-, apoE-/-, and catK-/- //apoE-/- mice. Cells were cultured in standard 
RPMI culture medium containing L-glutamine, HEPES, 10% fetal calf serum, 100 IU/
mL penicillin/streptomycin, and 15% L929 cell conditioned medium. Macrophage 
polarization was induced by culturing BMM for 16 h at a density of 1x 106 cells/ml in the 
aforementioned medium supplemented with 10 ng/ml LPS, to induce M1 polarization, 
or 20 ng/ml IL-4 to induce M2 polarization. 
126
Chapter 8
Quantitative RT-PCR
RNA was extracted from BMM lysate with Nucleospin RNA II kit (MACHEREY-
NAGEL). cDNA was generated with iSCript TM CDNA synthesis kit (BIO-RAD). 
Real-time PCR was done with a Taqman IQ TM SYBR Green Super Mix (BIO-RAD). 
Cyclophilin A was used to normalize RNA quantity . Primer sequences of arginase, MR 
(mannose receptor), IL-10, Nos2, IL-18, IFN-γ and cyclophilin are shown in table 8.1. 
The data were expressed as ratio of the quantity of specifi c transcripts to the quantity 
of the cyclophilin A gene. The relative gene expression data from WT, catK-/-, apoE-/- 
and catK-/-//apoE-/- background was then normalized to the data of WT background.
Table 8.1
Forward primer (5’-3’) Reverse primer (5’-3’)
Arginase ATGGAAGAGACCTTCAGCTAC GCTGTCTTCCCAAGAGTTGGG
MR GCAAATGGAGCCGTCTGTGC CTCGTGGATCTCCGTGACAC
IL-10 TCTTACTGACTGGCATGAGGATCA GTCCGCAGCTCTAGGAGCAT
Nos2 CAGCTGGGCTGTACAAACCTT CATTGCAAGTGAAGCGTTTCG
IL-18 ACAACTTTGGCCGACTTCAC GGGTTCACTGGCACTTTGAT
IFN-γ TGGCTGTTTCTGGCTGTTACTG GCTCTGCAGGATTTTCATGTCA
Cyclophilin CAAATGCTGGACCAAACACAA TTCACCTTCCCAAAGACCACAT
Elastase and collagenase activity assay
BMM were isolated from the femur and tibia of WT, catK-/-, apoE-/-, and catK-/-//
apoE-/- mice. Cell lysates were extracted using cold RIPA buffer containing 25mM 
Tris HCl, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS. Protein 
concentration in the samples was determined with BCA protein assay reagent kit 
(PIERCE). Collagenase and elastase activities in the cell lysates were determined using 
EnzChek gelatinase/collagenase assay kit (Molecular Probes). Assays were performed 
at room temperature in 200 ul reaction buffer containing 20 ul of DQ collagen I (D-12060, 
Molecular probe), 20 ul of DQ collagen IV (D-12052, Molecular probe), or 50 ul of DQ 
elastin (provided by the kit) and 100ul of the protein extracts at 200 ug/ml. Substrate 
hydrolysis was monitored at 0, 1, 2,3 and 4 hours at room temperature by fl uorescence 
spectometry in a fl uorescence microplate reader (λexc=485 nm; λem=538 nm; with a 
lower cut-off at 515nm). Values were corrected for background fl uorescence, refl ecting 
non-enzymatic probe hydrolysis.
127
Effect of CatK on artery remodeling
Statistics
Statistical analyses were performed using a nonparametric Mann–Whitney U test. Data 
are expressed as mean±SEM, and differences were considered statistically signifi cant at 
P<0.05.
Results
Intimal lesions in apoE-/- mice have increased catK protein expression
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Figure 8.1 CatK expression in macrophage-rich 
(apoE-/-) and macrophage-poor (WT) fl ow ces-
sation-induced intimal lesions. A. Representative 
pictures of catK staining in WT and apoE-/- mice. 
Full color fi gures are shown on page 174. B. Rela-
tive catK-positivity was calculated by dividing the 
anti-catK Ab stained area by the total intima area 
(P=0.027; n=5 for WT, n=12 for apoE-/-). 
A
B
CatK expression in fl ow cessation-induced intimal lesions of WT mice was very low 
and mainly confi ned to SMCs and the ECM (n=5). In contrast, macrophage-rich lesions 
of apoE-/- mice showed pronounced expression of catK (n=12, fi gure 8.1B), primarily 
residing in cytoplasm of macrophages, but also in SMCs and, in a more diffuse manner, 
in the extracellular matrix (fi gure 8.1A). Full color fi gures are shown on page 174.
CatK defi ciency attenuates fl ow cessation-induced intimal hyperplasia in apoE-/- but 
not WT mice
CatK defi ciency did not alter serum cholesterol level in neither apoE-/- nor WT mice 
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(n=14-15 for apoE-/- and catK-/-//apoE-/- mice; n=7 for WT and catK-/- mice, fi gure 
8.2). 
ApoE defi ciency signifi cantly enhanced lumen area (p=0.027), average lesion area 
(p=0.006) and total vessel area (p=0.009) compared to WT background, indicating a 
prominent outward remodeling in apoE-/- background. Average lesion area, total 
vessel and lumen area were comparable in WT and catK-/- mice (n=6-8, fi gure 8.3B). 
In sharp contrast, catK defi ciency was found to protect against intimal hyperplasia in 
apoE-/- mice. Average lesion and total vessel area were signifi cantly reduced in catK-
/-//apoE-/- compared to apoE-/- mice (n=14-15, fi gure 8.3B), whereas lumen area was 
not signifi cantly different (n=14-15, fi gure 8.3B). In fact, lesion size and total vessel area 
of catK-/-//apoE-/- mice were almost identical to that of normolipidemic WT and 
catK-/- mice. Representative micrographs showing HE staining of intima lesions in 
WT, catK-/-, apoE-/- and catK-/-//apoE-/- mice are shown in fi gure 8.3A. Full color 
fi gures are shown on page 174. Thus, apoE defi ciency induced a prominent outward 
remodeling and neointimal growth in ligated right carotid artery compared to WT. 
CatK defi ciency almost completely reversed this outward remodeling to basal levels of 
WT mice.
CatK defi ciency did not alter lesion composition in apoE-/- and WT mice
There was no difference in SMC content, collagen content and cell density in lesions of 
WT and apoE-/- mice (fi gure 8.4A-C). Macrophage number (n=14-15,  fi gure 8.4A), CD3 
+ T cell number  (n=14-15, fi gure 8.4A) SMC number (n=13-15, fi gure 8.4A) as well as 
collagen content (n=14-15, fi gure 8.4B) did not differ between apoE-/-//catK-/- and 
apoE-/- mice. Total cell number tended to be higher in macrophage-rich lesions of catK-
/-//apoE-/- than of apoE-/- mice (n=14-15, fi gure 8.4C). As cleaved caspase-3 positive 
cells were scant but present at essentially similar numbers in catK-/-//apoE-/- and 
apoE-/- lesions (data not show), the increased cell density in catK-/-//apoE-/- mice 
is probably not attributable to a decrease in apoptotic rate. SMC, collagen content and 
total cell density of macrophage-poor lesions of WT and catK-/- mice were comparable 
(n=6-8, fi gure 8.4A-C). 
Despite the strikingly different effect of catK defi ciency on intimal hyperplasia and 
the differential intimal catK expression in WT and apoE-/- mice, catK defi ciency did 
not affect medial elastic laminae fragmentation  in both mouse strains (n=6-8 for WT 
background and 14 for apoE-/- background, respectively; fi gure 8.5A), suggesting 
that catK is not a critical elastolytic protease in fl ow cessation induced elastic laminae 
breakdown.
Macrophage elastolytic activity is not markedly affected by catK defi ciency in both 
129
Effect of CatK on artery remodeling
Figure 8.2. The absence of catK did not affect serum 
total cholesterol in both WT and apoE-/- mice. Values 
represent the mean ± SEM. (n=14-15 for apoE-/- and 
catK-/-//apoE--/- mice; n=7 for WT and catK-/- 
mice).
Figure 8.3 Effect of catK defi ciency on intimal hy-
perplasia. A. Representative micrographs showing 
HE staining of intima lesions in WT, catK-/-, apoE-
/- and catK-/-//apoE-/- mice. Full color fi gures 
are shown on page 174. B. CatK defi ciency did not 
affect lumen, intima and total vessel area in WT 
mice. CatK defi ciency signifi cantly reduced intima 
(P=0.019) and total vessel area (P=0.024) in apoE-
/- mice. Values represent the mean ± SEM. (n= 6-8 
for WT and catK-/- mice, n=14-15 for apoE-/- and 
catK-/-//apoE-/- mice).
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0
10
20
30
40
C
ol
la
ge
n 
co
nt
en
t (
%
)
P=0.068
apoE-/- catK-/-//apoE-/- C57Bl6 catK-/-
0.0
0.5
1.0
1.5
2.0
To
ta
l c
el
l p
er
 in
tim
a 
ar
ea
 (%
) Figure 8.4 CatK defi ciency did not affect macrophage, 
CD3 and SMC content in the macrophage-rich lesions 
of apoE-/- mice (A). CatK defi ciency also did not alter 
SMC content in the macrophage-poor lesions of WT 
mice (A). The number of Mac3-positive, CD3-positive 
and α-SMA-positive cells in the intima area were cor-
rected for the total number of cells in the entire intima 
area. CatK defi ciency did not change collagen content 
in the intima area in apoE-/- and WT mice (B).  CatK 
defi ciency did not signifi cantly alter cell density in the 
intima area in apoE-/- and WT mice (C). Total cell number in neointima lesion was corrected for the cor-
responding lesion area. Values represent the mean ± SEM. (n= 6-8 for WT and catK-/- mice, n=14-15 for 
apoE-/- and catK-/-//apoE-/- mice).
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WT and apoE-/- mice
Ivan et al have shown that macrophages increase expansive arterial remodeling and 
intimal hyperplasia by promoting matrix degradation10. Therefore, we studied the 
proteolytic activity of BMM isolated from catK-/-//apoE-/-, apoE-/-, catK-/-, and WT 
mice. Elastinolytic activity in apoE-/- derived BMM was not affected by catK defi ciency 
(fi gure 8.5B). Furthermore, collagen type I and collagen IV degradation in apoE-/- 
derived BMM was unchanged in catK-/- macrophages (fi gure 8.5C and D). Similarly, 
catK defi ciency in WT BMM did not infl uence degradation of collagen type I, IV and 
elastin (fi gure 8.5E-G). 
Peripheral immune activity was altered in catK defi cient apoE-/- mice but not in catK 
defi cient WT mice
As outward remodeling was more pronounced in the single apoE-/- mice, which is 
possibly mediated by intimal leukocytes, we investigated the infl ammatory status of 
catK defi cient mice in more detail. Peripheral immune activity was assessed by FACS 
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Figure 8.5 A: CatK defi ciency did not affect medial elastin break frequency in apoE-/- and in WT mice. 
Frequency is expressed as average number of breaks per cross-section. Elastin, collagen I and IV degrada-
tion activity was not signifi cantly altered in BMMs of CatK-/-//apoE-/- mice compared to apoE-/- mice 
(B-D). CatK defi ciency in the C57Bl6 background also did not lead to altered collagen I, IV and elastin 
degradation activity in BMMs as measured by fl uorometric enzyme (E-G). Values represent the mean ± 
SEM. (n=6 for each group).
analysis. There was no difference in CD3+ T cells (expressed as percentage of total 
living cells) in spleen and blood between WT and apoE-/- mice. However, apoE-/- 
signifi cantly enhanced natual killer (NK) cells (expressed as percentage of total living 
cells) in blood compared with WT mice (p=0.0041). Furthermore, apoE-/- dramatically 
reduced the percentage of regulatory T cells (CD4+CD25+FoxP3+  relative to CD4+ T 
cells) in spleen (p=0.0021) and blood (p=0.0012) compared with WT mice.  In addition, 
apoE-/- mice showed signifi cantly decreased level of of infl ammatory monocytes 
(CD11b+Ly6G-Ly6C high) in blood compared with WT mice. Thus apoE-/- mice showed 
increased levels of circulating NK cells and decreased regulatory T cell and infl ammatory 
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monocyte numbers compared with WT mice. 
CD3+ T cells in spleen and NK cells in blood decreased in catK-/-//apoE-/- mice 
compared with apoE-/- mice (n=6, fi gure 8.6A). While the total CD3 T cell content of 
spleen was reduced in catK-/-//apoE-/- mice, the percentage of regulatory T cells 
(CD4+CD25+FoxP3+  relative to CD4+ T cells) was signifi cantly increased in blood of 
catK-/-//apoE-/- mice (n=6, fi gure 8.6B). This is consistent with an increase in splenic 
regulatory T cells in catK-/-//apoE-/- mice (n=6, fi gure 8.6B). Thus, catK defi ciency 
normalizes regulatory T cell levels in apoE-/- mice to levels found in WT, Although 
evidence implicating the direct role of regulatory T cell on vascular remodeling is lacking, 
regulatory T cell deletion signifi cantly augmented post-ischemic neovascularization13. 
These effects were correlated with enhanced accumulation of CD3+ T cells in the 
ischemic leg13. On the other hand, treatment of CD28–/– mice with anti-CD3+ antibody 
enhanced the number of endogenous Treg cells and led to a signifi cant reduction of the 
postischemic infl ammatory response and neovascularization13. Thus, regulatory T cell 
might inhibit outward remodeling through abrogating infl ammatory responses. 
Interestingly, there was a signifi cant increase in the percentage of infl ammatory 
monocytes (CD11b+Ly6G-Ly6Chigh) in blood of catK-/-//apoE-/- compared with 
apoE-/- mice (n=6, fi gure 8.6C). Consistently, the percentage of CD11b+Ly6G-Ly6C- 
cells of monocytes was signifi cantly reduced in catK-/-//apoE-/- relative to apoE-/- 
mice (n=6, p=0.047, fi gure 8.6C). In contrast, catK defi ciency in normolipidemic C57Bl6 
mice did not affect peripheral immune profi les (n=6, fi gure 8.6D, E and F). Thus, catK 
defi ciency in apoE-/- mice dramatically reduced systemic CD3+ and NK cell counts 
and an increase in Treg cell population, which in fact were normalized to base levels of 
WT mice, whereas no effects on these cell populations were seen in the WT mice. Based 
on the above fi ndings, the systemic anti-infl ammatory potential of catK defi ciency in 
apoE-/- mice might explain the observed protective effect of catK defi ciency against 
macrophage-rich lesion formation as apoE-/- mice develop a macrophage-rich 
neointima after carotid artery ligation that is characterized by stronger infl ammatory 
responses compared to WT background14 
CatK defi ciency tended to shift non-stimulated apoE-/- BMM to M2a phenotype
Several studies have shown that macrophage-derived infl ammatory growth factors 
contribute to intimal lesion enlargement15, 16,17. CatK defi ciency has been shown to 
affect macrophage foam cell formation5, however the effect of catK on macrophage 
polarization is unknown. We therefore studied the effect of catK defi ciency on 
macrophage polarization in vitro. The expression of M2 macrophage markers such 
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Figure 8.6 Flow-cytometric analysis of the effect of catK defi ciency on CD3+, NK, CD4+CD25+Foxp3 
regulatory T cells and CD11b+Ly6G-Ly6Chigh/- monocytes in spleen and blood. Percentage of CD3+ T 
cells in spleen (P=0.025) and NK cells in blood (P=0.025) were signifi cantly reduced in catK-/-//apoE-
/- mice compared with apoE-/- (A). The regulatory T cell population defi ned as CD4+CD25+Foxp3+ 
cells, was signifi cantly increased in catK-/-//apoE-/- mice in blood (B, P=0.025). CD11b+Ly6G-Ly6Chigh 
monocytes were signifi cantly increased (P=0.035) and CD11b+Ly6G-Ly6C- monocytes signifi cantly 
reduced (P=0.047) in blood of catK-/-//apoE-/- compared with apoE-/- mice (C). CatK defi ciency in 
the WT mice did not affect peripheral immune activity (D, E and F). Values represent the mean ± SEM. 
(n=6 for each group).
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as arginase-1 (marker for M2a macrophage), IL-10 (marker for M2b macrophage), 
mannose receptor (MR, marker for M2a), and M1 macrophage markers such as IL-18, 
Nos2 and IFN-γ were measured in BMM from catK-/-//apoE-/-, apoE-/-, catK-/-, and 
WT mice without prior stimulation to assess baseline polarization. Compared to WT, 
apoE-/- signifi cantly enhanced both M1 macrophage marker IL-18 (p=0.006) and M2 
macropahge marker arginase (p=0.004), MR (p=0.037) and IL-10 (p=0.055). However, 
Nos2 expression was signifi cantly reduced in apoE-/- mice compared to WT (p=0.004).
CatK defi ciency in WT mice did not markedly alter macrophage polarization. Compared 
to WT, catK-/- BMM only showed a tendency towards enhanced arginase expression 
(n=6, fi gure 8.7A). Furthermore, the expression of IL-10, MR, Nos2 and IL-18 were not 
different between catK-/- and WT –derived BMM (n=6, fi gure 8.7A). The expression 
of IFN-γ was below detection limit. In sharp contrast, BMM-derived from catK-/-//
apoE-/- mice displayed a signifi cantly decreased expression of IL-10 (n=6, fi gure 8.7B), 
while conversely arginase expression was increased compared with BMM-derived 
from apoE-/- mice (n=6, fi gure 8.7B). In addition, a tendency to a decreased expression 
of the M1 macrophage marker of IL-18 was found in catK-/-//apoE-/- BMM compared 
with apoE-/- BMM (p=0.078, n=6, fi gure 8.7B). There was no difference in Nos2 and 
MR expression between catK-/-//apoE-/- and apoE-/- -derived BMM (n=6, fi gure 
8.7B). Again, the expression of IFN-γ by non-stimulated cells was below detection limit. 
Therefore, defi ciency of catK in the apoE-/- background skewed basal macrophage 
polarization towards a M2a macrophage phenotype.  
Cytokine induced macrophage polarization towards M2 and M1 is amplifi ed in catK 
defi cient apoE-/- bone marrow macrophages 
We next analyzed the capacity of BMM to polarize in response to IL-4 (M2) or LPS 
(M1) in vitro. CatK defi cient macrophages showed amplifi ed response to polarizing 
cytokines. CatK defi ciency in WT mice did not affect M2 marker expression upon IL-4 
stimulation (n=6, fi gure 8.7C).  However catK defi ciency signifi cantly enhanced LPS-
induced IL-18 and Nos2 expression (n=6, fi gure 8.7D). Therefore, catK defi ciency in WT 
mice skewed macrophage polarization towards a M1 phenotype.
Upon stimulation with IL-4, catK-/-//apoE-/- -derived BMM tended to increase both 
arginase-1 (n=6, fi gure 8.7E) and MR expression (n=6, fi gure 8.7E) compared with apoE-
/- -derived BMM. There was no difference in IL-10 expression between catK-/-//apoE-
/- and apoE-/- BMM upon IL-4 stimulation (n=6, fi gure 8.7E), while that of IL-4 was 
below detection limit for all the samples. Intriguingly, LPS stimulation led to increased 
induction of NOS2 and to a lesser extent IL-18 in catK-/-//apoE-/- versus apoE-/- 
- BMM (n=6, fi gure 8.7F). There was no difference in LPS-induced IFN-γ expression 
between the two groups. Thus, catK defi ciency in apoE-/- mice enhanced the cytokine 
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Figure 8.7 Effect of catK defi ciency on M1 and M2 macrophage marker expression of non-stimulated and 
IL-4/LPS stimulated BMM. BMM from WT, catK-/-, apoE-/- and catK-/-//apoE-/-  mice were isolated 
and  cultured in the absence or presence of LPS/IL-4 for 16 h. BMM cell lysates were analyzed for M1 and 
M2 marker expression. CatK-/- did not signifi cantly change M1 and M2 marker expression in BMM (A). 
CatK-/-//apoE-/- -derived BMM increased arginase expression (P=0.004) and signifi cantly decreased 
IL-10 expression (P=0.004) compared with apoE-/- -derived-BMM (B). The defi ciency of catK in WT mice 
signifi cantly enhanced LPS-induced IL-18 expression without altering the expression of other M1/M2 
markers (C and D). Upon stimulation with IL-4, catK-/-//apoE-/- -derived BMM did not signifi cantly 
change both arginase and MR expression compared with apoE-/- BMM (E). Nos2 expression was 
signifi cantly increased in catK-/-//apoE-/- -derived BMMs upon LPS stimulation (p=0.004, F). Values 
represent the mean ± SEM. (n=6 for each group).
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induced expression of both M2 and M1 macrophage marker, although the effect on 
IL-4-induced M2 macrophage marker expression was moderate and borderline 
signifi cant. 
Discussio n 
Vascular remodeling (include both outward and inward remodeling) is defi ned as the 
adaptation of vascular wall geometry in response to (patho)physiologic stimuli18. It 
includes a progressive and persistent change in vessel size and structural alterations of the 
vessel wall, including degradation and reorganization of the ECM. Vascular remodeling 
is a common feature both in atherosclerosis, after invasive vascular interventions, such 
as percutaneous transluminal coronary angioplasty, and in fl ow cessation- induced 
vessel retraction7, 8, 10, 18. Pivotal in vascular remodeling are degradation of the elastic 
laminae and the ECM, vascular infl ammation and SMC phenotypic changes. ApoE-/- 
mice have been used to study vascular remodeling processes under pathophysiological 
conditions, and ligation of the carotid artery in these mice was employed to emulate 
fl ow cessation-induced vascular remodeling and infl ammatory hyperplastia19,10,20. 
In this model, remodeling processes are dependent on both macrophage content10 
and macrophage-derived proteolytic activity 21. The key role of the cystein protease 
catK in atherosclerosis5 and proteolysis of ECM and in particular collagen 2, 22 led us 
to investigate the contribution of this protease in fl ow cessation-induced remodeling 
of the carotid artery. We here show that catK defi ciency normalizes the excessive, 
infl ammatory intimal hyperplasia observed in hyperlipidemic apoE-/- mice , suggesting 
that catK is a key player in apoE-/--associated vascular remodeling in fl ow cessation. 
Moreover, we provide evidence that catK may do so by modulating apoE-/- associated 
hyperinfl ammatory status rather than via its elastolytic activity.
First, we demonstrated that catK protein is more abundantly expressed in lesions of 
hyperlipidemic apoE-/- compared to WT mice, and mainly co-localized with lesional 
leukocytes. In vivo studies revealed that intimal hyperplasia and vascular remodeling is 
much more pronounced in apoE-/- than in WT mice. CatK defi ciency was seen to only 
protect against macrophage-rich (apoE-/-) but not macrophage-poor lesion formation 
(WT mice) and almost completely prevented the induced hyperplasia and remodeling 
observed in apoE-/- mice. This suggests that catK is instrumental in the hyperlipidemia 
associated augmented hyperplastic response to fl ow cessation. 
Consistent with previous reports 10, 20, apoE-/- mice show more pronounced expansive 
remodeling in response to fl ow cessation than WT mice. Interestingly, Eschert et al 
recently showed that apoE-/- mice fed a normal chow diet displayed ‘maladaptive’ 
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constrictive remodeling, while cholesterol-fed apoE-/- mice displayed outward/
expansive remodeling20. The extent of this phenomenon is overtly linked to macrophage 
content and function as intimal lesions of both WT and apoE-/- mice fed a normal 
diet contained virtually no macrophages20. Outward remodeling was postulated to be 
driven by macrophage expression of MMP, which was supported by the observation 
that MMP9-/-//apoE-/- mice showed a prominent reduction in the total vessel and 
intima area after carotid artery ligation21. In our study, catK defi ciency induced a 
similar lesion phenotype and inhibited macrophage-rich lesion formation in the apoE-
/- mice. In contrast to the study by Lessner et al, in which MMP9 defi ciency resulted in 
a decrease in collagen and SMC content, we did not observe any changes in the relative 
collagen and SMC content in lesions of catK defi cient apoE-/- and WT mice, despite 
a complete normalization of the aggravated remodeling response in the former. As 
discussed above, our study also did not reveal any effect of catK defi ciency on elastin 
laminae fragmentation and macrophage proteolytic activity in both mouse strains. 
Apparently the reduced proteolytic activity in catK defi ciency may only partly underlie 
the normalized vascular remodeling response to carotid artery ligation in apoE-/- mice. 
Interestingly, in addition to its role in ECM degradation, catK was also reported to have 
proinfl ammatory activity by participating in infl ammatory signaling pathways such as 
TGF-β3 and TLR-94. Therefore, we investigated the infl ammatory status of catK defi cient 
mice in more detail. Consistent with literature fi ndings, apoE-/- mice showed increased 
levels of circulating NK cells and decreased Treg cell numbers compared with WT mice. 
Of note, catK defi ciency in apoE-/- mice was accompanied by dramatically reduced 
systemic CD3+ and NK cell counts and an increase in Treg cell population, which in fact 
were normalized to base levels of WT mice, whereas no effects on these cell populations 
were seen in the WT mice. 
CatK defi ciency not only alter T-cell but also myeloid differentiation. Phenotypically, 
Ly6Chigh subsets of monocytes are characterized as infl ammatory monocytes.  Ly6Chigh 
monocytes have the capacity to migrate to sites of peripheral infl ammation and are 
important for the resolution of infl ammation, whereas Ly6C- monocytes enter the 
tissues and replenish the tissue-resident macrophage and DC population23. Surprisingly, 
apoE-/- mice showed signifi cantly decreased level of circulating CD11b+Ly6G-Ly6Chigh 
monocytes compared with WT mice. This fi nding is not consistent with the previous 
report showing an elevated Ly6Chighmonocyte in circulation in apoE-/- vs WT mice24. 
Interestingly, the blood monocyte population of catK-/-//apoE-/- mice was enriched 
in infl ammatory CD11b+Ly6G-Ly6Chigh, whereas that of resident Ly6C- monocytes 
was signifi cantly reduced compared with apoE-/- mice. Thus, catK defi ciency under 
apoE-/- background normalized Ly6Chigh monocyte population to base level of WT 
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background. The implications of this fi nding for the normalized vascular remodeling in 
catK defi ciency remain to be addressed.
CatK defi ciency may not only affect monocyte differentiation but also monocyte/
macrophage polarization. Our data show that catK defi ciency tends to shift non-
stimulated apoE-/- BMM to an anti-infl ammatory M2a phenotype, which are deemed 
instrumental in wound healing responses25, 26. CatK defi ciency, however, had a more 
pronounced effect on LPS or IL-4 induced macrophage polarization towards M1 and 
M2, respectively. CatK defi ciency in apoE-/- mice led to an augmented polarization, 
whereas in WT BMM it favored M1 polarization. Combined, the inhibitory effects of 
catK defi ciency on intimal hyperplasia in apoE-/- mice is at most partly attributable to 
a shifted macrophage polarization. 
As mentioned above, catK defi ciency signifi cantly reduced circulating CD3 T-cell 
numbers and increased the regulatory T cell subset in apoE-/- but not WT mice.This 
raises the possibility that the observed immunomodulatory effects of catK defi ciency 
are opportune in hyperlipidemic apoE-/- mice only, attenuating the elevated systemic 
infl ammatory level in apoE -/- mice to that of normolipidemic WT mice. The fact 
that the increased hyperplastic and remodeling response of apoE-/- mice was almost 
completely prevented in catK defi ciency suggests that catK may directly or indirectly 
be responsible for the aggravated fl ow cessation associated vascular remodeling in 
apoE-/- mice. Whether or not this is related to hyperlipidemia or to the absence of 
apoE remains to be determined. Interestingly subphysiological plasma levels of apoE 
were shown to inhibit intimal hyperplasia in an arterial injury model, suggesting that 
apoE may, independent of plasma cholesterol levels, inhibit intima formation27. Thus, 
the systemic anti-infl ammatory potential of catK defi ciency in mice might lead to a 
protection against macrophage-rich lesion formation in the apoE-/- mice, but not in 
the WT mice. The molecular mechanism underlying the anti-infl ammatory potential 
of catK defi ciency might involve TLR9 and TGF-β signaling pathway. CatK inhibition 
led to reduced TLR9 responses4 and stimulated TGF-β signaling3.  Although TLR4 was 
reported to involve in outward arterial remodeling in apoE-/- mice28, the role of TLR9 
in vascular remodeling is less defi ned. In this study, we focused on the role of catK 
defi ciency on infl ammatory status. Nevertheless, whether or not catK defi ciency will 
infl uence lesion component of T cells, macrophage polarization or specifi cally TLR9 
and TGF-β activity remains to be addressed.
In summary, catK defi ciency completely normalized the increased vascular remodeling 
response to fl ow cessation in apoE-/- mice, but did not affect macrophage-poor lesion 
formation in wild type mice. This identifi es catK as a major culprit in fl ow cessation-
induced infl ammatory remodeling and possibly vessel retraction. Furthermore 
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our data suggest that catK defi ciency does so by inhibiting the apoE-/- associated 
hyperinfl ammatory status, rather than by attenuating ECM degradation.  
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Infl ammation and extracellular matrix (ECM) remodeling are common features of 
several vascular pathologies such as atherosclerosis, aortic aneurysm formation and 
neointima formation1. In addition, infl ammation and ECM degradation are linked at 
multiple levels during initiation and progression of these pathologies. Infl ammatory 
cells such as monocytes/macrophages and T cells are ubiquitously involved at every 
phase of atherogenesis. In the early stage, monocyte-derived macrophages, smooth 
muscle cell (SMC) and T cells are involved in intimal thickening/intimal xanthoma 
formation2, 3.  Cytokines, chemokines, growth factors and especially proteolytic enzymes 
secreted by the infl ammatory cells such as macrophages and at a later stage also by T 
cells stimulate the degradation of the fi brous cap, which may lead to plaque rupture4. 
Another vascular disease that shows features of infl ammation is an abdominal aortic 
aneurysm (AAA). Infl ammatory cells such as macrophages, T cells, B cells and mast 
cells are present in AAA5, 6. In addition to infl ammation, AAA is typifi ed by a permanent 
dilation of the abdominal aorta as a result of matrix degradation by excessive protease 
activity7. During neointima formation, proliferation and migration of SMC from the 
media to the intima facilitated by ECM  degradation, contribute to intima formation8, 
9.  In addition to SMC as the constituents of the neointima, infl ammatory cells secrete 
proinfl ammatory cytokines and growth factors, which may facilitate their recruitment 
into the neointima10, 11. 
Thus, in all three vascular pathologies, infl ammation and matrix degradation are common 
denominators. In this thesis we explored the therapeutic potential of calcineurin-
dependent immunosuppression (part 1). We hypothesized that calcineurin-NFAT 
signaling pathway inhibition protects against infl ammation-related vascular pathology. 
In part 2, the potential role of cathepsin K (catK), a potent lysosomal cysteine protease, 
in these vascular pathologies were discussed. As ECM degradation by protease is a 
common feature of AAA and neointima formation, we hypothesized that defi ciency 
of catK protects against these vascular pathologies. As infl ammatory and proteolytic 
pathways are dependent, a link between the NFAT-dependent calcineurin and catK 
signaling pathways is discussed. The major fi ndings of the experiments performed 
in this thesis are summarized in table 9.1. In short, we found that low-dose but not 
high-dose FK506 treatment protected against collar-induced atherosclerosis formation, 
whereas the low-dose was ineffective in preventing angiotensin II (Ang II)-induced AAA 
formation. Moreover, NFATC2 defi ciency in hematopoietic cell lineages did deteriorate 
rather than protect against atherosclerosis formation. Finally, catK defi ciency protected 
against ligation-induced neointima formation in apoE-/- mice, leaving neointima 
formation in WT and aneurysm  formation in apoE-/- mice unaffected. 
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Table 9.1
Treatment Model Outcome Possible mechanism
FK506 low-dose Collar-induced 
atherosclerosis in 
apoE-/- mice
Reduced Low and high dose of FK506 differentially 
skewed Th1/Th2 balancehigh-dose No effect
FK506 (low dose)
Ang II-induced 
AAA in apoE-/- 
mice
No effect
The distinct pathological characteristics of 
atherosclerosis and AAA formation might 
explain the differential effect
NFATC2-/- BMT
Atherosclerosis 
in aortic arch in 
LDLr-/- mice
Enhanced
NFATC2-defi cient T cells showed an 
enhanced proliferative activity and displayed 
a memory T cell phenotype more prone to 
migrate to the atherosclerotic plaque
CatK-/-
Ang II-induced 
AAA in apoE-/- 
mice
No effect
Compensatory increase in proteolytic activity 
exerted by catS/C in catK-/-//apoE-/- mice. 
Increase in circulating granulocytes and 
effector T-helper cells in catK-/-//apoE-/- 
mice.
CatK-/-
Ligation-induced 
neointima 
formation in apoE-
/- mice
Reduced
CatK defi ciency corrected apoE-/- associated 
proinfl ammatory effect on peripheral 
immune response whereas had no effect on 
peripheral immune response in C57Bl6 mice.
Ligation-induced 
neointima 
formation in 
C57Bl6 mice
No effect
Part 1: Immunosuppressive therapy in vascular disease 
Local immunosuppressive effect of FK506 in atherosclerosis
FK506 is a widely used immunosuppressive drug that inhibits the calcineurin-NFAT 
signaling pathway. As shown in chapter 3, low- but not high-dose treatment with FK506 
reduced collar-induced atherosclerotic lesion formation in apoE-/- mice. We already 
discussed in chapter 3 that low- and high-dose FK506 affected atherogenesis differently 
probably by differentially skewing the Th1/Th2 balance. An alternative explanation 
could be that the presence of FK506-binding proteins (FKBPs) in atherosclerotic tissues 
is responsible for the dose- dependent effect of FK506 on atherosclerosis formation. 
Evidence suggests that the effects of FK506 are controlled by the relative expression 
profi le of FKBP or immunophilins in particular tissues12, 13. This implies that identical 
doses of FK506 could affect diverse tissues differently. 
A large number of immunophilins belonging to the FKBP family have been discovered, 
with FKBP12 considered as the archetypal member14. It is generally recognized that 
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FK506 binds to FKBP12 and effectively inhibits the downstream calcineurin signaling 
pathway15, 16. Interestingly, gene expression profi ling of human in-stent-restenosis 
showed that FKBP12 was upregulated in the neointimal tissue retrieved by helix-
cutter atherectomy17. Moreover, immunohistochemistry staining of FKBP12 revealed 
a signifi cant increase in FKBP12 expression in human in-stent restenosis atherectomy 
specimens compared to that in primary stable atheroma 18. This suggests that restenosis 
might be sensitive to FK506. Indeed, a FK506-eluting stent in both a porcine coronary 
artery model and a canine model, effectively suppressed neointima formation in 
comparison with bare stents19, 20. 
To investigate changes in FKBP expression profi les further, we have explored our 
existing microarray data base in which gene expression profi les of human atherosclerotic 
lesions are analyzed. Analysis showed that FKBP12 was signifi cantly upregulated in 
stable advanced carotid lesions compared to early carotid lesions (fold change: 1.10255, 
p=0.00032). The fact that stable advanced atherosclerotic lesions  had signifi cantly 
higher expression of FKBP12 suggests that advanced atherosclerotic lesions compared 
to initial lesions might be more sensitive to FK506 treatment. Therefore, the low-dose 
of FK506 might exert its protective effect not only via a systemic immunosuppressive 
effect, but also at the level of the vessel wall by directly binding to FKBP12. Whereas at 
a high dose, FK506 might bind to other FKBPs (discussed in the next paragraph) and 
therefore might overrule the effect of   FKBP12. The lack of sensitivity of AAA for FK506 
may suggest that FKBP12 expression is low.  However, we do not have data on FKBP12 
expression in aneurysm tissue. 
In addition, other FKBP family members such as FKBP38, 51, and 52 not only consist 
of a single FK506 binding domain (FKBD), but also contain additional functional units, 
such as tetratricopeptide repeat TPR domains, calmodulin binding and transmembrane 
motifs. Thus they were not only able to bind to FK50621, but are also associated with 
other functions21 such as heat shock protein 90-dependent signal transduction22, nuclear 
translocation of progesterone receptor, glucocorticoid receptor and ternary complexes23.
Thus, next to the level of expression of FKBP12 as a determinant of the local FK506 
effect, it is possible that other FKBPs mediate actions beyond calcineurin inhibition. 
Theoretically, a high concentration of FK506 does not only bind to FKBP12, but also to 
other FKBPs (although the affi nity to FK506 of these FKBPs is not as strong as FKBP12), 
which will mediate functions other than calcineurin inhibition. This might possibly 
explain the various side effects related to high dose FK506 treatment24. In favor of this 
hypothesis, our microarray data showed that other FKBPs such as FKBP9, 10, 11, 14 
were signifi cantly enhanced in advanced atherosclerotic lesions compared to initial 
lesions. It indicates that these other FKBPs could ‘overrule’ FKBP12-FK506 interaction 
and even have less ‘benefi cial effects’.
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Although a low-dose FK506 treatment reduced collar-induced atherosclerosis, low-
dose FK506 treatment had not effect on Ang II-induced AAA formation in apoE-
/- mice (chapter 4). As discussed in chapter 4, the difference in the pathogenesis 
of atherosclerosis and AAA might explain this discrepancy. Atherosclerosis is an 
infl ammatory Th1 mediated disease, where as AAA is a permanent dilation of arterial 
wall and elastin degradation contribute critically to AAA formation7. Protease release 
by mast cells are thought to be involved in the pathogenesis of AAA6. Treating Ang 
II-infused apoE-/- mice with a mast cell degranulation inhibitor signifi cantly reduced 
the dilatation of the aorta and the infl ammatory response compared with the untreated 
group25. However, the effect of FK506 on mast cell protease release is not clear. Given 
the fact that a MMP inhibitor signifi cantly inhibited AAA formation26, it is possible that 
the inhibition of proteolytic activity is more effective than the inhibition of  cytokine 
function in the treatment of AAA. Moreover, different from atherosclerosis, AAA 
formation was associated with increased TGF-β signaling and could be prevented by 
a TGF- β antagonist 27. FK506 on the other hand, activated TGF-β signaling in SMC28 
and  mink epithelial cell line29. This activation of TGF- β may have dominated over the 
immunosuppressive effect of low-dose of FK506 in AAA.
The lack of effect of FK506 on AAA could in addition be explained by the possible 
accumulation of FK506 in atherosclerotic lesions rather than in aneurysm lesions. In 
human transplantation recipients, FK506 blood concentrations are routinely monitored 
to ensure suffi cient drug levels. However, the blood FK506 concentration is only a 
surrogate marker of that at the site of action30, 31. Ninety-fi ve percent of FK506 binds to 
erythrocytes (bound fraction) and fi ve percent resides in plasma (unbound fraction) 32. 
The pharmacological activity is considered to be dependent on the unbound fraction of 
FK506. At steady state, FK506 is distributed extensively in the body and the majority 
of the drug resides in the tissues outside the blood compartment 32. Thus, kidney 
accumulation of FK506 was found to be more than 30 times higher compared to 24-hour 
whole blood levels in mice, given a FK506 dose of 0.5 mg/kg/day24. 
To understand the pharmacokinetics of FK506, compound characteristics  have to be 
considered. FK506 is highly lipophilic and might accumulate in atherosclerotic lesions 
in apoE-/- mice. Given the high lipid content of atherosclerotic lesions in our model, in 
which mice are fed a western type diet, and the high lipophilic nature of FK506, local 
tissue dynamics of FK506 may be a factor in the sensitivity of the disease. 
In our AAA study, however, AAA was induced by subcutaneous infusion of Ang II in 
apoE-/- mice with normal diet. AAA lesions in apoE-/- mice do not show abundant 
presence of foam cells and lipid core. As a consequence, there will be less FK506 
accumulation in AAA compared to atherosclerotic lesions. To test this hypothesis, we 
have pursued the methods to evaluate tissue levels of FK506 in mice, but were unable 
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to optimize the method.
Translation of the FK506 dose from the mouse studies to clinical use and vice versa 
FK506 dose appears as a critical factor in the potential therapeutic application of FK506 
in atherosclerosis. However, an appropriate method to translate FK506 dose from mouse 
study to clinical practice is lacking. The Food and Drug Administration has suggested 
to use the normalized body surface area (BSA) to translate the dose used in animals 
studies to the starting dose in clinical trial, which is represented in mg/m2 33. The human 
equivalent dose (HED) to be converted from the dose used in mouse, can be calculated 
using the formula shown in reference 33. To convert the low-dose FK506 that we used 
in our mouse studies to the HED, 0.05 mg/kg (FK506 low-dose in mouse) is multiplied 
by the Km factor (3) for a mouse33 and then divided by the Km factor (37) for a human33 
(with Km representing body weight to BSA ratio). This calculation resulted in a HED 
of 0.004 mg/kg. With this method, we can also translate the clinically used FK506 dose 
to mouse.  A dose between 0.05 mg/kg and 0.25 mg/kg of FK506 is used clinically in 
human, and this is equivalent to a dose in the range between 0.62 mg/kg and 3.08 mg/
kg for mouse. Therefore, the high dose FK506 treatment of 1 mg/kg/day in mice in 
our study is within the dose range in transplanted patients. Furthermore, if we want to 
translate the low-dose regime from mouse study to clinical use, a FK506 concentration 
of 0.004 mg/kg might be a starting point.
VIVIT treatment-an alternative way to study the role of NFAT in vascular pathologies? 
As mentioned previously, we found that low- but not high-dose of FK506 reduced 
collar-induced atherosclerosis formation in apoE-/- mice13. FK506 is a widely used 
immunosuppressive drug that inhibits the calcineurin-NFAT signaling pathway.
Calcineurin, a phosphatase, controls the function of miscellaneous effector proteins, 
ranging from transcription factors to enzymes, transmembrane ion channels, 
and proteins involved in apoptosis34. The major setback of calcineurin inhibitors 
(FK506/Cyclosporine A) is that they intervene in calcineurin activity, and not only 
dephosphorylate NFAT, but also affect other downstream signal transduction pathways 
of calcineurin (such as protein kinase C activation or calcineurin-mediated NF-κB 
activity), resulting in undesired side effects and toxicity such as nephrotoxicity, and 
hypertension35. Several mechanisms have been postulated to explain the nephrotoxicity 
and hypertension due to calcineurin inhibition36. Firstly, calcineurin inhibition induces 
endoplasmic reticulum stress, which in turn regulates activities of pro-apoptotic BCL-2 
family protein BCL-2-associated agonist of cell death (BAD)37. This may induce apoptosis 
and renal toxicity38. Secondly, hypertension was reported as an important side effect of 
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immunosuppressive therapy. Thus calcineurin inhibiton, lead to reduced prostacyclin 
and nitric oxide synthesis and enhanced thromboxane and endothelin release, leading 
to vascular constriction39, 40. Furthermore, FK506 and cyclosporine A have been shown 
to be associated with an increase in allograft vasculopathy, suggestive of a hampered 
tolerogenic response 41. In our in vitro study in chapter 3, both low- and high-dose of 
FK506 in vitro treatment on Jurkat T cells signifi cantly reduced nuclear expression of 
NFATC2, whereas there was no difference in NFATC2 expression between the low- 
and high-dose treatments. The dose-dependent effect of FK506 on collar-induced 
atherosclerosis formation might result from unwanted calcineurin inhibition with 
high dose treatment. In order to circumvent inhibiting unwanted targets in calcineurin 
signaling pathway such as BAD37, we choose to focus on one component of the signaling 
pathway NFAT. 
NFATC1, C2 and C3 are the three NFAT family members that are expressed in the 
immune system and involved in calcineurin signaling pathway. During calcineurin 
inhibition, the translocation of NFAT proteins from the cytoplasm to the nucleus of 
activated cells is suppressed42.  Indeed, studies by both our group and others showed 
that FK506 treatment suppressed NFATC1, NFATC2 and NFATC3 protein expression 
in the nucleus of activated T cells (chapter 3)43. Suppression of NFATC1, C2 and C3 
activity might therefore explain the athero-protective effect of low-dose FK506 treatment. 
However, we chose to study the effect of NFATC2 defi ciency instead of C1 and C3 
on atherosclerosis formation (reasons see below, chapter 5).  We hypothesized that 
leukocyte NFATC2 defi ciency protects against atherosclerosis for the following reasons. 
Firstly, intervention in the calcineurin-NFAT pathway by low-dose FK506 was earlier 
shown to be atheroprotective13, although the actual molecular NFAT target mediating 
this effect remains to be identifi ed. Secondly, NFATC2 was recently reported to control 
regulatory T-cell function and its defi ciency led to a Th2 biased T-cell response44-46, both 
processes that were shown to attenuate the atherogenic response. Thirdly, NFATC2 
defi cient mice display an enhanced allergic phenotype characterized by eosinophilia, 
enhanced IgE production and increased production of Th2 cytokines in vivo and in 
vitro45, 47-49. Finally, both NFATC1 and C3 defi cient mice appeared to be involved in 
processes that might aggrevate atherosclerosis.  Thus NFATC1-defi cient T cells showed 
impaired production of IL-4 and other Th2 cytokines and reduced titres of IgE50, 51, and 
NFATC3 defi ciency resulted in a mild hyperactivation of peripheral T cells52.
Contrary to what we expected, leukocyte NFATC2 defi ciency deteriorated 
atherosclerosis. We found that NFATC2-/- bone marrow transplanted mice displayed 
an enhanced rather than compromised immune response. Thus, NFATC2 defi cient T 
cells had enhanced proliferative activity, displayed memory/activated T cell phenotype, 
and had robust migration capacity to atherosclerotic lesions. Our FACS data further 
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showed a reduction in CD4+/CD8+ ratio and enhanced Fox3+ regulatory T cells (Treg) 
in NFATC2 defi cient chimeras, however the functional consequence of  these circulating 
immune response for plaque development needs further validation.
The enhanced immunological responses in the NFATC2-/- chimera might disqualify 
NFATC2 as a proper target to prevent atherosclerosis development. However, the 
enhanced immunological responses in NFATC2-/- chimeras could be an unwanted 
consequence of redundancy in NFAT-regulated function. It is possible that other NFAT 
family members or cofactors have compensated for the lack of NFATC2 in maintaining 
an immunocompetent status in NFATC2 defi ciency47, 53. Indeed western blot analysis 
of whole cell lysates showed increased levels of NFATC1 and NFATC3 in NFATC2−/− 
CD4+ T cells54. The high degree of similarity of the Rel-homology regions among the 
different NFAT family members indicates common DNA-binding specifi cites, which 
might further explain the redundancy in some NFAT-regulated functions55. Thus the 
observed enhanced immune response in NFATC2-/- chimeras might be caused by a 
compensatory activation of other NFAT members. NFATC2 knockout mice therefore 
might not represent the ideal tool to study the function of NFATC2. Targeted NFATC2 
inhibition, due to its function in Th2 mediated response could still be a promising 
target in the treatment of atherosclerosis. However a rather ‘smart’ therapy that 
specifi cally intervenes in NFATC2 without activating other NFAT members or of 
NFAT independent pathways is needed.  VIVIT-an alternative inhibitor of calcineurin-
NFAT signaling pathway could be a choice. Being a promising inhibitor of calcineurin-
NFAT signaling, VIVIT is a small organic molecule inhibitor of the calcineurin-NFAT 
signaling pathway, which specifi cally inhibits binding of the calcineurin to its substrate 
NFAT and acts at the protein–protein contact and not at the calcineurin catalytic site34. 
VIVIT displays a preference for NFATC2 compared to other isoforms56. VIVIT, unlike 
FK506 and cyclosporine A, displays a favourable therapeutic profi le as it does not 
inhibit calcineurin signaling, which could initiate unwanted toxic effects. VIVIT has 
been tested in several cardiovascular diseases and proved to prevent cardiac myocyte 
hypertrophy in animal models and reduce neointima formation and neointimal SMC 
proliferation in a rat carotid artery balloon injury model (reviewed in 56 ). 
However, the effect of VIVIT on atherosclerosis has not been investigated. Although 
VIVIT could effi ciently hinder calcium/calmodulin activated NFATC1, NFATC2, and 
NFATC3 dephosphorylation, it displays a clear preference for NFATC2 compared to 
other isoforms56. Therefore, as an effective inhibitor of NFATC2 signaling pathway, 
VIVIT treatment might be considered an alternative to study the role of NFATC2 in 
atherosclerosis. Unlike the possible compensatory activation of other NFATs in the 
NFATC2-/- mice, VIVIT treatment is unlikely to induce a compensatory activation of 
other NFAT isoforms56.
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Part 2: CatK- friend or foe in vascular pathologies? 
CatK is a potent lysosomal cysteine protease involved in ECM degradation and 
infl ammatory responses. In an earlier study from our laboratory, systemic disruption 
of the catK gene reduced atherosclerosis lesion growth, but also enhanced macrophage 
foam cell formation by increased lipid uptake through CD36 and caveolins57, 58. Guo et 
al demonstrated that the absence of leukocyte catK in BMT recipient mice decreased 
collagen and increased macrophage content of atherosclerotic lesions while lesion 
size was not affected59. These fi ndings indicate that abolishing catK in leukocytes is 
detrimental for plaque stability. 
In chapter 7, we studied the effect of systemic catK defi ciency on AAA formation. 
Unexpectedly, we showed that catK defi ciency in apoE-/- mice did not confer 
protection against AAA formation, and did not affect the number of elastin breaks and 
or proteolytic activity in AAA lysates.  In contrast, our previous study demonstrated 
that the number of elastin breaks in the media underlying the atherosclerotic plaque 
even was substantially decreased in advanced lesions of catK-/-//apoE-/- compared 
with apoE-/- mice57. The differential outcome of catK defi ciency in these two vascular 
pathologies indicated fundamental differences in the proteolytic and possibly 
infl ammatory processes that underlie AAA and atherosclerosis. In Ang II- induced 
AAA lesions, catS and catC-positive cell numbers were signifi cantly increased in 
both the aneurysm and adventitia of catK-/-//apoE-/- mice compared with apoE-/- 
mice, which might have compensated for the defi ciency of catK-derived proteolysis in 
the aneurysm tissue of catK defi cient apoE-/- mice. However, catS and catC protein 
expression was not signifi cantly different in atherosclerotic lesions of catK-/-//apoE-
/- compared with apoE-/- mice57. This discrepancy could be explained by the possible 
effect of the Ang II infusion needed to induce AAA. There was a signifi cant increase 
in circulating granulocytes and activated T cells numbers in catK-/-//apoE-/- mice 
with Ang II infusion but not in control mice. Indeed, Ang II was reported to contribute 
to several steps in the infl ammatory cascade that appear during AAA60. Although our 
in vitro study on BMM showed that Ang II treatment by itself could not signifi cantly 
enhance catS and catC mRNA expression, this may not refl ect the in vivo situation 
in pathological lesions, where catS and catC-positive cells were more abundantly 
present in aneurysm lesions. To avoid the unwanted pro-infl ammatory effect of Ang II, 
intraluminal infusion of elastase and periaortic incubations of calcium chloride might 
be a better model to study the effect of catK defi ciency in AAA formation7.  
Proteolytic arterial remodeling and infl ammatory responses are present in vascular 
remodeling such as AAA formation6 and intima formation.  In chapter 8, we studied 
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the role of catK defi ciency on vascular remodeling and neointima formation in a carotid 
artery fl ow cessation model in catK-defi cient apoE-/- and wt mice. We found that 
catK defi ciency in the apoE-/- mice signifi cantly protected against macrophage-rich 
neointima formation, but not against macrophage-poor neointima formation in wt mice. 
Furthermore, we discussed the theory that catK defi ciency reversed the aggravated 
remodeling response in hyperlipidemic apoE-/- mice, suggesting that catK could 
directly or indirectly be a critical player in fl ow cessation-induced vascular remodeling. 
This profound effect was attributed not so much to catKs’ capacity to degrade ECM, 
but rather to its anti-infl ammatory activity on peripheral immune activity. In the next 
paragraph, we will therefore focus on the potential anti-infl ammatory effects of catK 
defi ciency.
As macrophage-rich lesion formation is associated with increased macrophage foam cell 
content10 and various studies showed that macrophage-derived infl ammatory growth 
factors contribute to intima lesion enlargement11, 61, we studied basal and cytokine-
induced polarization of BMM. Surprisingly, catK defi ciency in apoE-/- background 
skewed macrophages towards M2a phenotype. Intriguingly, after in vitro stimulation 
with LPS or IL-4, catK-/-//apoE-/- macrophages were tended to be polarized to either 
M1 or M2 phenotype, which is still hard to explain. Our earlier study showed that catK 
defi ciency reduced plaque progression but enhanced macrophage foam cell formation57 
possibly through increased lipid uptake mediated by CD36 and caveolins58, indicating 
a less favorable role of catK defi cient macrophages in protecting against atherosclerosis 
formation. Combined, the inhibitory effect of catK defi ciency on intimal hyperplasia in 
apoE-/- mice is at most partly attributable to a shifted macrophage polarization to M2a 
phenotype. 
We further investigated the peripheral infl ammatory status of catK defi cient mice in 
more detail using FACS analysis. Interestingly, catK defi ciency in apoE-/- mice was 
accompanied by a reduction in systemic CD3 cell populations and an enhanced Treg cell 
population, whereas no effects on these cell populations were seen in the WT mice. This 
raises the intriguing hypothesis that the observed immunomodulatory effects of catK 
defi ciency are opportune only in hyperlipidemic apoE-/- mice, which are typifi ed by an 
increased systemic infl ammatory status compared to WT mice. However, the molecular 
mechanism underlying the anti-infl ammatory effect of catK defi ciency is not clear. To 
our knowledge, this is the fi rst report showing that catK defi ciency reduced circulating 
CD3 cell and enhanced Treg population in apoE-/- mice. The enhanced Treg numbers 
in catK-/-//apoE-/- mice might involve toll like receptor 9 (TLR9) signaling, as a role 
for TLR9 signaling in the regulation of Treg function has been reported.  Stimulation 
of Treg with TLR9 agonists, resulted in decreased IL-10 and IFN-γ synthesis and a 
concurrent loss of regulatory function in Treg62. TLR9 responses are recently reported 
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to be involved in catK signaling63, 64, 65, in that catK inhibition led to compromised TLR9 
responses63, 64.  Administration of the potent orally active catK inhibitor, NC-2300, in 
rats with adjuvant-induced arthritis not only suppressed bone resorption by osteoclasts, 
but also instigated anti-infl ammatory effects, resulting in reduced paw swelling. 
Further studies showed that catK inactivation led to the blockade of essentially all the 
downstream pathways of TLR9 signaling in dendritic cells, showing a crucial role for 
catK in TLR9 signaling63. The possible mechanism for the involvement of catK in TLR9 
signaling was further studied by Ewald et al65. It was shown that the cleaved form of 
TLR9 in endo-lysosomal pathway was able to recognize and bind to CpG ligand and 
recruit MyD88 on activation, whereas full-length TLR9 lost this recruiting ability. It 
indicated that the truncated receptor, rather than the full-length form, is functional. 
Furthermore, blocking TLR9 cleavage by inhibiting various cellular proteases resulted in 
a non-functional receptor65. Thus inhibition of catK using protease inhibitors prevented 
TLR9 signaling function63, 64. However in a study using transgenic mice, macrophages 
and dendritic cells from catK-/-, catS-/-, catB-/-, and catS/catL-/- mice did not show 
defective TLR9 sginaling65. This study suggest that multiple proteases instead of single 
cathepsin are needed for functional processing of the receptor65. 
In our study, catK defi ciency in apoE-/- background might lead to a compromised 
TLR9 response which reduces Th1 response, limits infl ammatory reaction and in 
addition might deactivate plasmacytoid dendritic cell (pDC)66, as a consequence 
reduces macrophage-rich lesion formation. However, the function of pDC in vascular 
remodeling is unknown. Whether or not catK defi ciency resulted in reduced Th1 
response needs further study.
Part 3: CatK is regulated by NFATC1 
Infl ammatory and proteolytic pathways at times act in concert in the development 
of vascular diseases. Infi ltrating leukocytes are not only a prominent feature of 
atherosclerotic and AAA lesions, they also functionally contribute to lesion progression 
due to the release of cytokines, chemokines and growth factors. In addition, different 
subsets of leukocytes regulate vascular remodeling by producing proteases. In this 
thesis, we focused on the calcineurin pathway in view of the therapeutic possibility 
of immunosuppressive therapy in several vascular pathologies. However, studies in 
literature describe a link between NFATC1 as a component of calcineurin signaling 
pathway and catK.  
At the molecular level, NFAT and especially NFATC1 was found to stimulate catK 
expression through Receptor Activator of NFκB ligand (RANKL)-associated signaling in 
certain cell types (reviewed in 67). RANKL via the cytoplasmic membrane receptor RANK 
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(receptor activator of NFκB), induced both osteoclast differentiation and activation68. 
RANKL was able to stimulate catK mRNA expression in isolated mature rat osteoclasts69. 
Moreover, RANKL was reported to be present in the ECM surrounding the calcium 
mineral deposits of the plaques70. In addition, RANKL leads to the phosphorylation of 
NFATC1 by p38 mitogen-activated protein kinases, thereby inducing translocation of 
NFATC1 into the nucleus and binds to the cis-elements, N1 and N2, that are present in 
the upstream promoter region of the catK gene71. Cyclosporine A, an inhibitor of the 
phosphatase activity of calcineurin, inhibited NFAT activation and repressed RANKL-
induced catK mRNA expression67. Recently, NFATC1 binding sites were identifi ed 
on the transcription initiation site of the catK promoter72. In conclusion, the fact that 
NFATC1 signaling is a functional regulator of catK, illustrates the interaction between 
infl ammatory and proteolytic pathways. However whether or not FK506 treatment or 
NFATC2 defi ciency inhibited catK activity and possibly catK related proteolytic activity 
was not reported and need further study.
Concluding remarks
Although infl ammatory processes and vascular remodeling are common features of 
several vascular pathologies such as atherosclerosis and aneurysm formation, calcineurin 
targeted immunosuppressive therapy only protected against atherosclerosis formation, 
but was completely ineffective in aneurysm formation. Likewise, catK defi ciency 
protected against macrophage-rich neointima formation leaving macrophage-poor 
neointima and aneurysm formation unaffected, suggesting that although infl ammatory 
and proteolytic pathways contribute to these vascular pathologies, immunosuppressive 
or anti-proteolytic therapy was not equally effective. 
The differences in the underlying infl ammatory pathophysiology (discussed in chapter 
4) and possibly different stimulus to induce mouse model of atherosclerosis and AAA 
formation might explain the different outcome after low dose FK506 treatment. The 
more enhanced infl ammatory status in apoE-/- mice could explain our observation 
that catK defi ciency only protected against macrophage-rich, but not macrophage-poor 
neointima formation. It suggested that the anti-infl ammatory effect of catK defi ciency 
was evident only on a hyperlipidemic and hyperinfl ammatory (apoE-/-) background.  
While immunosuppressive agents are widely used in clinical practice to improve survival 
of transplanted organs, several side effects and a toxic profi le limit their use.  Although 
application of a lower dose for FK506 or cyclosporine A could be an option, this will 
compromise the required immunosuppressive effect. Further studies on the signaling 
pathways would enable to identify the major cellular ‘actor’ that is responsible for the 
therapeutic effect. In this way, a small peptide VIVIT was developed that intervened 
in NFATC2 signaling pathway specifi cally without inhibiting calcineurin function and 
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without inducing a compensatory activation of other NFAT members. Furthermore, 
abundant FKBP12 expression was found in intimal lesions and already proved to be a 
novel target for intima development. This could lead to the design of selective ligand 
that specifi cally binds to FKBP12. 
Interventions in proteolytic pathways are also promising for osteoporosis and probably 
atherosclerosis. Relacatib is a catK inhibitor that has been validated in the treatment of 
osteoporosis and proved effective73. Furthermore, several catK inhibiting compounds 
are being tested in clinical trials to study their effects on osteoporosis or osteoarthritis, 
and effi cient inhibition of bone resorption and improved bone formation has been 
shown74, 75. However, our study shows that the mode of action for catK is not solely 
confi ned to proteolysis but also affects infl ammatory processes. The recent discovery 
of the involvement of catK in atherosclerosis and neointima formation warrants further 
investigation of the therapeutic potential of catK inhibitors in these vascular pathologies. 
Nevertheless, adverse effect of catK inhibition on macrophage function should be 
avoided. The most promising therapy should specifi cally target the key component of 
the signaling pathway that contributes to disease progression without the potential side 
effects.
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Summary
Infl ammation and extracellular matrix (ECM) remodeling are common features of 
several vascular diseases such as atherosclerosis, aortic aneurysm formation and vessel 
remodeling. Infl ammatory cells are present in various stages of vascular diseases and 
can secret proteolytic enzymes that contribute to ECM degradation and therefore 
vascular remodeling. This suggests that infl ammation and ECM degradation act 
not in an independent manner but in mutual interaction and are linked at multiple 
levels in these vascular diseases. In this thesis, we investigated two hypotheses on the 
therapeutic potential of immunosuppressive and anti-proteolytic therapy in several 
vascular diseases. Firstly, as the calcineurin-NFAT signaling pathway was seen to be 
essential for an adequate immune response, we argued that inhibition of this pathway 
will protect against the aforementioned vascular diseases. Secondly, proteolytic arterial 
remodelling is a key process in aneurysm formation, atherosclerosis and neointima 
formation, therefore we hypothesized that inhibition of a key protease, cathepsin K, 
will protect against several vascular diseases that are characterized by excessive ECM 
remodeling. 
Chapter 2 provides an update of current literature on the potential of immuno-
modulatory drugs as therapeutic modality for cardiovascular disease. After a short 
overview of the specifi c infl ammatory pathways involved in atherosclerosis, we have 
reviewed the perspectives of several immunosuppressive drugs that are currently used 
for the prevention of (organ) transplant rejection (e.g. FK506, sirolimus, cyclosporine A 
and mycophenolate mofetil), for treatment of (clinical) atherosclerosis.
FK506 is a widely used immunosuppressive drug that inhibits the calcineurin-NFAT 
signaling pathway. Whereas we have previously shown that low-dose treatment with 
FK506 attenuated the progression of murine atherosclerosis, other studies in cholesterol-
fed rabbits reported that high dose FK506 treatment deteriorated atherosclerosis. In 
chapter 3, we therefore hypothesized that the dosage of FK506 is critical for its effects 
in the initiation  of atherosclerosis. This led us to investigate dose-dependent effects of 
FK506 in our mouse model of collar-induced atherosclerosis. Unlike low-dose FK506, 
high-dose FK506 did not protect against atherosclerosis. We provide evidence for a 
dose dependent effect of FK506 on peripheral immune activity. Cytokine analysis of 
conditioned media of CD4+ T cells isolated from FK506-treated mice revealed that low-
160
Summary
dose FK506 signifi cantly increased the IL-4/IFN-γ and IL-10/IFN-γ ratio suggestive of 
moderate Th2 skewing, whereas high-dose treatment decreased this ratio. These results 
unveil dosage as a critical factor in the effects of FK506 on atherosclerosis, probably by 
differentially skewing the Th1/Th2 balance.
An aneurysm is a permanent pathological dilation of the arterial wall, and is prone to 
rupture. Infl ammatory processes play a signifi cant role in abdominal aortic aneurysm 
(AAA) formation. Given the infl ammatory features of AAA and the potential 
immunosuppressive effect of low-dose FK506, we hypothesized that low-dose FK506 
treatment could decrease AAA formation. In chapter 4, we describe the effect of low-
dose FK506 treatment on angiotensin II (Ang II)-induced aneurysm formation in the 
abdominal aorta of apoE-/- mice. Contrary to our expectations, FK506 treatment did 
not protect against murine AAA formation.  The distinct underlying pathophysiology 
of atherosclerosis and aneurysm formation might explain the differential effect of low-
dose FK506 in these vascular pathologies.
As intervention in the calcineurin-NFAT pathway by low-dose FK506 treatment was 
shown to be atheroprotective, we further investigated the effect of a defi ciency of one 
of the potential FK506 targets, NFATC2, in the hematopoietic lineage on atherosclerosis 
in chapter 5. Surprisingly, NFATC2 defi ciency in haematopoietic cells resulted in 
more advanced lesion development and CD3+ T cell content was sharply increased in 
NFATC2-/- plaques. We found that NFATC2 defi ciency result in an enhanced rather 
than compromised immune response in that NFATC2 defi cient T cells had enhanced 
proliferative activity, displayed a memory/activated T cell phenotype, and had robust 
migration capacity to atherosclerotic lesions. These fi ndings suggest that NFATC2 
defi ciency enhances immune responses critical for atherosclerosis progression.
Chapter 6 presents a literature review on the role of cathepsins in vascular remodeling 
and atherosclerosis. 
In chapter 7, we focused on the effect of lysosomal cysteine protease-cathepsin K (catK) 
in AAA. CatK exerts strong elastinolytic and collagenolytic activity and is implicated 
in a wide range of pathological disorders including cardiovascular diseases.  CatK 
expression was found to be elevated in human aortic aneurysm pointing to a role in this 
vascular disease. Conceivably a defi ciency of catK could decrease aneurysm formation. 
To test this hypothesis, we investigated the effect of catK defi ciency on Ang II-induced 
aneurysm formation in the abdominal aorta of apoE-/- mice. Much to our surprise, catK 
defi ciency did not protect against murine aneurysm formation, nor did it affect medial 
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elastin breaks. Proteolytic activity in abdominal aortic lysates was comparable between 
apoE-/- and catK-//-apoE-/- mice. Adventitial presence of catS and catC-expressing 
cells was signifi cantly increased in catK-/-//apoE-/- versus apoE-/- mice, which 
might have compensated for the defi ciency of catK-derived proteolysis in the aneurysm 
tissue of catK defi cient apoE-/- mice. Moreover, circulating granulocyte and activated 
T cell numbers were signifi cantly increased in Ang II-infused catK-/-//apoE-/- mice 
compared to apoE-/- mice. In conclusion, the fi nding that catK defi ciency did not protect 
against aneurysm formation is remarkable given the previously reported unfavorable 
effects of this protease in atherosclerosis and once again underpins the fundamental 
differences in the proteolytic processes that underlie AAA and atherosclerosis.
This fi nding has prompted to a study of the role of catK in another vessel wall pathology, 
fl ow cessation-elicited carotid artery remodeling, under conditions of normo- (wild 
type/WT mice) and of hyperlipidemia (apoE-/- mice) (chapter 8). Surprisingly, catK 
defi ciency completely blunted the augmented hyperplastic response to fl ow cessation 
in apoE-/- (macrophage-rich lesions), while having no effect at all on vascular 
remodelling in WT mice. Interestingly, catK defi ciency signifi cantly reduced circulating 
CD3 T-cell numbers, but increased the regulatory T cell subset in apoE-/- but not WT 
mice. In addition, apoE-/- hyperplastic remodeling was characterized by signifi cantly 
enhanced number of circulating natural killer cells and reduced numbers of regulatory 
T cells in spleen compared to WT mice. Furthermore, catK defi ciency tended to bias 
macrophage polarization towards an M2a phenotype, which is instrumental in wound 
healing responses. Therefore, catK defi ciency almost completely blunted the increased 
vascular remodeling response of apoE-/- mice to fl ow cessation, possibly by correcting 
hyperlipidemia-associated pro-infl ammatory effects on peripheral immune response. 
In chapter 9, the fi ndings and implications of the results presented in this thesis are 
discussed in relation to the available literature. 
Infl ammatory processes and vascular remodeling are common features of several 
vascular pathologies such as atherosclerosis and aneurysm formation. Nevertheless, 
an immunosuppressive therapy only protected against atherosclerosis formation and 
was completely ineffective in aneurysm formation. Likewise, catK defi ciency protected 
against macrophage-rich lesion formation but not macrophage-poor lesion and aneurysm 
formation, suggesting that although infl ammatory and proteolytic pathways contribute 
to all of the aforementioned pathologies, immunosuppressive or anti-proteolytic 
therapy are not equally effective. While immunosuppressive agents are widely used 
in clinical practice to improve survival of transplanted organs, several side effects 
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and a toxic profi le that is related to calcineurin inhibition, limit their use.  Alternative 
solutions for immunosuppressive therapy in the treatment of vascular pathologies 
include refi nement/optimization of the dosage, disease-specifi c interventions and novel 
small-peptide inhibitors that more specifi cally interfere with the calcineurin/NFAT 
pathway. Interventions in proteolytic pathways are also promising for the treatment 
of atherosclerosis. The recent discovery of the involvement of catK in atherosclerosis 
and neointima formation warrants further investigation of the therapeutic potential 
of catK inhibitors in these vascular pathologies. The most promising therapy should 
specifi cally target the key component of the signaling pathway that contributes to 
disease progression without the potential side effects.
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                 (Dutch summary)
Verschillende aandoeningen van de grote vaten zoals aderverkalking (atherosclerose), 
verwijding van de grote buikslagader (aneurysma vorming) en structuurveranderingen 
van de vaatwand (vaatwand-remodelering) tijdens neointima vorming, worden 
gekenmerkt door ontstekingsprocessen en veranderingen in het bindweefsel, ook wel de 
extracellulaire matrix (ECM) genoemd. Deze ontstekingsprocessen en veranderingen in 
de ECM zijn bovendien onderling aan elkaar gerelateerd, aangezien ontstekingscellen 
enzymen (proteases) kunnen uitscheiden die de ECM kunnen afbreken. In dit 
proefschrift werden 2 hypotheses onderzocht. De eerste hypothese richtte zich op het 
afremmen van de ontstekingsreactie. Calcineurine en NFAT zijn belangrijke moleculen 
in de ontstekingsreactie. Onze veronderstelling was dat remming van deze moleculen 
beschermend zou werken tegen atherosclerose en aneurysma vorming. De tweede 
onderzoeksvraag betrof een belangrijke protease, cathepsine K, die betrokken zou zijn 
bij verschillende aandoeningen van de grote vaten. Onze hypothese was dat remming 
van cathepsine K zou beschermen tegen vaataandoeningen die gepaard gaan met 
veranderingen in de ECM, zoals aneurysma en vaatwand-remodelering.
In hoofdstuk 2 wordt een overzicht gegeven van de huidige literatuur over het 
gebruik van ontstekingsremmers bij de bestrijding van vaataandoeningen. Deze 
immunosuppressiva, zoals FK506, sirolimus en cyclosporine A worden nu met name 
gebruikt om afstoting tegen te gaan na orgaantransplantatie.
FK506 is een veelgebruikt immunosuppressivum dat aangrijpt op de eerder genoemde 
moleculen calcineurine en NFAT. Hoewel we eerder hebben aangetoond dat een lage 
dosis FK506 de progressie van atherosclerose in muizen verlaagde, liet een studie in 
konijnen zien dat FK506 de ontwikkeling van atherosclerose juist verergerde. In deze 
konijnenstudie werd echter een relatief hoge dosis FK506 toegediend. In hoofdstuk 
3 hebben we onderzocht in hoeverre de dosis een kritische factor is, in het effect van 
FK506 op de ontwikkeling van atherosclerose. In een muis model van atherosclerose 
(apoE defi ciënte muizen) zijn de dosisafhankelijke effecten van FK506 vervolgens 
bestudeerd. In tegenstelling tot een lage dosis FK506, beschermde een hoge dosis FK506 
niet tegen de ontwikkeling van atherosclerose. Verdere analyse in celkweken, met 
geïsoleerde (CD4-positieve) T cellen uit FK506 behandelde muizen, toonde aan dat een 
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lage dosis FK506 secretie van bepaalde ontstekingsmediatoren (cytokines) die wijzen 
op een ontstekingsremmende werking (Th2 respons) signifi cant verhoogde, terwijl 
een hoge dosis FK506 juist zorgde voor ontstekingsbevorderend effect (Th1 respons). 
Deze resultaten tonen aan dat de dosering een kritische factor is bij de effecten van 
FK506 behandeling van atherosclerose, en dat de Th1/Th2 balans hier mogelijk een 
belangrijke rol in speelt.
Een aorta aneurysma is een verwijding van de vaatwand van een slagader. Het is 
aangetoond dat ontstekingsprocessen een cruciale rol spelen in de ontwikkeling van een 
aneurysma van de grote buikslagader, ook wel een abdominaal aorta aneurysma (AAA) 
genoemd. Gezien het feit dat ontsteking een belangrijke rol speelt in de ontwikkeling 
van AAA en dat een lage dosis FK506 de ontstekingsactiviteit onderdrukt, stelden we 
de hypothese dat een lage dosis FK506 de ontwikkeling van een AAA voorkomt. In 
hoofdstuk 4 wordt het effect van een lage dosis FK506 beschreven in de ontwikkeling 
van aneurysma’s in een muismodel. In dit model ontstaat door een continue infusie 
van het molecuul angiotensine II (Ang II) een aneurysma in de abdominale aorta van 
apoE defi ciënte muizen. In tegenstelling tot onze verwachtingen beschermde FK506 
niet tegen AAA vorming in deze muizen. De aard van de ontstekingsmechanismen van 
atherosclerose en aneurysma zijn blijkbaar verschillend, met als gevolg dat FK506 geen 
effect heeft op de ontwikkeling van aneurysma’s in ons muismodel. 
 
Zoals eerder vermeld in hoofdstuk 3, verminderde een lage dosis FK506 de ontwikkeling 
van atherosclerose. In hoofdstuk 5 hebben we in meer detail onderzocht of de 
beschermende werking van FK506 terug te voeren is op een remming van NFATc2, 
één van de aangrijpingspunten van dit immunosuppresivum. Hierbij werd gebruik 
gemaakt van NFATC2 defi ciënte muizen; de beenmergcellen van deze muizen zijn 
daarbij getransplanteerd in atherosclerotische muizen, waarna de effecten op het 
ontstaan van atherosclerose zijn bestudeerd. Onze hypothese was dat de afwezigheid 
van NFATC2 in, van het beenmerg afkomstige ontstekingscellen, zou beschermen 
tegen het ontstaan van atherosclerose. In tegenstelling tot onze verwachtingen, leidde 
NFATC2 defi ciëntie tot ontwikkeling van grote gecompliceerde atherosclerotische 
lesies, met een verhoogd aantal (CD3-positieve) T cellen. Bovendien leidde NFATC2 
defi ciëntie tot een verstoorde algehele ontstekingsactiviteit. NFATC2 defi ciënte T 
cellen waren actiever en vertoonden zowel een verhoogde celdeling als een verhoogde 
bewegingsactiviteit (verhoogde T cel migratie) richting de atherosclerotische lesie. Deze 
bevindingen suggereren dat NFATC2 defi ciëntie bijdraagt aan de verdere progressie 
van atherosclerose door een verhoging van de ontstekingsactiviteit.
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In hoofdstuk 6 wordt een overzicht gegeven van de huidige literatuur over de rol 
van cathepsines in het herstructureren van de vaatwand (vasculaire remodelering) en 
atherosclerose.
In hoofdstuk 7 bestuderen we het effect de protease cathepsin K in AAA. Cathepsine 
K kan de ECM componenten elastine en collageen zeer effi ciënt afbreken. Onderzoek 
heeft aangetoond dat cathepsine K verhoogd aanwezig is in humane AAA, wat 
suggereert dat cathepsine K een rol speelt in deze aandoening. Onze hypothese was 
dat afwezigheid van cathepsine K, aneurysma vorming zal verminderen. Om dit te 
testen werd het in hoofdstuk 4 beschreven model gebruikt, waarin met behulp van een 
continue Ang II infusie een aneurysma van de buikslagader is opgewekt in muizen 
met een defi ciëntie in cathepsine K en apoE. In tegenstelling tot onze verwachtingen, 
beschermde cathepsine K defi ciëntie niet tegen aneurysma vorming in deze muizen. 
Nader onderzoek van het aneurysma weefsel toonde aan dat het vermogen om ECM 
componenten af te breken vergelijkbaar was in cathepsine K defi ciënte en controle 
muizen. Dit werd waarschijnlijk veroorzaakt door de verhoogde aanwezigheid van 2 
vergelijkbare cathepsines: er werden namelijk meer cathepsine S- en C-positieve cellen 
gevonden in het aneurysma weefsel van de cathepsine K defi ciënte muizen. Bovendien 
was de algehele ontstekingsactiviteit in de cathepsine K defi ciënte muizen duidelijk 
verhoogd na Ang II infusie (meer granulocyten en geactiveerde T-cellen aanwezig in de 
bloedbaan). Concluderend kan gesteld worden dat afwezigheid van cathepsine K wel 
de ontwikkeling van atherosclerose kan remmen, maar geen effect heeft op aneurysma 
vorming in muizen. 
In hoofdstuk 8 werd de rol van cathepsine K in structuurveranderingen van de vaatwand 
(vasculaire remodelering) verder bestudeerd. Hiervoor werd gebruik gemaakt van 
een model waarin de bloedstroom van één van de halsslagaders van apoE defi ciënte 
of controle muizen werd afgesloten. Hierdoor zal de vaatwand zich aanpassen; door 
ophoping van cellen in de vaatwand ontstaat een zogenaamde neointima en het vat zal 
structuurveranderingen ondergaan (vasculaire remodelering). In de apoE defi ciënte 
muizen bestaat de neointima met name uit een bepaald type ontstekingscellen, de 
macrofagen, terwijl in de controle/wildtype muizen de neointima met name bestaat 
uit gladde spiercellen. Uit de resultaten bleek dat in afwezigheid van cathepsine K 
de vorming van de macrofaag-rijke neointima in de apoE defi ciente muizen volledig 
geremd is, terwijl dit totaal geen effect had op de vorming van de neointima in de 
controle/wildtype muizen. Bovendien was het aantal circulerende (CD3-positieve) 
T-cellen verminderd en het aantal regulatoire T-cellen verhoogd in cathepsine K 
defi ciënte apoE-/- muizen, maar niet in de controle/wildtype muizen. Verdere analyse 
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in celkweken van geïsoleerde macrofagen toonde aan dat cathepsine K defi ciënte 
macrofagen in het algemeen een hogere ontstekingsremmende activiteit bezaten dan 
controle macrofagen (M2a fenotype). Uit deze bevindingen kan geconcludeerd worden 
dat de verhoogde vasculaire remodeleringscapaciteit, zoals waargenomen bij apoE 
defi ciënte muizen, bijna volledig geremd is in afwezigheid van cathepsine K. Dit wordt 
waarschijnlijk veroorzaakt door een correctie van de verhoogde ontstekingactiviteit in 
apoE defi ciënte muizen. 
In hoofdstuk 9 worden de bevindingen uit dit proefschrift bediscussieerd. Hoewel 
ontstekingsprocessen en vasculaire remodelering gemeenschappelijke kenmerken 
zijn van verscheidene vasculaire aandoeningen zoals atherosclerose en aneurysma 
vorming, stelden we vast dat een bepaalde ontstekingsremmende therapie alleen 
bescherming biedt tegen atherosclerose, maar niet effectief is tegen de ontwikkeling 
van een aneurysma. Ook bleek dat afwezigheid van de belangrijke protease cathepsine 
K beschermde tegen de vorming van een macrofaag-rijke neointima, maar niet tegen 
aneurysma vorming en het ontstaan van een gladde spiercelrijke neointima. Deze 
resultaten suggereren dat, hoewel ontstekingsprocessen en ECM afbraak onderdeel 
zijn van alle genoemde vaataandoeningen, een ontstekingsremmende therapie of een 
therapie gericht op voorkoming van ECM afbraak, niet even effectief was. Ondanks 
aanzienlijke bijwerkingen worden immunosuppressiva nog vaak toegepast/veel 
gebruikt in de klinische praktijk om orgaanafstoting tegen te gaan. Deze bijwerkingen 
staan een ruimer gebruik van deze geneesmiddelen in de weg. Er zijn echter wel 
experimentele ontwikkelingen die een meer specifi eke remming van de betrokken 
moleculen mogelijk maakt. Dit opent perspectieven voor een aanpak, waarbij specifi eke 
moleculen in bepaalde vaataandoeningen geremd kunnen worden en er minder risico 
is op bijwerkingen. Concluderend kan gesteld worden dat een ontstekingsremmende 
therapie of een therapie gericht op voorkoming van de ECM afbraak alleen effectief kan 
zijn als de therapie gericht ingrijpt op mechanismen die cruciaal zijn voor het ontstaan 
van de vasculaire aandoening.
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Figure 3.2 E Effects of low and high dose FK506 treatment on collar-induced atherosclerotic plaque 
development in common carotic arteries of apoE-/- mice. Representative HE stained cross-sections of 
right carotid artery of control, low dose versus high dose FK506-treated mice, respectively. 
Control Low High
WT NFATC2-/-
Figure 5.2 Effects of leukocyte NFATC2 defi ciency on atherosclerotic lesion formation in aortic arch. 
Representative HE stained cross-sections of aortic arch of control versus NFATC2-/- transplanted 
mice, respectively. 
WT NFATC2-/-
Figure 5.3B Leukocyte NFATC2 defi ciency signifi cantly increased the amount of CD3-positive cells rela-
tive to total cells in advanced lesions compared with controls. Representative pictures of CD3+ staining 
of aortic arch of control and NFATC2-/- transplanted mice are shown.
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Figure 5.8F NFATC2 defi ciency led to enhanced migration of CFSE+ cells to atherosclerotic aortic arch 
lesions. CFSE+ positive cells in sections from frozen aortic were quantifi ed.  Nuclei were counter-
stained using Mounting Medium with DAPI. Overlay images were acquired using fl uorescence micro-
scope. Representative overlays of fuorescence image of the aortic arch from apoE-/- mice that receive 
WT and NFATC2-/- CFSE+ splenocytes respectively are shown.
WT NFATC2-/-
apoE-/-
catK-/-//apoE-/-
apoE-/-
catK-/-//apoE-/-
Figure 7.2F epresentative photographs showing Elastica-von Giesson staining of aneurysms in apoE-
/- and catK-/-//apoE-/- mice. Both groups displayed complete medial breaks and subsequent lumen 
expansion (left panel) and adventitial thickening (right panel).
Figure 7.3H Effect of catK defi ciency on collagen content in AAA lesions. Representative pictures 
showing Sirius red staining of AAA lesions from catK-/-//apoE/- and apoE-/- animals.
apoE-/- catK-/-//apoE-/-
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Figure 8.1A CatK expression in macrophage-rich (apoE-/-) and macrophage-poor (WT) fl ow cessation-
induced intimal lesions. Representative pictures of catK staining in wt and apoE-/- mice are shown.
C57Bl6 apoE-/-
 Figure 8.3A Effect of catK defi ciency on intimal hyperplasia. Representative micrographs showing HE 
staining of intima lesions in WT, catK-/-, apoE-/- and catK-/-//apoE-/- mice. 
WT catK-/-
apoE-/- catK-/-//apoE-/-
